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Abstract 
 
Regulation is a key part of product commercialisation, where different 
stakeholders must continually negotiate what are often conflicting regulatory 
drivers. High technology regulation is particularly problematic as is found in 
nanotechnology, and nanoparticle products, where there is much 
misunderstanding about what these products are and how they work. 
Nanotechnology is the application of small products, ranging between one 
hundred million and one billion times smaller than a metre, considered as the 
????? ???????????? ????????????? ?? the vanguard of nanotechnology products, 
nanoparticles are examined in this study, where rapid technological advances are 
creating much debate within the discipline of law for how to best regulate the 
nuanced physicality of these products. Extant arguments have focused on how to 
regulate the R&D, production, sale, consumption and end-of-life of these 
products, with varying considerations of physicality which is pivotal to this 
endeavour. Critically, and fundamental to any discussion about regulating 
nanotechnology is whether these products sit inside of current regulations, or 
whether they require new regulatory approaches to more adequately capture their 
physicality. Confusingly, there has often been an erroneous presupposition that 
nanotechnology will function as a direct mirror of larger products, which is often 
not the case. On this basis, this study engages with the physicality of 
nanoparticles to build a foundation of knowledge, asking pivotal questions about 
regulation, to better inform academic and industrial regulatory discourses. 
Attention is given to regulatory frameworks including the Precautionary 
Principle, Regulation, Evaluation, Authorisation and Restriction of CHemicals 
(REACH), and potential for nanotechnology registries for monitoring 
nanoparticle physicality. Importantly, for any collection of highly nuanced novel 
physical products as found within nanotechno??????????????????????????-size-fits-
?????? ???? in depth examinations being made with different specific sectors to 
draw out the major challenges related to the physicality of this wide ranging 
collection of products.  
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Glossary 
 
Antimicrobial: A chemical solution used to kill microorganisms, 
potentially including bacteria, yeast, fungi and 
viruses (Dana, 2012). 
Asbestos: Naturally occurring silicate materials that have 
been heavily used in construction but have been 
found to be highly toxic (Alleman and Mossman, 
1997).  
Bulk: Macroscale phenomena which can typically be 
viewed without the aid of a microscope (Dana, 
2012). 
Construction: The use of discourse to convey a view or 
perception of reality (Wood and Kroger, 2000). 
Dermis:  The layer of skin between the most outer layer 
??????????? ???? ????????? ??????? ???????????? ????
subcutaneous (inside) tissue (William, Berger and 
Elston, 2005). 
Discourse: Communicative interchanges either in an uttered or 
textualised format (Wood and Kroger, 2000). 
Emic: An approach into how people sensitised to a 
particular environment think (Kottak, 2006). 
Etic:  An approach to shift the thinking of a sensitised 
individual to the role ??? ???? ????????????? ?????????
2006). 
Health and Safety: Regulatory system for reducing harm to 
individuals often in a workplace environment 
(Arrow et al, 1996).  
Ingestion: The consumption of a substance by an individual, 
typically through the mouth into the stomach.  
Inhalation: Breathing in a substance through the mouth or nose 
into the lungs (Palmieri, 2009).  
	  	  	   	  	  	  	  	  xiii	  
Insurance:  A system whereby the risk of loss is equitably 
transferred from individual/organisation to another, 
alongside a payment (Birds, 2013). 
Micro: A scientific scale existing between one thousand 
and one hundred million times smaller than a metre 
(Dana, 2012). 
Nano: A scientific scale existing for phenomena between 
one hundred million and one billion times smaller 
than a metre (Dana, 2012). 
Nanomaterial:  Materials with at least one physical dimension 
between one hundred million and one billion times 
smaller than a metre (Dana, 2012). 
Nanoparticle: Materials with all three physical dimension 
between one hundred million and one billion times 
smaller than a metre (Dana, 2012).  
Nanotechnology: The manipulation of materials at a scale between 
one hundred million and one billion times smaller 
than a metre, towards a commercial goal (Dana, 
2012). 
Pollution: Release of materials into the natural environment 
that may cause negative effects (Dana, 2012).  
Precautionary Principle: An approach to risk management, where if an 
action or policy is suspected of causing a negative 
impact, and without supporting scientific evidence 
to the contrary, the activity is not carried out (Dana, 
2012).   
Registry: An administrative database system for recording 
data (Bosso, 2010). 
Regulation: A legal device to shape conduct, with a spectrum 
of options being available between self and 
external agents setting and determining such 
activities (Brazell, 2012).  
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Risk: Typically perceived as the potential of something 
negative occurring, although in its widest context, 
it can also be beneficial (Brazell, 2012).  
Risk Management:  Procedures to identify assess and regulate risk  
(Dana, 2012). 
Socio-Linguistic: The interrelationship between the way that 
language and society influence each other (Wood 
and Kroger, 2000).  
Therapeutic: A substance to aid in healing or stabilising a 
disease state (Dana, 2012). 
Toxicology: The scientific study of chemicals and substances 
perceived or regarded as creating negative (toxic) 
effects (Brazell, 2012).  
Waste: Material that is perceived as unwanted or unusable 
(Dana, 2012). 
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Chapter 1. Introduction 
 
 
1.1. Motivation and Aim 
 
In an increasingly competitive and globalised marketplace, high technology 
research and development (R&D) through commercialisation is a common driver 
for many high technology companies to increase their market share and achieve 
growth (Wang, Lin and Huang, 2010). Due to the potential for physical and 
social benefit as well as harm from high technology products, the regulatory 
environment that high technology products exist within is often widely contested 
for how and why to regulate products (Baldwin, Cave and Lodge, 2012). Extant 
??????????????????????????????????????????????????????????????????????????????????
safety, and create some degree of certainty for manufacturers, it can also create 
barriers to commercial activities and increase the cost-to-market (Rogers, 2011). 
Regulation is thus ??????? ????????? ????????? ????? ??????? ???? ?????? ????????
depending on the stakeholder view used. Manufacturers must meet regulatory 
challenges if they wish to market their products, and depending on the type of 
regulation being applied, this ???? ??? ??? ?????? ????????????? ???????? ????
understandable regulation is thus pivotal for commercial activities, particularly 
as the operating environments for high technology companies are often complex 
with high costs, irrespective of ?further? pressures brought from regulatory 
obligations (Jolly, 1997). Managers must be able to navigate and make sense of 
????? ??????????? ????????????? ???? ??? ????? ??? ????? ????-for-????????? ??????????
(Badawy, 2010). Inherent within all of these activities is the aspect of risk and 
uncertainty, which arises from the products themselves as well as manufacturer 
pursuits of regulatory compliance (Zhang, Mei and Zhong, 2013). As the level of 
technology increases there can be a propensity for the level of unknown risk and 
uncertainty to also rise, which is a factor that can be addressed through 
regulation.  
 
In high technology arenas, technological product complexity can be particularly 
acute, particularly in business sectors including biotechnology, pharmaceuticals 
and nanotechnology. These sectors can have unique social and physical 
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considerations, which ??????? ??? ?????????? ???????? ???????????? ??? ????????
commercialisation but also to ensure public safety (Henderson and Clark, 1990). 
Where these aspects are not adequately controlled, commercialisation may fail, 
which is common in the pharmaceutical sector (CMR, 2006) and the public may 
be exposed to health risks as in the case of Thalidomide (Friedrich, 2005).  
 
It has been suggested that nanotechnology will be one of the most important 
technology sectors of the 21st century (Delgado, 2010). It is the science and 
commercialisation of small products and materials, with a nanomaterial being 
between one hundred million and one billion times smaller than a metre (which 
is not visible to the ??????? eye). The small size of these materials creates market 
opportunities for novel and unique size and surface related properties, but also 
brings new challenges for understanding the associated risks.  
 
Within the field of nanotechnology there are three products or material 
classifications, which are (1) nanoparticles, which have all three dimensions 
within the nanoscale range; (2) carbon nanotubes, which have two dimensions 
within the nanoscale range; and (3) thin-films, which has one dimension within 
the nanoscale range. Nanoparticles are of interest to this study as they are at the 
vanguard of nanotechnology product commercialisation and are the most widely 
utilised of all nanotechnologies in a variety of sectors (SCENIHR, 2006).  
 
Problematically, there is and has been a lack of understanding of how these 
technologies and products interact with humans and the wider environment, 
leading to much uncertainty and poorly defined risk (Fadeel and Bennett, 2010). 
Although there are and have been challenges to regulating nanoparticles, their 
relatively ubiquitous use in R&D and marketing has provided an opportunity to 
examine numerous regulatory aspects of nanoparticles. As such and due to the 
????????? ??????????? ?????????? ????? ?????????????? ??????? ???????? ????? ????????
specific regulation for a transformative and highly pervasive product class 
(Zonneveld, 2008), this study engaged with the regulatory aspects of this 
technology. 
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While many discourses have been provided and utilised for regulatory 
considerations of nanoparticles and nanotechnology from scientific sources, 
scientists have tended to favour promoting the benefits of these technologies, 
skewing public and key stakeholde?? ????????????? ?????? ???? ???????? ?????
regulatory discourses (Fadeel and Bennett, 2010). Beyond scientific 
constructions of nanoparticles and nanotechnology, wider and more varied socio-
linguistic uses of nano-laden terminology i.e. ?ipod nano?????????????d discursive 
cultural references, which are not within scientific constructions of these 
products, i.e. they are small but not within a size regime of between one hundred 
and one billion times smaller than a metre. Thus the ??????? ?????? is used to 
promote the perception of high technology benefits rather than being 
scientifically nanoscale (Fadeel and Bennett, 2010). Regulators must navigate 
this set of discourses, as well as scientific, legal and other discourses to discern 
how and why to regulate nanoparticles.  
 
Examining the phenomenon of nanoparticles from a physical perspective, much 
confusion exists for what, if any relationship a nanoparticle has to a larger bulk 
product. For example, can a silver nanoparticle be regarded as identical in risk to 
a silver ring worn on a finger? What if the ring is coated with nanoparticles? 
Aspects such as this are directly explored in this study to bring new 
understanding to this area, and highlight the challenge of regulating a relatively 
untested collection ??? ???????? ????????. Specifically and coupled with this is a 
consideration of the unknown nature of nanotechnology products, particularly for 
toxicity, environmental impact, and how the longer-term commercial aspects of 
nanoparticle products will play out (Oberdörster, Oberdörster and Oberdörster, 
2005; Beer et al, 2012). It is well known that all of these aspects can result in 
consumers rejecting products if these areas are not adequately addressed 
(Sjoberg, 2000). 
 
When considering regulation, it is critical to highlight that it is carried out, 
conceived and constructed through human actors. In high technology regulation, 
key stakeholder groups are commonly used to inform how something should be 
regulated, why, and potential benefits and risks from doing so. In line with this 
view, different regulatory stakeholders are addressed throughout this study as 
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necessary, to demonstrate various thoughts and concepts perceived necessary to 
the argument of regulating nanoparticles as nanomaterials, as opposed to their 
bulk counterparts.  
 
Summing up this section and drawing on the study by Dana (2012), there is a 
general lack of understanding regarding nanoparticle regulation. Following on 
from other high technology arenas, aspects including the regulation of health and 
safety, insurance, and commercial aspects of nanotechnology, amongst others 
have been considered. As a starting point, the following section goes on to 
identify current perceived research gaps derived from extant literature. 
 
 
1.2. Identified Research Gaps 
 
??????????????????????????????????important research gaps still to be filled, to bring 
to light new and vital knowledge within and between disciplines. Although based 
within law, this legal study draws on the arena of science due to the pivotal 
importance of scientific knowledge to this study.  
 
The main theme for this study is the paucity of physical information for how 
nanoparticles should be regulated, where business innovation can still be 
facilitated and encouraged, but risk is minimised. While prior studies have 
focussed on nanoparticle regulation, there has often been a lack of consideration 
of the physicality of nanoparticles (McHale, 2008). Suggestions have however 
been made that regulation should be made on a case-by-case basis for 
nanoparticle products, but with little consideration of how this relates to 
nanoparticle physicality (Kobe, 2012). Other arguments have been made that 
alternatively that little to no regulatory changes should be made due to the high 
number of nanoparticle products on the market (Chaudry, 2012: WP), and if 
attempts were made to construct and implement nanoparticle specific regulations, 
it might harm commercial activities. Thus, this aspect is directly considered 
within this study for how to regulate within these arguments.  
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The political system which nanotechnology sits within cannot be ignored, as it is 
well recognised that many other high technology products, such as 
pharmaceuticals, biologics and medical devices operate within a neo-liberalist 
framework, where commercial innovation is a primary driver (Abraham and 
Lewis, 2002). Nanotechnology is found within these sectors, with this study 
attempting to explicate the regulation of nanoparticle products against this 
political zeitgeist. It could of course be argued that this debate has already 
occurred for prior technologies, but I contend that due to the inherent nuanced 
complexity and less knowable detection methods for nanoparticle and 
nanotechnology products, many other considerations must be made, particularly 
for issues such as toxicity.  
 
The importance of language to law cannot be underestimated, particularly where 
there is technical complexity and opacity surrounding technical terms. While 
other disciplines have sought to engage with the refracting and restructuring 
medium of language (Rorty, 2009) for high technology products such as 
nanotechnology (Davies, 2011), little consideration has been paid towards high 
technology products from legal studies for this aspect. This study addresses this 
short fall by considering scientific language used, the meaning of technical terms 
and definitions, and where appropriate, contextualising this information against 
wider socio-linguistic constructions, which different stakeholders may encounter.  
 
At present, there is a propensity to frame nanotechnology and nanoparticle 
????????? ?????????????????? ????????????????????????????????????????????? ?????????
????????????????????????????? (Kjølberg, 2009). Prior attempts to engage with this 
aspect have often been surface based, which has failed to capture the intricacy of 
nanotechnology physicalities. While helpful for simplicity, regulation arguably 
demands a more encompassing and nuanced approach where subtlety can be 
imbibed to more adequately reflect product realities, which in reality are rarely 
just good or bad.  
 
Prior high technology products such as genetically modified organisms (GMOs) 
and Thalidomide (Sheetz et al, 2005) have resulted in speculative concerns in the 
former product and actual disasters in the latter, and left a mark of concern over 
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new products. Coupled with a high-level of uncertainty and opacity, and a fear of 
????? ??????????? ??????????? ???? ???????? ????????? ??????? ??????? ????? ????? ???
addressed within this tempestuous set of discourses. From a commercial 
viewpoint, there is also the need to understand how nanotechnology products 
ought to be insured, if at all. Thus, these aspects are synthesised and examined as 
?????????????????????????????????? 
 
Finally, the use of nanoparticle products and the health, safety and environmental 
impacts are considered. This is an encompassing view that has sought to cover 
this issue from product inception, all the way through R&D, manufacture, use, 
and disposal for workers and consumers. Prior studies have often considered 
numerous demarcated aspects of health, safety and the environment (Hull and 
Bowman, 2010), arguably at the expense of a product life-cycle overview. This 
study has therefore sought to expand this element, and take a more holistic 
overview and approach to explicate the challenges facing nanoparticle products.  
 
After examining all of the research gaps, this study then (in Chapter 8) produces 
a broad but in depth consideration overviewing all of the these aspects, and 
contextualising them against extant literature, showing how the research gaps 
have been filled.  
 
 
1.3. Research Methodology 
 
???????????????????????????????????????odological view, the method used in this 
study is more challenging to unpick and explicate than in other arenas such as the 
natural and social sciences. This is perhaps in part due to the natural and social 
sciences seeking to more overtly highlight the underlying methodological aspects 
????????????????????????????????????????????????????????????????????????????????
and/or warranted (Bryman and Bell, 2011). This is not to say that legal studies do 
not engage in research methodology, as they clearly do, but more that the 
underlying asp??????????????????????????????????????????????????? 
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While constructing a methodological approach, the question was continually 
asked, about how important it was to engage in methodological considerations. 
Perhaps like many aspects within law, this is a widely debated and contested area, 
???????????????????????????????????????????????????????????????????????????????
??????????????????????????? ????????????????????????????????????????????????????
that this study is not based within an empirical paradigm, I drew on the notion 
that method is ultimately a part of methodology, and if explication of meaning 
can be aided by engagement with these considerations it should be carried out. 
Drawing on Hycner (1999), I followed the research methodology advice that the 
phenomenon should dictate the method. Thus with this being a legal study 
examining high technology and in particular nanotechnology and nanoparticle 
regulation, without empirical research, I undertook a method that can broadly be 
?????????????????????????????????????????????????????????????While content analysis 
can be taken as a varied collection of methods (grounded within different 
methodological underpinnings), from the perspective of this study, it is a way of 
meaningfully engaging with texts. Although many content analysis methods can 
focus on elucidating aspects such as word frequencies to elaborate potential 
social structures etc. this study has not sought to do so. Instead of fully imbibing 
a concretised method, a perspective has been selected. In practicality, this means 
that I have engaged with texts as a means to infer discursive, social, scientific 
and legal structures from within them, and what might in many ways be 
??????????????????????????? of the phenomenon. An example of this can be taken 
from the word nanotechnology, where in section 3.3 (and following sub-sections) 
?????????????????????????????????????????????????????????????????? ????????????
???? ????????????? ???? ???? ?????????? ???????? ???????????? ??????????? ???? ??????
structures influence and are influenced by this word. Thus, no singular meaning 
of any word is concretised, but multiple interpretations accepted showing the 
distortive capabilities of language (Searle, 2011), and the difficulties for law, 
particularly in engaging with high technology albeit with a need for discursive 
clarity. Due to the expansive and incomplete nature of nanotechnology 
discourses, this study might be considered a bricolage of important emergent 
themes from what is at present an incomplete picture of nanotechnology and 
nanoparticle regulation. At this early formative stage, varying degrees of 
attention have been paid to different aspects of regulation, and as such, an 
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??????????????????????????????????????????????????????????????????????????????????
content analysis approach, this study has pulled together what were considered 
the most pivotal themes.  
 
Alongside the methodological factors discussed so far is how I as the researcher 
interacted with this study. In positivist and predominantly natural science based 
studies, a researcher will predominantly undertake the ????????? ??? ???? 
researcher?, where claims are made about research being objective, attempting to 
minimise uncontrolled interactions with the research i.e. where the researcher is 
?objective?. At the other end of the spectrum, and often found within non-natural 
sciences research, a researcher will undertake an embedded position within their 
research, where ?????????????????????????????????????????????????????????????????
?????? ????? ??? ???? ?????????? ?? ?????????? ????? ??????? ???????? ???? ???????????? ???
emics and etics (Kottak, 2006). In principal, this led me to acknowledge my 
sensitisation for how people from a particular environment think, known as an 
emic approach and broadly subjective. My emic sensitisation occurred through 
my having engaged with the commercial aspects of nanotechnology companies 
operating within the shade of high technology regulation. This gave me insights 
into this environment but this also had the potential to bias my construction of 
this study. The important aspect for having undergone emic sensitisation is the 
acknowledgement of this fact, bringing it to life, and contextualising it against an 
etic approach. Undertaking an etic stance obligates a research shift on my part as 
the re????????? ??? ?????? ??? ?????? ???? researcher?, where knowledge must be 
routed through the lens of extant literature, pulling the research and the 
researcher towards objectivity. Drawing on both an emic and etic approach 
provided a unique opportunity to utilise in depth culturally derived knowledge, 
and then contextualise it as the researcher, and I argue that this gives a greater 
potential to subjectively and objectively mirror the reality and phenomenon of 
this study, i.e. nanoparticle regulation.  
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1.4. Research Question, Aim and Objectives 
 
Taking an emic approach through my sensitisation to the sector, and an etic 
stance from extant literature, the following main research question was used to 
address gaps in the literature and guide this study:  
 
1. How should nanoparticles be regulated so that risk is minimised while 
business innovation and commercialisation is encouraged? 
 
It is accepted that a variety of stakeholders may be involved with regulation and 
is addressed throughout this study. Drawing on this main question and theme, it 
is recognised that other minor themes as questions would need to be drawn out to 
complement the main question, and include:  
 
2. How are high technology products regulated, and how does the neo-
liberal regulatory framework influence this? 
 
3. What are nanotechnology and the product class of nanoparticles, from a 
scientific and socio-linguistic perspective? 
 
4. How are nanotechnology and nanoproducts used commercially, and what 
are the perceived negative and positive attributes potentially influencing 
their regulation? 
 
5. How are nanoparticle products perceived from a risk perspective, and 
how does this influence their insurance? 
 
6. What are the health, safety and environmental implications of 
nanoparticle products, and how might regulation be used to address this 
issue? 
 
7. What are the regulatory approaches to nanotechnology and nanoparticles 
that might best result in regulation promoting innovative 
commercialisation while addressing needs to mitigate risk? 
	  	  	   	  	  	  	  	  10	  
Building on the research question and extant literature, and previous questions, 
the research aim is:  
 
To examine the rationales for regulating nanotechnology and 
nanoparticles, with a predominant focus on risk and benefits, drawing 
on Europe and the USA as appropriate.  
 
The approach taken for these questions and aims is set out in the following three 
research objectives:  
 
1. Through a literature review and examination of current 
regulatory discourses, to understand how the arguments for and 
against nanoparticle regulation are constructed; 
 
2. Based on (1) to contextualise these discourses against the 
underlying rationales for nanoparticle and nanotechnology 
regulation;  
 
3. Based on (1) and (2) to draw the literature together and 
make suggestions for the regulation of nanoparticles and 
nanotechnology products.  
 
Utilising concepts from the previous section on research methodology, the 
approach set out in this section, enables the fusion of subjective and objective 
approaches, coupled with knowledge derived from emic knowledge but also 
contextualised through the lens of the researcher, through an etic stance.  
 
Drawing on the research questions, aims and objectives, the following section 
details the significance and contribution of this research as it relates to the extant 
literature.  
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1.5. Significance and Contribution of this Research 
 
The research carried out in this study has provided an in depth examination of 
the challenges surrounding and facing the regulation of nanoparticles, as well as 
highlighting challenges facing nanotechnology more generally. Prior to this 
study academic inspection was limited to either legal or scientific discourse, as 
predominantly separate studies, with few studies having attempted to engage 
with nanotechnology through multiple academic lenses including law and 
science.  
 
As a starting point, this study has argued that nanoparticles and nanotechnology 
are not regulated on any specific quality inherent to their nuanced physicalities as 
nanomaterials. Instead, current regulatory systems have been used to varying 
degrees. Thus, depending on the product application, sector, and perceptions of 
non-nanoscale products, different aspects of nanoparticle physicalities have been 
?unintentionally? regulated. The current lack of specific regulations for 
nanotechnology can perhaps be argued as in keeping with neo-liberal regulatory 
underpinnings to facilitate product commercialisation. This has however been at 
the expense of a more rigorous approach to nanoscale phenomena.  
 
Unfortunately, while product commercialisation is facilitated through neo-
liberalist approaches, the physicality of nanoparticles dictates they are not a 
mirror image of larger products, and potentially a poor physical reflection of the 
way that larger products behave. Coupled with a potential to change their size, 
shape and toxicity due to processes such as Ostwald Ripening, the current 
regulatory frameworks fail to capture many aspects of product physicalities. 
Assumptions that nanoparticle products will function as bulk products is often 
?????????????? ??????????????????????????? ?????????????????????Looking back at 
forerunner technologies such as microtechnology, which also came about 
through miniaturisation, there has perhaps been a propensity to assume that 
nanotechnology is simply a linear extension of this technology. This however is 
not the case, as although nanotechnology products are smaller than 
??????????????????????????????????????????????????????????????????????????????
sizing for microtechnology, where new properties are clearly observed for 
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nanotechnology. Importantly, while novel properties have been demonstrated 
from scientific studies, there has been a propensity not to examine at the same 
level, the potential risks from nanoparticles. This has led to a paucity of data, 
meaning that it is more difficult to construct risk assessments to mitigate 
problems associated with toxicity etc.  
 
A critical foundation for engaging with nanoparticles as a part of nanotechnology, 
led to the examination of some of the language-based aspects of these two words. 
In particular, numerous non-scientific influences have been highlighted for both 
nanoparticles and nanotechnology as unhelpful. Instead, the recommendation 
from this study is for regulators to utilise scientific constructions and definitions, 
with the acknowledgement that at present there is no legal definition for either 
word. Scientific constructions, although potentially varying are more likely to 
ground the phenomena of nanoparticles and nanotechnology as being nanoscale 
physical entities, with novel properties, potentially suggesting a greater focus 
towards treating them as novel materials, not well captured under current 
regulatory systems. Although, this statement must be clarified, as is described in 
this study, how well a regulatory system captures the phenomenon is based upon 
aspects such as product physicality, and application.  
 
The aspect of risk is critical for nanoparticle and nanotechnology regulation, as it 
is unlikely that current regulations will enable toxicity to be unpicked and 
elucidated. This may have profound impacts on the future of nanoparticle and 
nanotechnology products, where risk assessments are at some level unworkable 
due to the unknown nature of nanoproducts, based on a lack of rigorous scientific 
testing. In turn this may echo into the insurance of these products, where there is 
currently much debate about how nanoparticle products should be insured, or 
more bluntly at times, whether they should be insured at all. Pivotally, more 
physical data on risks is needed from fit-for-purpose testing.  
 
The approach used in this study, has facilitated novel findings as discussed so far 
and has highlighted new ways of looking at the challenge of nanoparticles and 
nanotechnology as not only a scientific phenomenon but an arena that must 
undergo rigorous investigation from the arena of regulation, potentially resulting 
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in specific regulations being discussed and brought into being. I argue that the 
strongest aspect of this study has been grounding the approach within the 
physicality of nanoparticles and nanotechnology, something that no other study 
has done. This has enabled a view that is in some ways similar to other high 
technology products that are also high risk, such as pharmaceuticals, biologics 
and medical devices. Drawing on these other high technology product areas, the 
notion of examining risk related to toxicity through the use of different trials is 
????????????? ???????????????? ??? ???????????? ????? ???????????????? ?????????????????
while in their current formats would enable nanoparticle toxicities to be much 
better understood. My main recommendation from this study is therefore, that an 
approach is taken to regulate nanoparticles as separate and distinct from their 
bulk scale equivalents, unless there is evidence to the contrary. This would 
change the current status quo, which seeks to regulate nanoparticles as their bulk 
materials. It is too simple to regard nanoparticles as a mirror reflection of larger 
materials, particularly where novel composite materials have no bulk equivalent.  
At some level this would require manufacturers to engage with increased testing 
??? ???????????? ?? ?????? ??? ????????? ????????? ??? ???????? ??????? ???? ????????? ??
higher level of nanoparticle toxicity might be more acceptable for a therapeutic 
????? ????????? ??? ??????????? ????? ?? ????? ??????ening illness, in comparison to 
nanoparticles in clothing.  
 
In suggesting a move towards regarding nanoparticles as separate from their bulk 
counterparts, multiple aspects of different regulatory systems may require 
adjustment, from manufacture through to use and disposal. Creating national and 
international nanomaterial databases, with required testing, will reduce long-term 
commitments to test materials that have already become well understood. 
Arguably, with further testing, a more nuanced understanding of the behaviour of 
nanomaterials will be elucidated, building a platform of knowledge that can be 
implemented in various regulatory systems such as REACH and ISO. With such 
limited information at the present other than there being differences between the 
bulk and nanoscales, it is difficult to suggest further changes, as ideally basing 
regulation on product physicality should be evidence based, due to product 
testing.  
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1.6. Thesis Outline 
 
Chapter 1. Introduction 
 
This chapter introduces the study, research question, aim and objectives as well 
as detailing the significance of the research carried out in light of contributions to 
academia and regulators. The structure of the thesis is also presented.  
 
Chapter 2. Regulation of High Technology Products 
 
This chapter examines the regulation of high technology products, with 
fundamental aspects being explored that underpin this study. As such the history 
of regulating high technology products are considered alongside how innovation 
is regulated. With the aim of this study being the examination of nanotechnology 
products, the forerunner product class of microtechnology is also considered, 
leading on to the current status of nanotechnology regulation. Finally, a 
discussion is made of neo-liberal regulation, which is the framework that 
nanotechnology operates within.  
 
Chapter 3. Nanotechnology and Nanoparticles 
 
This chapter focuses on the area of nanotechnology, and in particular the product 
class of nanoparticles is examined due to this being a vanguard technology. The 
difficulty of varying definitions within science, wider culture, and no legal 
definition is considered, alongside an in depth exploration of nanotechnology as 
a physical commercial phenomenon. An explanation of the differences between 
nanoparticles, thin-films and carbon nanotubes is also made, as well as how 
nanotechnology is set apart from other technologies. Finally, an exploration of 
underlying drivers for regulating high technology products is made.   
 
Chapter 4. The Commercial use of Nanotechnology and Nanoparticles 
 
The focus of this chapter is on the commercial use of nanotechnology and 
nanoparticles. The two main aspects of benefit and risks are set up for later 
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discussion in this chapter, particularly for what is attractive about 
nanotechnology, potential applications, but also detrimental considerations that 
must be made, including product uncertainty and toxicity.   
 
Chapter 5. Risk and Insurance 
 
The focus of this chapter is on risk and insurance, and how these aspects are 
influenced by the potential benefits and often-unknowable characteristics of 
nanoparticles and nanotechnology. Thus the notion of risk management and risk-
benefit ratios are examined, alongside the concept of acceptable risk. Importantly 
this section looks at risks associated with prior technologies, which include 
asbestos and the link to similarities with nanotechnology. The Precautionary 
Principle and how it is applied is discussed alongside risk analyses and self - 
regulation. The second part of this chapter is devoted to insurance, which is 
necessary to observe how insurance underwriters view nanoparticle products and 
cover them against unknown risks and hazards. This includes sections on how 
companies engage with nanotechnology and insurance, commercial insurance 
coverage and the future of nanotechnology insurance.  
 
Chapter 6. Health, Safety and the Environment 
 
This chapter focuses on the arena of health, safety and the environment, with an 
in depth examination of the three main routes of human exposure, including 
dermal penetration, inhalation and ingestion. The dangers of working with 
nanoparticles are highlighted with exemplar areas of food, medicine and 
cosmetics. These areas are considered for a variety of environments ranging from 
manufacture to home use.  
 
Chapter 7. Regulatory Approaches to Nanotechnology 
 
The focus of this chapter is on national and EU regulations already in place for 
high technology products and questions whether they are suitable for 
nanotechnology. This is against a backdrop where current strategies 
predominantly treat nanotechnology products as equal to larger bulk scale 
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materials and products, even if the benefits and risks are different. The regulatory 
landscape is considered for how disasters such as Thalidomide and asbestos can 
be avoided, potentially through the use of Nanomaterial Registries such as those 
set up in France, Belgium and Denmark, plus the voluntary registries that are in 
the process of being set up in the USA, by DuPont. This is alongside the use of 
REACH and the Precautionary Principle for mitigating risk and aiding in 
commercialisation.  
 
Chapter 8. Discussion and Conclusions 
 
This chapter pulls together all of the research findings and main themes derived 
from this study, with an examination against extant literature, to construct a 
discussion and conclusions. Building on these aspects, contributions for the 
knowledge base derived from the research question, research aim and research 
objectives are highlighted as well as implications for regulators. Finally, research 
limitations are considered alongside recommendations for future research.   
 
The following chapter starts an examination of the extant literature on 
nanotechnology and nanoparticles.  
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Chapter 2. Regulation of High Technology Products 
 
 
2.1. Introduction 
 
This chapter sets out to examine the regulation of high technology products, and 
is broadly driven by the question ??ow are high technology products regulated, 
and how does the neo-liberal regulatory framework influence this?? To answer 
this question, multiple themes are examined including the history of regulating 
high technology, the regulation of innovation, neo-liberalist regulation and how 
the forerunner technology to nanotechnology known as microtechnology was 
regulated. Finally, the current regulation of nanotechnology is examined.   
 
Before these aspects are considered in more detail it is worth pointing out that 
there will always be arguments made for and against regulating technology 
products and services. Where there are many stakeholders, many divergent views 
on how to regulate technologies are often voiced with competing reasons why. 
Simply, it must be remembered that any regulation is a balancing act between 
multiple discourses and rationales. The complex physical nature of high 
technology products means that it can be difficult to discern risks and benefits, to 
construct fit-for-purpose regulations based on product physicality. It arguably 
necessitates in depth product knowledge, whereby the risks and benefits of 
products can be rapidly and more easily understood. However, and as will be 
discussed throughout this chapter, this is not always the case, as different 
individuals utilise different levels of knowledge.  
 
As a starting point to address the research question posed for this chapter, the 
following section starts to construct an answer by considering the regulation of 
high technology products.   
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2.2. Regulating High Technology Products 
 
High technology products are physical entities that can be considered at the 
????????? ?????? ??? ?????????????? ???????????? ???? ????? ???????? ????????? ??? any 
sector, what is considered ??????????????????????? ?????????????????????????????
??????? or low technology tomorrow. As technology products become better 
understood, there is the potential to regulate them more effectively based on 
known information, rather than speculative assessments, although the debate can 
always be continued for how well any product is really known. It is important to 
understand however that while I maintain the importance of regulation based on 
product physicality, this is but one of many parts of product regulation. However, 
as this area is often neglected for high technology products, this study has 
undertaken to engage directly with this issue. Coupled with these aspects is the 
pivotal aspect of the stakeholders carrying out regulation, as within human actors, 
regulation could not be achieved.  
 
As might be expected from any area with multiple drivers and stakeholders, 
explicating what regulation is, is no small challenge and is often contested 
(Mitnick, 1985). A commonly discussed construction of regulation is that by 
Selznick (1985), who sets out that regulation is positioned as a sustained and 
focused control, exercised by a public agency, often on the behalf of a state. 
Drawing on the suggestion of Black (2002), it is perhaps more helpful to regard 
regulation as being used in the following ways, including (1) as a specific set of 
commands, (2) as deliberate state influence, and (3) as forms of social or 
economic influence. Within these notions is often the idea that regulation is 
??????? ?????? ??? ????????? ???? ????????? ???????????? ??? ??? ?? ????? ???????? ????? ???
actuality a broader perspective is more useful as it engages with the concept that 
??????????? ???? ????? ??? ?? ??????? ??????? ???????? ??????????? ???? ???????????? ???
encouraged (Harlow and Rawlings, 2009). 
 
Regulation of products, including high technology is predominantly orientated 
???????? ?????????? ???????????? ????????? ???????? ?? ???? ??? ????????????? ????
????????????????????????????? ?????) argued, high technology regulation sets 
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???? ??? ????????? ???? ???????? through the state. Black (2002: 19) went on to 
define this as:    
 
??????????ined and focussed attempt to alter the behaviour of others 
according to defined standards or purposes with the intention of 
???????????????????????????????????????????????????? 
 
This type of regulation can be undertaken by a variety of regulatory stakeholders, 
not just government, so that a range of outcomes albeit positive or negative can 
be obtained, as well as encouraging certain types of behaviour (Brownsword, 
2007). For example, and drawing on the pharmaceutical sector, the three areas of 
safety, efficacy and quality of products are heavily addressed through regulation 
(Abraham and Shephard, 1999), with an aim to balance societal needs and safety, 
with those of industry, where bluntly commercialisation of innovative products 
???????????????????????????risk mitigated (Wiener, 2004). 
 
High technology products are often unique in the way that they are researched, 
developed, and sold into the marketplace. While there are commonalities, heavy 
regulation for risk-laden high technology products has greatly influenced the way 
that the market operates (Abel-Smith and Grandjeat, 1978). The nature of the 
regulatory forces has meant that there are market imperfections in not only the 
supply, related to patent protection, and demand, where medical organisations 
often dictate what product should be used with a patient (Mossialos and Mrazek, 
2004).  
 
Regulation is not fixed immemorial, but is instead a fluid socio-historic construct 
embedded within culture, without permanence, where social, economic, medical 
and technoscientific drivers may change regulatory trajectories. As Gaudilliè and 
Hess (2013) commented:  
 
?ways of regulating are therefore categories or frames used in 
thinking about, choosing between, and organizing practices that are 
?????????????????????????????in a given duration, each representing a 
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????????? ??? ???????? ????? ?????? ??? ???????????? ??????? ????? ???
isolation??? 
 
Thus while it is perhaps easy to imagine that all regulatory pathways are along a 
beneficial evolutionary pathway, it is perhaps better to consider that the path is 
adaptive to current and perceived needs. As Gaudilliè and Hess (2013) stated:  
 
?Regulation may then be viewed as a series of dispositifs, or purviews, 
not only targeting commercial practices but also aiming to define 
production standards or to set norms for medical uses. Regulation is 
not exclusively a problem of government control and marketing 
authorizations; it is also a problem of legitimate patterns of action 
??????????????????????????????????????????????????????????????????tion 
room??? 
 
Approaches often taken towards regulating high technology products include 
different regulatory frameworks, which might include Government Guidelines, 
Directives, Regulations and Acts to cover a host of potential aspects from 
inception through to use and disposal (Hull and Bowman, 2010). For example, 
within the EU, State Law can be useful for setting out what is required but 
through wide distribution requirements, facilitating regulatory uptakes, it has 
however been criticised as being too cumbersome, rigid, slow and costly (Moran, 
1995; Sinclair, 1997) and being a barrier to commercialisation. This can be 
problematic in rapidly evolving fields such as nanotechnology, suggesting that in 
the short term, State Law regulation ????? ???? ??? ???? ????? appropriate or 
?????????????? ??? ????????? ????????? ?????? ??? ???? ??????????? (Hull and Bowman, 
2010). ????????? ??????? ????? ????????? ??? ???? ?????????? ??? ???? ??????? ?????where 
government has a limited role in its operation, although as demonstrated in high 
technology sectors such as pharmaceuticals, medical devices and biologics, 
regulatory agencies are often heavily involved on the behalf of the state (Jackson, 
2012).  
 
The many types of soft law regulation used to regulate high technology products 
include industry codes, risk management frameworks and voluntary codes of 
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conduct as they are able to adapt to a changing environment more quickly than 
state based regulation (Ayres and Braithwaite, 1982; Sinclair, 1997). This 
arguably can help promote innovation and creativity as it is often said that 
regulation stifles innovation (Hull et al, 2010: 78). Black (2002: 25) reminds us 
?????-regulation is neither a new phenomenon, nor one which is likely to 
??????????? but it is not without controversy as it is often ????????????????????????
????????????? ???????????????????????? ? (Hull and Bowman, 2010: 79). Soft law is 
discussed in more detail in Chapter 7. 
 
It is against this backdrop of regulatory approaches that nanotechnology and 
nanoparticles must be considered to address risks while promoting commercial 
innovation. To further understand high technology regulation, the following 
section goes on to consider a brief history of regulating high technology.  
 
 
2.2.1. A Brief History of Regulating High Technology 
 
Technology products, including high technology, have a long history of 
regulation in one form or another, which has included numerous aspects of 
product life cycles from inception through to manufacture, use and disposal 
(Daemmrich, 2004). In practicality, it is difficult to make broad and sweeping 
statements that encompass all high technology products throughout any time 
period, as due to application, sector and perceived risks and benefits amongst 
other drivers, there can be substantive variation. However, and to try to unpick 
some major themes from high technology regulation, an examination within this 
section of pharmaceutical products is made, to try to elucidate drivers to regulate 
and how this has been achieved over the years. As will be demonstrated, while 
?????? ?????????????????????????????????????????????????????????????????????????????
this is somewhat misleading, as while law is often a vital component, there are 
many other stakeholders and drivers beyond law, which feed into law to assist in 
regulatory decision-making.  
 
Examining pharmaceutical product regulation, there is a long and often 
incomplete history, and while it is not the purpose of this section, to dig too 
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deeply, it is intended to highlight the challenges and frequently recorded 
rationales for regulating technology products. Looking at an early example of a 
??????????????? ?????????????????????????????????? ??? ?????????????????????????????
?????? ??? ???????????? ???? ?? ??????????? ??? ?????????? ????????? ??? ??????? ?????
prepared, and used by King Mithridates VI in 120 BC (Mayor, 2003) with it 
?????????????????????????????????????????????????????????????????????????????????
initial regulation for manufacture was brought in via the Apothecaries Wares, 
Drugs and Stuffs Act in 1540. The early to middle part of the last millennia was 
arguably the start of medical regulation in a way that has some similarity to 
modern times. For example, the Salerno Medical Edict issued by Fredrick II of 
Sicily (1240) stipulated that medicines must be prepared in a similar way, which 
can be linked to current manufacturing practices, whereby there is still this 
necessity, albeit to a much higher standard today. These previous regulatory 
practices also resulted in the further move of health care related technologies to 
being recorded in documents, via pharmacopoeias, and although pharmacopoeias 
are still used, there has been a wide range of new documentary systems for 
regulation. In essence, what can be gleaned from this practice was a need to 
record and at a relatively minor level monitor the production of medicines to 
ensure a basic level of quality in manufacture. In comparison to techniques and 
regulatory practices used in the present time, such practices were limited, but 
arguably created a very basic framework, from which modern regulatory systems 
for safety, efficacy and quality can be traced back to.  
 
In Britain, regulation has a history from at least the Tudor and Stuart periods 
(Ogus, 1992). It was not until the nineteenth century however that regulation 
??????????????????????????????????????????????????????????????????????????????????
for example public health (Craig, 2003). This rapidly expanded into goods and 
services bought and sold, where controls were introduced for prices, safety, and 
quality of products and services (Foreman-Peck and Millward, 1992). From the 
1930s, the number and scope of regulation increased, which increased again 
post-1945. While regulation increased, this ultimately led to many varied debates 
about how well regulation served society and different stakeholders (Lodge, 
2008), which is still on going.  
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As is perhaps not surprising, regulatory systems have changed substantially over 
the years, and earlier iterative forms often now only bear a weak resemblance to 
today. With advances in knowledge and technological and scientific innovation, 
particularly from the natural sciences, the ability and potential to manufacture 
higher technologically based products increased. These advancements created a 
greater ability to understand how products can negatively interact with biological 
entities such as humans. Examples of this were the 1937 poisoning of over one 
hundred people in the USA from the use of sulfanilamide elixir with diethylene 
glycol (Mann and Andrews, 2014), where the use of the diethylene glycol 
solvent had not undergone safety testing. This incident was a driving force for 
the introduction of The Federal Food, Drug and Cosmetic Act in the USA, which 
required market notification of new drugs starting in 1938. In countries lacking 
or with low-levels of regulation for contamination of medicines, deaths due to 
the presence of diethylene glycol have still been noted (Bogdanich and McClean, 
2000). Not surprisingly, contamination occurring during manufacturing practices 
has not been limited to diethylene glycol, as numerous other contamination 
incidents with different chemicals also took place over the past centuries 
(Thompson, Poms, Martin, 2012). Importantly, as knowledge into adverse effects 
from products increased, so did the ability to understand how they could harm 
humans, and particularly through biochemical damage. With this knowledge 
came further regulatory drivers to safeguard public health, coupled with trying to 
safeguard commercial innovative activity.  
 
A further critical milestone in the development of high technology health care 
regulation was the introduction of Thalidomide into the marketplace, which 
posed the greatest challenge to regulated medicines in the past century, and 
?????????????????????? ?????????????????????????????? ???? ??????????? ???????? 
(Friedrich, 2005). Simply, and disturbingly, the use of Thalidomide led to the 
death and deformation of foetuses and babies, from pregnant women using this 
product. The impact on the regulatory landscape from this disaster cannot be 
underestimated, as the fear of another such scandal is frequently discussed in 
many regulatory circles (Mann and Andrews, 2014). Since this disaster, there has 
been much regulatory movement to reduce the potential of another scandal, and 
with nanotechnology often being claimed to be poorly understood for health risks, 
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Thalidomide is frequently mentioned as a driver to avoid harm from 
nanotechnology products. In many ways, such statements are of course overly 
simplistic, but as will be shown throughout this study, there are very real 
potential risks from nanotechnology and nanoparticle products, which if not 
handled and regulated accordingly could easily dwarf the Thalidomide scandal. 
While numerous aspects have been raised in this section, the following section 
goes on to consider the paradigm of neo-liberal regulation in which 
nanotechnology and nanoparticle products exist within    
 
 
2.2.2. Neo-Liberal Regulation 
 
Over the past decades, and facilitated by paradigmatic shifts in regulation by the 
Thatcher government in 1979, the UK, moved closer towards neo-liberal 
regulation for technology based products. In practicality, this shift did not occur 
in the UK alone, as changes were also noted in numerous European States, and 
the USA. One of the most important goals of neo-liberal regulation was the 
reduction in state-based intervention in state economies. Technology companies, 
particularly those involved in high technology R&D, manufacture and sales, 
where regulatory obligations were arguably the most onerous, championed a 
major driving force for this change. It has been suggested that in the UK, the 
Thatcher government was sympathetic to industry, seeking to adjust the 
regulatory system to aid what has been considered the commercialisation of 
innovative products (Abraham and Lewis, 2002). Thus, changes were 
implemented towards enabling more rapid commercialisation, where products 
could be brought into the commercial arena and marketed more easily through 
lower regulatory barriers, reducing costs to these companies. This period has 
been a political attempt to reduce state intervention with the market place 
?????????????????????????????????????????????????????????????????????????????????????
consumer choice above the state as a form of collective decision-making??(Davis 
and Abraham, 2013: 137). According to Fisher (2009), this has been a process to 
liberalise medical markets, through relaxing regulations, and to reduce barriers to 
innovation and commercial exploitation of technologies. 
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Looking at the pharmaceutical industry as an insightful exemplar for neo-liberal 
shifts, moving towards neo-liberal regulation resulted in a several fold increase 
in products being brought to market. This raises many potential questions, but 
with two of the most pertinent being, (1) did this regulatory shift enable 
???????????????????????????????????????????????????????????????????????????????????
system impact on elements such as risk mitigation from potentially dangerous 
products?  Addressing decreasing regulatory burdens, it became possible for 
companies to rely on various sets of data for products already in the market place, 
????? ????????? ?? ????? ??? ?????? ???? ???????????? ???????????????????????? ??????? ?????
stimulating new product innovations, the R&D system became skewed by 
companies preferring easier routes to market, where they would reject innovative 
product design, on the basis that full-testing would still be required. 
Unfortunately, this has meant that much product R&D and commercialisation 
has had little benefit to society, and it could be argued that it has hindered novel 
drugs being discovered (Kaitlin and Di Masi, 2000). This is of course a 
somewhat sweeping statement, but one that I argue predominantly holds. Within 
this main R&D shift based on regulation, there are some benefits to society, such 
as potentially cheaper products, but there is still much to unpick and elucidate for 
how these structural regulatory shifts will go on to impact on product regulation 
in and outside of pharmaceutical drug production.  
 
Examining the second aspect of regulatory shift impacts on risk mitigation, it is 
worth highlighting that neo-?????????????????????????????????????????????ideology 
of innovation?? ???????et al, 2008: 40). Expanding on this, it has been further 
argued by Davis and Abraham (2013: 137) that: 
 
?neo-liberalism perpetuated the misleading ideology that innovation 
and public health benefit were as one and that, therefore, the goal of 
regulation should be to promote innovation per se, or at least that a 
??????? ?????? ??? ?????????? mechanisms should be given great 
emphasis based on expectations of health benefits?? 
 
Although caution should be taken from just drawing from the pharmaceutical 
sector, examination of other high technology health care related sectors such as 
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biologics and medical devices also indicate a similar problem, whereby a greater 
emphasis needs to be placed back on product safety and risk mitigation. 
Examining nanotechnology and nanoparticles, it would appear that there is a 
similar challenge, whereby rapid commercialisation has been encouraged for 
products. Drawing a similarity to the pharmaceutical sector, while on a technical 
point, many nanotechnology products are indeed innovative on the basis that 
there is something new and usually a nanomaterial, but it is often debatable 
whether adding nanomaterials to products enhances anything for society, or more 
the manufacturers.  
 
After examining the neo-liberal underpinnings in this section, the next section 
goes on to consider a critical aspect of neo-liberal regulation, that of risk.  
 
 
2.2.3. Regulating Risk 
 
Understanding and working with risk is an inherent part of neo-liberal regulation 
where products may go to market with variable assessments carried out on 
product safety. There is of a common perspective that regulation is inherently 
about controlling and where possible mitigating risks, spanning across many 
aspects of our lives (Rothstein, Huber and Gaskell, 2006). As stated by Baldwin, 
????? ???? ?????? ??????? ???? ?more formally, risk is usually defined as the 
probability of a particular event (or hazard) occurring and the consequent 
severity of the impact of that event??? ????????????? ?? ???????????? ???? ??? ??????
between risk and uncertainty, although in a common sense, they are often used 
interchangeably. Uncertainty is thus inherently difficult to measure, whereas risk 
???? ??? ????????? ????????? ??????? ????? ???????? ????? ??? ?????????? ????? ?????
????????????? ???????? ??? ?????? ???????? ????? ????????????? ???? ???? ??????????
Complicating risk is the element of uncertainty, where as in the case of 
nanotechnology, many aspects are at present unknowable, or at best difficult to 
measure and produce a risk assessment based on elements of risk uncertainty.  
 
Looking more broadly at risk, Beck (1999) has argued that we are now part of a 
????????????????????????????????????????????????????????????????????????????????
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???????????????????????????????????????????????????????????-active stance towards 
regulating their risk. The variety of risks arising particularly from high 
technology products has meant that states have implemented regulatory bodies 
?????????????????????????????????????????????????????????????????????????????????
risk, that might be unseen by those without high-level specific knowledge. 
Within this zeitgeist, problems have arisen, particularly for high-technology 
products over risk-?????? ????????? ?????????? ?????? ????? ??? ??????? ???? ??????????
While it is possible to accept that all products have an underlying level of risk 
attached to them, it seems strange to consider the use of a product that is unsafe. 
Healthcare products often straddle the safe-unsafe divide, where for example 
pharmaceutical drugs are not to be used without authorisation, to protect the 
public from potential harm. Thus we have products that by their nature may 
cause serious harm to a person, but yet, when weighed up against potential 
benefits, they should in principal have more to offer through benefit, than 
through harm. This concept is expanded on many times in this study for 
nanotechnology and nanoparticle products, where there is often a perceived level 
of risk, yet the products are sold. Perhaps most problematically for nanoparticle 
products are their unknowable nature, where current regulatory testing protocols 
often are incapable of detecting real harm.  
 
When considering the regulation of risk, it is easy to fall into the fallacy of not 
taking into account the human element and challenges associated with this aspect. 
In other words, no matter what risk regulation management practices are put into 
place, these are human ideas, constructions, and practices, which have their 
weaknesses within this area, and arguably their strengths too. For example, 
product stakeholders and consumers are all immersed in a sea of discourses 
where technology is framed differently, and an individual product technology 
may have to be negotiated for how risk is regulated and managed within this sea.  
 
Stepping beyond the discursive elements from wider conversations and media 
discussions about risk, is the requirement to assess and define risks, which 
themselves are still within the arena of the former discursive arena. While it may 
appear simple to suggest that the most severe risks most easily identifiable 
should be regulated as a matter of urgency, in practicality, this is not an easy 
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undertaking (Krimsky and Golding, 1992). Most pertinently, the question can be 
??????? ?????? ?????????? ??????? ???? ????? ??? ?????????????? ????????????????? ??? ????
easy to answer, and against low-level and slow to develop visible factors to 
???????????????????????????????????????????????????????????????????????????????????
data available, nobody could foresee the actuality of the problem (Brooks, 2007). 
Coupled with this is the difficulty of trying to discern when a risk might occur, as 
different environmental conditions, human interactions and product uses 
(intended and unintended) might also influence the categorisation of risk.  
 
Due to the small size of nanotechnology and nanoparticles, there is a potential 
that products might display voluntarily imposed risks and socially imposed risks. 
The former is a consequence of for example purchasing and using a product, 
where risk can be mitigated by the ???????????????????????????????????????????????
purchasing it. Socially imposed risks occur for example from a technology 
entering the environment, such as nanoparticles entering the water system from 
every day product usage. In this case, consumption choices will not necessarily 
reduce risks, and regulations must encompass both of these two aspects.  
 
According to Fischhoff et al (1978), a critical challenge facing risk studies is 
how to engage with risk, through perception, assessment, quantification, and a 
response should the need arise. All of these approaches work on a notional basis 
that the issue is often not about an event occurring in actuality, but more about 
other factors. These factors include, (1) technical perspectives, (2) economic 
perspectives, (3) psychological approaches, and (4) cultural theory (Gormley and 
Peters, 1992). Briefly, (1) technical approaches take a view to assessing the 
potential frequency of an event occurring over a given period of time, thus 
setting out a probability. This approach often also seeks to understand not only 
the probability of an event occurring, but often the social acceptability of the 
event, should it occur. Looking at (2) economic perspectives, comparisons 
between risks and benefits can be carried out, and has found particular favour in 
regulatory decision-making. Arguably, this is more subjective than the technical 
approach but is able to highlight many more factors in the complex mix of 
regulation. Moving onto consider (3) the psychological approach, draws out how 
individuals and groups perceive risk, and their preferences for their perceptions. 
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This area of risk assessment is open to examining wider socio-linguistic 
constructions, such as from the media, where a forerunner technology such as 
Thalidomide may be influencing current perceptions. Finally, (4) cultural theory 
suggests that individuals construct risk through cultural group biases, where they 
form attitudes for how to perceive a risk. Importantly, and while four aspects of 
risk have been discussed, it is likely that with such blunt segmentations, the 
reality is more complex and nuanced, but that these four areas can highlight 
different understandings of risk-laden products. Some of these aspects are given 
greater examination in chapter 5 for nanotechnology and nanoparticles.  
 
Moving on, the next section pulls together the current status of nanotechnology 
regulation, and is a pivotal foundation for building further knowledge throughout 
this study.  
 
 
2.2.4. The Current Status of Nanotechnology Regulation 
 
Concepts and practices associated with nanotechnology do not sit in isolation 
from previous and current product regulations. Thus, a brief regulatory glance 
back to how forerunner technologies have been regulated is carried out, to better 
understand the current state of nanotechnology regulation. Expanding on  Section 
2.2.1, an initial consideration is made of the forerunner technologies of 
microtechnology products and how they were and are regulated.  
 
When addressing nanotechnology, which is the technolog?? ??? ????? ??????? ????
????????????????? ??????? ????????????????????????????????? ?irst? And how was 
that regulated??? ??????????? ?????? ??????????? ??? ??? ?????????? ???? ??? ??????????
nanotechnology as being a simple downsizing of microtechnologies, where 
microtechnology exists between one thousand and one million times smaller than 
a metre and nanotechnology between one million and one billion times smaller 
than a metre. The way that microtechnology and nanotechnology products work 
are not necessarily the same, or by linear extension, as at the nanoscale, new 
physical properties are observed, which do not occur with microtechnology 
products. In other words, microtechnology products are miniaturised versions of 
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bulk scale products, with new capabilities but with similar physicalities. In 
practicality, this means that there is little difference between a larger object and a 
microscale object other than that of size. However, physical properties can vary 
substantially between the nanoscale and the micro/bulk scale. Thus, little was 
done to regulate microtechnology products as microtechnology products, and 
regulation was carried out through existing systems, as little concern was raised 
about any increased risk from producing a downsized technology class. This has 
remained the case until the present, and it is unlikely this will change any time 
soon, as only limited evidence exists for microtechnology toxicity (Simak, 2015).   
 
??????? ??? ??? ???????? ??????????????? ?????????? ???? ?????? ???? ????????????
effects may also lead to a much higher level of unknowable risk than any other 
set of products. This is compounded by the pervasive nature of 
commercialisation, with a high number of products already having gone to 
market. As nanotechnology matures and as the number of products containing 
nanomaterials available in the global market place increases, the debate 
concerning the necessity for nano-specific product regulation has become more 
intense (Bowman, 2010). This poses the question for how nanotechnology 
products are currently regulated. The simplest answer to this question is that, at 
present, they are regulated under current regulatory systems and not specifically 
as nanotechnology products. More simply, there is yet to be any adjustment to 
any regulation to specifically require adjustments to testing of materials or 
products based on them being nanoscale. In principal, this means that all 
nanotechnology products go through their regulatory journeys, with risk 
assessments and any other consideration being made as an equivalent to the 
micro or bulk scale. ????? ?? ??????????? ???????????? ????? ????? ????? ????????
requirement for companies engaged in nanotechnology commercialisation. This 
however may be an overly simplistic view. As although there may be no 
requirement, companies are free to engage in further regulatory procedures 
outside of any requirement, but there is ???????????????????????????????????????????
current regulation is one that is explored throughout this study, and while there 
has been a predominant exploration of a few commercial sectors and 
nanoparticle applications, it may well be the case that there is a limited like-for-
like between products. For example, if looking at pharmaceutical regulation, 
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there is a requirement for safety testing for new products, and nanoparticles 
would thus be examined under this system, albeit not specifically as 
nanoparticles. However, should silver nanoparticles be incorporated into socks, 
there would be limited scope for testing product safety from nanoparticles as 
nanoparticles or as part of the socks. Thus, there is much to examine in this study 
for the regulation of nanoparticles and nanotechnology products. 
 
After examining many aspects related to high technology regulation, the next 
section goes on to synthesise these findings in the summary.  
 
 
2.4. Summary 
 
This chapter has considered various aspects of the regulation of high technology, 
nanotechnology and nanoparticle products. Without going too wide to engage in 
already well-considered areas for high technology regulation, this chapter instead 
focussed on findings from what I considered the most pertinent extant literature 
for nanotechnology, and nanoparticles within a neo-liberalist framework. While, 
neo-liberal regulation certainly does not negate the importance of product safety, 
it can mean that there is a direct conflict between stakeholders on the one hand 
who seek to mitigate risk, and others who wish to pursue rapid 
commercialisation, with minimal regulatory barriers. In practicality, this means 
that this arena has to be negotiated, and perhaps like other areas of life, an equal 
balancing act is sought but rarely obtained. It is of course rather simplistic to 
construct current regulatory systems as being enthralled to commercial interests, 
although like with any statement, it would appear that there is some minor truth 
?????? ????????? ???? ???????? ?? ??????????? ????? ??? ????? ??????????? ??????????? ?????
products like Thalidomide, it would seem that many stakeholders are acutely 
aware of the risks from limited risk mitigation. Most challengingly however, is 
the potential to better regulate nanotechnology and nanoparticles. At present, 
?????? ??? ????? ????????? ??????????????? ???????????? ???? ????????? ????????ing 
discourses exist stating that nanotechnology should be specifically regulated, 
which is a view I share, and the opposite, whereby current regulations are 
constructed as being in essence fit-for-purpose to adequately capture the 
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phenomenon of nanotechnology. The latter view is one I disagree with on the 
basis of the physicality of these products. Importantly, while current data is 
???????? ???????? ???? ???? ??????? ?????? ????? ???????????????? ?? ???????? ??? ??? ???
sufficient to warrant a stronger stance towards regulating nanotechnology as a 
new collection of physical entities, at least where scientific data supports this 
claim. To expand on this more, the new chapter goes on to consider and examine 
nanotechnology and nanoparticles as physical entities.  
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Chapter 3. Nanotechnology and Nanoparticles 
 
 
3.1. Introduction 
 
????? ???????? ??? ???????? ??????? ??? ???? ????????? ????????? ?????? ????
nanotechnology and the product class of nanoparticles, from a scientific and 
socio-??????????? ?????????????? In this chapter there is a predominant focus on 
nanotechnology and nanoparticles as a collection of products, in which over one 
thousand six hundred nanotechnology products are currently sold into a global 
marketplace (CPI, 2014). While introducing nanotechnology, the main focus is 
towards nanoparticles, which are currently at the vanguard of nanotechnology 
commercialisation (Huber, 2004). By examining nanotechnology as well as 
nanoparticles, the link between the two areas can be highlighted where 
appropriate, while still honing in on specific aspects for nanoparticles where 
appropriate. As part of this examination, a consideration is also made of the 
different discourses surrounding nanoparticles and nanotechnology, in which 
regulators must navigate to understand the physical phenomenon of these 
products. Alongside these aspects, commercial drivers for nanotechnology R&D 
and commercialisation are drawn out to contextualise the importance of 
nanotechnology and nanoparticles to organisations (particularly businesses). 
Addressing these aspects, an examination is made of the history of 
nanotechnology, as well of the challenge of defining nanotechnology and 
nanoparticles, as well as the regulation of high technology phenomena. These 
themes, predominantly focussed towards nanotechnology and nanoparticles, have 
been worked to highlight the importance of the physicality of high technology 
products. Against a lack of physical contextualisation often displayed from 
extant literature within regulatory arenas for nanotechnology and nanoparticles, 
this is an important contribution, particularly with a major theme of this study 
being risk mitigation. As a starting point, and to create a historic 
contextualisation, the next section considers the history of nanotechnology.   
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3.2. The History of Nanotechnology 
 
The rapid growth of manufactured nanotechnology products is a relatively recent 
phenomenon. The creation of natural nanoscale entities has however existed for 
???????????????????? ???? ????????? ????? ??????????????? ???? ???????????materials. 
Nanotechnology has an origin based on the talk delivered by the physicist 
Richard Feynman (1959) called ????????? ??????? ??? ????? ??? ???? ???????. 
Although Feynman did not use the term nanotechnology at this point, the 
suggestion of nanoscale phenomena and potential products was given. From this 
inceptive discourse, i????????????????????????????????????-???????????????????????
by Norio Taniguchi, and until 1986 for the term nanotechnology to be 
popularised by ????? ?????????? ?????? ?Engines of Creation?. Advances in 
nanotechnology have arguably been techno-scientific in nature (Pirani and Varga, 
2008), where technical and scientific advances have jointly driven product 
advances (Kroto et al, 1985). Social contextualisation of these advances has been 
through a variety of cultural sources, such as the media, television, novels and 
commercial and legal discourse (Davies, 2011). 
 
While there is the potential to view ??????????????? ??? ??? ????????? ??????
collection of small products, this is an overly simplistic view. It certainly is the 
case that nanotechnology products can be viewed with current advanced 
instrumentation. However, before advanced instrumentation existed, 
nanotechnology products were often created as part of larger materials, but 
without the knowledge on the part of the manufacturer that these small-scale 
products existed. Put simply these constituent parts and materials were just too 
?????????????? and were part of larger scale materials. As an example, the oldest 
known example of nanomaterials usage is with nanoparticles in the Lycurgus 
Chalice (shown in Figure 3.1), which was made in the fourth century AD, 
currently held at the British Museum.  
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Figure 3.1.The Lycurgus Chalice (The Trustees of the British Museum, 2013)    
 
The Lycurgus Cup is an exemplar of products created without the explicit 
knowledge of nanoscale phenomena, but with the knowledge that some materials 
created physical properties of interest. Thus, the image of the Spartan lawmaker 
Lycurgus is embedded with nanoparticles, which produce enhanced colours from 
within the glass. When light is reflected from it, the glass appears green but when 
light is shone through it, the glass appears red. This colour change has been 
attributed to the gold, silver and copper nanoparticles that are dispersed in the 
glass. Importantly, in the pre-nanotechnology era, bulk scale materials were 
known to create desired effects, but knowledge of the nanoscale functionality 
was unknown.  
 
Looking at other examples of nanoparticles used throughout the pre-
nanotechnology era, the phenomenon can be found in ninth century AD pottery 
from the Mesopotamian era (Leonhardt, 2007). In these products, nanoparticles 
were used in the glaze on ceramic pottery (again without the explicit knowledge 
that these small scale entities existed). Such techniques were brought to Spain in 
medieval times, as Arabian culture spread, where it migrated to Italy, for use in 
Renaissance pottery (CPD, 2004). Stained glass windows are another example of 
nanoparticle incorporation into glass to enhance the perceived visual effect of a 
material. While it may appear that the use of nanomaterials prior to the 
Lycurgus	  cup	  with	  diffused	  light	   Lycurgus	  cup	  with	  focussed	  light	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nanotechnology era was limited to aesthetic appeal, this is not necessarily the 
case, as the use of carbon nanotubes (CNTs) were incorporated into Arabian 
swords to increase their strength (Reibold, 2006). From such simple beginnings, 
and as awareness of nanomaterials increased, and the desire to use them 
knowingly, so did the need for regulation, and rationales for regulation.  
 
To further understand the phenomena of nanotechnology and nanoparticles, and 
the mirror of language with the physicality of these entities with discourse, the 
following section considers defining nanotechnology and nanoparticles.  
 
 
3.3. Defining Nanotechnology and Nanoparticles 
 
Constructing useful and workable definitions is no small challenge and raises 
many challenges, for what is sought from this endeavour. Perhaps most 
????????????????????????????????????????????????????????????????????????????????????????
that others can follow to share meaning, and to engage with the physical and 
social world through. While definitions can be useful, when cons?????????????????
without clear demarcation points, confusion can reign, where meaning is not 
easily shared, and in effect reduces the value of the definition. With these aspects 
in mind, this section has sought to understand the construction and potential use 
of definitions of nanotechnology and nanoparticles, and how different 
stakeholders use them.  
 
To understand nanotechnology and nanoparticles, much discourse has focussed 
????????????????????????????????????????????se words into their root parts (Hull 
and Bowman, 2010). For example, nanotechnology is composed of two 
???????????????????????????? and ?technology??????????????????????????nano? and 
???????????? ???? ??????? ????? ??? ???????? ????? ???? ?????? ????? ??????? meaning 
??????? and in scientific arenas is commonly used to refer to a material with at 
least one dimension between 100 million times and one billion times smaller 
than a metre (× 10-7 to × 10-9), although for nanoparticles, all three dimensions 
are argued as needing to be within this scale. Examples of nanotechnology and 
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nanoparticle definitions are shown in Table 3.1 and Table 3.2 and highlight size 
as a predominant factor of definition.  
 
Number Definitions of Nanotechnology 
1 Nanotechnology is the creation of functional materials, devices and 
systems through control of matter on the nanometer length scale (1-100 
nm), and exploitation of novel phenomena and properties (physical, 
???????????????????????????????????????????? ????????????????????????CIRS, 
2013) 
2 The branch of engineering that deals with things smaller than 100 nm 
(especially with the manipulation of individual molecules) 
(hyperdictionary.com, 2015). 
3 The development and use of devices that have a size of only a few 
nanometres (Physics.about.com, 2015). 
4 The study of phenomena and manipulation of materials at atomic, 
molecular and macromolecular scales, where properties differ 
significantly from those at a larger scale (Royal Society of London, 2015). 
6 Nanotechnology is the understanding and control of matter at dimensions 
of roughly 1-100 nm, where unique phenomena enable novel applications 
(National Nanotechnology Initiative (NNI), 2015). 
7 ?Matter at dimensions between approximately 1 and 100 nanometers??
(Drexler, 2015). 
 
Table 3.1 Definitions of Nanotechnology.  
 
Examining the definitions shown in Table 3.1, there is a predominant focus on 
constructing nanotechnology as a size related phenomenon, no doubt linking 
these definitions to scientific constructions, which is shown when references are 
examined. Coupled with this is the often-framed requirement for materials or 
products to be related to an application potentially through commercial usage, 
with a frequent push that nanotechnology is by nature a scientific endeavour. 
These aspects are also predominantly found for nanoparticles, but with a 
??????????????????????????????????????????????????????????????????????????????
Table 3.2.  
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Number Definitions of Nanoparticles 
1 Ultrafine unit with dimensions measured in nanometers - billionths of a 
metre (Brittanica.com, 2015). 
2 A particle spanning 1-100 nm (diameter) (ISO (Wiley, 2013). 
3 An ultrafine particle whose length in 2 or 3 places is 1-100 nm (ASTM 
(Wiley, 2013). 
4 At least one side is in the nanoscale range (SCCP (Wiley, 2013)). 
5 A particle with diameter between 1 and 100 nm, or a fibre spanning the 
range 1-100 nm (NIOSH (Wiley, 2013). 
6 All the fields or diameters are in the nanoscale range (BSI (Wiley, 2013). 
 
Table 3.2 Definitions of Nanoparticles.   
 
As can be observed from Table 3.1 and Table 3.2 definitions of nanotechnology 
and nanoparticles often vary, which as argued by Fleischer, Jahnel and Seitz 
(2010) has in turn created numerous challenges for meaningful legal engagement 
with nanotechnology based on unclear definitions and meanings. Importantly, the 
word nano does not have any legal definition attached to it and there are 
arguments about the lexical (dictionary) definition. Coupled with multiple legal, 
scientific and social constructions of nano, much confusion has been created. 
Even though there is variation, attempts to draw on etymological meaning have 
also been confusing, as nano coming ?????????????means dwarf. At some level it 
is helpful to conclude it probably means something small or short, but any 
attempt to construct the phenomenon of nano to human size is ultimately 
unhelpful and misleading. More sense can be made if nano is linked to scientific 
size, which is predominantly the case in scientific discourse, but unfortunately is 
still linked to the word nanos as dwarf. The dwarf aspect should be dropped as 
adding no clearer understanding to the physical phenomena of nanotechnology 
and nanoparticles.  
 
Looking beyond the use of nano with nanotechnology and nanoparticles, it is 
interesting to note that the word technology has received much attention, but 
particle(s) very little. It is unclear why this is the case, but might be that 
nanotechnology is assumed to subsume nanoparticles, so if the technological 
definition of nanotechnology is determined, this can be extrapolated to 
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nanoparticles? To gain further understanding, it is worth looking at attempts to 
define technology, which can also often vary depending on the discipline, 
application or research paradigm. For example Glen (2014) utilised an 
etymological basis for technology by examining the root Greek words of techne 
and logia to mean, ?art, skill, cunning of hand? and the use of this art to solve a 
problem, respectively. Importantly, this approach has found much favour in 
academic discourse regarding this area, and suggests that technology is a process 
for making products. Thus nanoparticles are products with all three dimensions 
at the nanoscale, and more detailed consideration of a nanoparticle is not 
perceived as particularly relevant for a definition. As is shown in Section 2.4, 
this is misleading for the physicality of nanoparticles.  
 
The aspects of definition are pivotal for understanding nanotechnology and 
nanoparticles, particularly in legal discourse, where scientific constructions of 
these products are utilised to inform legal decision-making. A greater exploration 
of the challenge of definition is therefore considered in the following section.  
 
 
3.3.1. The Challenge of Definition 
 
The creation and use of definitions can be helpful for creating common meaning 
about all phenomena, with the need and challenges for achieving clarity of 
meaning arguably being even greater for high technology products. Definitions, 
thus act as language-based symbolic representations of reality, where 
demarcation points are drawn around phenomena to create shared meaning 
(Harris, 2003: 2007). Common understanding for nanotechnology through 
definition is important, as in comparison to many other disciplines, law more 
overtly relies on the possibility of determining discursive meanings, resulting in 
definitions becoming an important part of modern jurisprudence (Harris, 2007). 
While there has been much discourse regarding the use and production of 
definitions by law, arguably all definitions are ?wrong? but some are useful, and 
some certainly more useful than others. In other words, no definition can truly 
capture any part of the physical world, but it can capture enough as in the 
example of nanotechnology to be useful and aid in shared meaning and legal 
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discourse. At worst, definitions may fail to capture physical phenomena drawing 
poor demarcation points and misconstructing the physical world that hinders 
legal discourse and shared meaning.   
 
There are two main types of definition, which are the stipulative and common 
(lexical), with Mill (1884: 1) stating for both that:  
 
?The simplest and most correct notion of a Definition is, a 
proposition declaratory of the meaning of a word; namely, either the 
meaning which it bears in common acceptation, or that which the 
speaker or writer, for the particular purposes of his discourse, 
intends to annex it??? 
 
What Mill describes, ??? ????????? ???? ??? ???? ????????? definition, and can be 
considered a culturally relevant shared meaning from a certain point in time 
(Robinson, 1954: 35). Without getting drawn too deeply into linguistic debate, 
???? ??????? ??? ?lexical definition is used to report the meaning that a word 
already has in language?????????? 1988: 82). Stipulative definitions however are 
communicated and potentially explained before their contextual use. When 
considering the two approaches to definition, the questions can be asked, which 
should be selected? And why? For clarity and making sense of definitions, a 
common meaning should be used, unless there are reasons to move towards a 
stipulative definition. Looking at technical, scientific and legal definitions, they 
too should follow this rule. Importantly, it might appear that technical, scientific 
and legal areas are not common and thus should be considered stipulative, but 
this is not so. Commonality is only required inasmuch as it is common to a group 
of users, such as lawyers, or scientists. Thus new definitions can be created and 
enter common meaning, although it must be recognised that no claim is made to 
the way that individuals engage with common definitions, which can vary.  
 
Arguably the creation and use of any definition should be approached with 
linguistic reflexivity and an awareness of what has gone before, where shadows 
from other terms and definitions may be cast over what is currently being used. If 
this is not fully considered, misconstructions of physical reality may occur, 
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leading to unintended links to other words, meanings and definitions. Definitions 
for high technology products have suffered from this aspect, whereby individuals 
creating names and definitions have sought to capture the physical essence of the 
phenomenon being named. Nanotechnology is an exemplar of this approach, 
which has brought much linguistic ambiguity to understanding what is meant by 
the name. Unfortunately the linguistic sign (the name) of nanotechnology is not 
arbitrary and as such carries ????????????artefacts????eating a shadow for which the 
newly constructed definition operates within. Harris (2007: 18) commented on 
this aspect:  
 
?A word does not mean what it does because there is some hidden 
principle determining what meaning that particular sequence of 
sounds or letters must have. In principle, any form might have any 
meaning, and any meaning be expressed by any form????? 
 
To be able to communicate meaning in a common way, even bet???????????????
requires that a linguistic sign used be not unduly influenced by prior historic 
constructions. Nanotechnology suffers from this, which has led to much 
confusion over what nanotechnology means, not only within law, but science and 
the wider social world. This has arguably resulted in a lack of consensus over 
what is meant by nanotechnology. According to Brazell, (2012: 2) the term is ?????
? suited to the subject matter, while major uncertainties remain even as to the 
scientific understanding of the subject.?? ????????????????????????????????????????
the ability to use language to fully capture complex and opaque physical 
phenomena, there is as Wittgenstein (1961: 13) argued, ?? ?requirement that 
simple signs be possible [and] the requirement that signs be determinate?? ???
??????? ???????????? ??? ??????? ?how things are??? ???? ????? ?????? ??? ?? ????????????
that words and definitions be usable for arguably not only individuals and 
organisations within the field of law, but also for others outside of law who will 
seek clarity over meaning. As an example of this and drawing on the area of 
intellectual property (IP) law, if meaning is unclear, the patent holder ?may have 
to live with the uncertainty as to whether someone will dispute their claim at 
some point down the road? (Berger, 2007 [posted in Nanowerk May 11th]). 
Importantly, with nanoparticles existing within the shade of nanotechnology, any 
	  	  	   	  	  	  	  	  42	  
uncertainty with nanotechnology is potentially reflected onto the phenomenon of 
nanoparticles. To more fully explore wider constructions of the phenomenon of 
nanotechnology, and potential challenges for law, the following section considers 
wider socio-linguistic constructions of nanotechnology. 
 
 
3.3.2. Socio?Linguistic Constructions  
 
The confusion surrounding nanotechnology has in part been a consequence of the 
variety of common, scientific, and social meanings, which as argued by Boholm 
and Boholm (2012: 16) extend beyond a scientific definition of size, and has 
included the following constructions:    
 
?????Very small X, where X is an object that is small, for example, 
nanocar, an activity that is short, for example, nanosemester, or an 
activity involving small objects, for example nanoblog. In none of 
these cases is the relevant scale of description that of nano in the 
technical sense of billionth part;  
[2] Nanometre-sized X, where X is an object for example 
nanoparticle; 
[3] X operating at nanoscale, where X is an activity, process or agent, 
for example, nanoscience, nanoanalysis and nanoresearcher; and  
[4] Nanotechnological X, where X is an object resulting from some 
activity operating at the nanoscale but not necessarily itself 
nanometre sized. For example, nanoclothes ? which can often mean 
both nanometre sized and nanotechnological (containing for instance 
nanotubes)?.  
 
This example suggests that nano as a prefix or stand-alone word can mean a 
variety of different things in different social groups and disciplines and while it 
may predominantly mean small, does not necessarily have to be between one 
billion and one hundred million times smaller than a metre. It is not just the word 
nano that can be viewed in a wider socio-linguistic sense but also the word 
technology. As a brief example, while technology can be seen to be ushering in a 
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silver bullet to heal societal ills, it has also been perceived as unnatural, 
potentially catastrophic and generally damaging to mankind (Fischhoff et al, 
1978; Slovic, 1987, 1992). Negative views of nanotechnology have been affected 
for example by religious beliefs (Ho et al, 2010), which resulted in a lack of 
acceptance and even resistance to emerging technologies (Gaskell et al, 2004; 
Nisbet, 2005; Ho et al, 2008; Brossard et al, 2009).  
 
There have been a number of media studies that have described the concepts of 
nanotechnology, with varying opinions being put forward (Dudo et al, 2011). It 
is important to consider that extant studies highlight both positive and negative 
aspects of nanotechnology, with different social sources producing different 
opinions, and for example the natural sciences predominantly being positive 
(Kjølberg, 2009). If Europe as a whole is considered and compared to the USA, 
newspaper reporting in the USA has focussed on positive aspects, whilst Europe 
has shown a higher level of concern about potential negative affects of 
nanotechnology on society (Friedman and Egolf, 2005).  
 
Through discourse produced from the media and academic disciplines the 
discussion amongst different stakeholder groups including the discipline of law 
has increased (Simons et al, 2009). However, studies and opinion surveys have 
shown that while non-scientist familiarity of the term nanotechnology is 
increasing, the overall level of understanding and awareness of what 
nanotechnology is and its risks is still low (Schütz and Wiedemann, 2008; 
Simons et al, 2009; Priest et al, 2010). Problematically, ideas about what 
nanotechnology is, is within a sea of discourse produced from various cultural 
sources such as various science fiction (literary and film), and often as a vehicle 
to promote the harm that can be produced from the use of this technology. 
????????????????????????????????????????????? book By the Light of the Moon, 
which tells a story about nanomachines that devours humans. This can be 
coupled with ??????????????????????????????? 2003), which has become somewhat 
culturally embedded as the perceived consequence of poorly controlled and 
regulated nanotechnology i.e. all life is reduced to grey goo. Alternatively, 
nanotechnology has been promoted as a medical panacea, in productions such as 
????????????????????????????????????????mportant to acknowledge that knowledge 
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????? ??? ???????????? ??? ???? ??????????????? ??????????????????? ??????? ??????????????
having influenced the formation and use of knowledge held.  
 
The variety of socio-linguistic constructions of nanotechnology has the potential 
to create confusion for shared meaning for what nanotechnology is (although this 
is not to suggest that a singular view has to exist, but more a commonly and 
scientifically accepted view is dominant). For example and drawing on the 
thoughts of Berger (2007: 2) the variety of constructions potentially creates ?a 
sure recipe for conflicting terminology and a dispute over what is meant and 
intended?. The following section on a positive and negative nanotechnology 
discourse focuses on the challenges within scientific and technological arenas for 
producing clarity.  
 
 
3.3.3. Positive and Negative Discourses 
 
Nanotechnology exists in an ever-changing sea of discourse, and under a simple 
view can be segmented into positive and negative persuasive ??????????????????? 
be delivered. Importantly, there have been numerous promises made about 
nanotechnology, which impact on the way that nanotechnology is discussed, 
scientifically tested and casts a discursive shadow within which law must operate. 
With nanotechnology products entering and currently being sold into the 
marketplace, the issue of the promises of nanotechnology being used to fuel 
perceptions of these products, particularly as being the ??????? ??? ????? ??????
larger products, cannot simply be ignored. This section critically engages with 
the different lenses through which nanotechnology can be viewed, by looking at 
examples of products that are already within the marketplace from a discursive 
perspective. It is worth reiterating an earlier premise that although blunt 
segmentations of positive and negative discourses have been used for simplicity, 
in practicality, discursive life is rarely this simple, and as nanotechnology 
discourse is engaged with, this should be remembered.  
 
Discourse is the vehicle for the way in which legal actors interact and construct 
meaning with the social and physical world of nanotechnology. Through 
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discursive framing, discourses from the natural sciences and social spheres echo 
into the arena of law, where it is reconstructed. Using a reductionist approach to 
discourse enables its segmentation into three areas including micro, meso and 
macro, where all may influence each other. In many ways it is pertinent to regard 
the three segments as entangled with each other, and with it not always being 
possible to isolate the effect of the different segmentations from each another. An 
example of this is perhaps most clearly observed from macro discourse such as 
the use of certain narratives to promote nanotechnology. In this chapter, it is the 
promotion of nanotechnology as a vehicle towards societal good and bad, 
particularly with regard to law that is of interest. This is perceived as important 
due to the high use of language to promote nanotechnology, and the difficulty of 
finding discourse about nanotechnology that does not sit under the shadow of 
this promotion, even within law. The extensive claims made about 
nanotechnology are not the direct focus of this study, but more the interaction 
with law. It is important to recognise the discourse-laden system prevalent for 
promoting nanotechnology, particularly for claims for whether it will bring 
economic and health benefits, or alternatively the next cataclysm. Table 3.3 gives 
a brief examination of this aspect, by showing some prevalent linguistic vehicles 
??? ???????? ??????????????? ??? ??????? ???? ???? ????????????Although criticisms 
?????????????????? ??????????? ??????-????????? ???????? ??????????? ????????-based 
vehicles, it is important to recognise that where complex, opaque and ambiguous 
phenomena exist, this discursive stance can enable an easier view to be made 
(Weick, 1995). As might be expected, there is a continuous balancing act 
between simplification and constructions from law and science, and where 
ultimately discourses must be navigated and negotiated so that stakeholders can 
make sense of what is being said.  
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Linguistic 
Vehicle 
Quotation Promoting 
Meta-
narrative 
?Nanotechnology is a technology which has 
a huge potential in the development of 
health technologies a??????????? ?????????? 
(McHale, 2008: 377). 
Medical and Health 
Benefits. Framed as good.  
Scientism ?Nanotechnology is regarded as a new kind 
of science, in which considerable hope and 
promise is invested on the basis of predicted 
applications?? ?Macnaghten, Kearnes and 
Wynne, 2007: 132). 
A new technological future 
of certainty and a 
countering of public 
mistrust in science. Framed 
as good.  
Metaphor ??????????????????Small robots, nanobots or 
micro machines?? ?????? ???? ???????????
2009: 10).  
Nanotechnology as 
???????????????????????????????
scenario is considered it is 
bad. 
Story-
telling 
?In the medical context, the use of this 
technology was facilitated by the scanning 
tunnelling microscope which enabled 
scientists not only to see atoms but also 
painstakingly to move them around??
(McHale, 2008: 377). 
High technology 
manipulation of physical 
matter is framed as good, 
thus nanotechnology is 
good.  
 
Table 3.3. Overt Linguistic Themes Promoting Nanotechnology 
 
While demonstrating some of the linguistic vehicles used to promote 
nanotechnology, it must be acknowledged that nanotechnology is increasing in 
importance in the global economy and in the number of individuals employed in 
this area (ETUC, 2008). The number of commercialised products available for 
sale within business-to-business (B2B) and business-to-consumer (B2C) is also 
expected to grow, further adding to the need for more understood regulation and 
governance. Unfortunately there is the argument I would make that the examples 
in Table 3.3 are distortive in nature particularly for the physicality of 
nanotechnology, which often functions differently in comparison to the linguistic 
vehicles. With such distortive discourse, poorly capturing the physicality of 
nanotechnology products, it is worth raising questions of what is law engaging 
with? As surely as shown in these examples, it is not the physical existence of 
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Sub-­‐nanometre:	  	  i.e.	  particles	  and	  atoms	   Nanoscale	  (1	  ?	  100	  nm)	  i.e.	  nanoparticles	  	   Macroscale	  (>	  100	  nm)	  i.e.	  cells	  and	  animals	  
nanotechnology. To expand the discussion on the physicality of nanotechnology, 
the next section explores scientific/technological constructions.  
 
 
3.3.4. Scientific/Technological Constructions  
 
The lens used within scientific and technological constructions of 
nanotechnology predominantly frame nanotechnology as small products. Under 
this simple view, all nanotechnology products must have at least one of their 
three physical dimensions smaller than one hundred nanometres. Conceptually, a 
human hair has a diameter one thousand times larger than the upper limit for the 
nanoscale (Engelmann, 2011). At the bottom end of the nanoscale (Watson and 
Crick, 1953), the nanoscale is depicted within Figure 3.2, relating it to the atomic 
scale (below the nanoscale) and the macro/bulk scale (above the nanoscale):  
 
 
 
  
 
Figure 3.2. Diagrammatic representation of the nanoscale. This figure depicts how the 
nanoscale fits in with smaller and larger units of measure (Dean, 2014).  
 
Nanotechnology products are thus very small, and it can be difficult to 
conceptualise just how small, and what exactly the size-defined regime of one to 
one hundred nanometres really means. This challenge arguably echoes 
throughout the legal, commercial and scientific arenas as multiple individuals 
and organisations try to come to grips with the reality of size-related products, at 
a scale rarely dealt with. Putting this a different way, products have rarely been 
defined by size at this scale, at least in a way pivotal to their labelling. An 
example of this is a hypothetical virus, which is fifty nanometres in diameter and 
sitting firmly within the nanoscale region, yet receiving virtually no scientific or 
legal discourse about the size, with functionality being preferred.  
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Creating understanding at the nanoscale can become difficult, as while it can be 
argued that nanotechnological entities exist between one and one hundred 
nanometres (ISO, 2008), creating upper and lower size limits, other definitions 
such as by SCENIHR (2007b) argue that nanoscale entities have dimensions less 
than one hundred nanometres, and are silent on a lower size limit. SCENIHR 
(2007b) is more ambiguous by remaining silent on a lower size limit for what 
can be considered nanoscale. Likewise the ISO (2008) definition is also 
problematic, as it appears to suggest that all three dimensions should be within 
the nanoscale size range of one to one hundred nanometres, which under this 
blunt view would mean that only nanoparticles are nanoscale. To explore this 
aspect further, the three main categories of nanotechnology products are shown 
in Table 3.4.   
 
Nanoscale 
Dimensions 
Common Name Description 
1 Nanowires and 
nanotubes 
Carbon-based, single atom and cylindrically shaped. 
2 Thin-films Thin nanoscale sheets. 
3 Nanoparticles Often constructed as spheroidal shapes which 
although have all three dimensions within the 
nanoscale are confusingly described as zero-
dimension. 
 
Table 3.4. Dimensional Segmentations of Nanomaterials (Bala, 2014).  
 
Looking at Table 3.4 there are three main classes products/materials/entities 
constructed within the arena of nanotechnology. Unfortunately, the consideration 
of nanotechnology definitions has shown limited interest in engaging with these 
three distinct segmentations of products found within this area. This is a problem, 
as when the physicality of nanotechnology is considered, all products exist with 
dimensions in x-y-z axes, with this aspect not being discussed. Simple 
definitional constructions of being less than one hundred nanometres are 
unhelpful as it presupposes a level of technical knowledge to apply this 
definition. For example nanoparticles have all three dimensions less than one 
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hundred nanometres, but a thin-film may only have one dimension in this size, 
with the other two dimensions being up to metre scale or larger.  
 
Moving on to look more at the physicality of nanoparticles as a physical 
phenomenon, this aspect is considered in the following section, to create a 
platform of knowledge, to support an understanding of their use in commercial 
settings, which will facilitate a deeper knowledge of the challenges faced by law 
in such instances.  
 
 
3.4. Nanoparticles as a Physical Phenomenon 
 
Nanoparticles have received a growing interest from numerous stakeholder 
groups, including organisations, companies, and governments etc. Interest has 
not just focussed on commercial exploitation but how to regulate this collection 
of activities, and has included entities such as REACH (Registration, Evaluation, 
Authorisation and restriction of CHemicals), EPA (US Environmental Protection 
Agency), NIOSH National Institute of Occupational Safety and Health), ENPRA 
(Risk Assessment of Engineered Nanoparticles) and IOM (Institute of 
Occupational Medicine). I believe that central to any engagement from any legal 
entity is an understanding that nanoparticles are small clusters of atoms within a 
size range between one billion and one hundred million times smaller than a 
metre for each nanoparticle. It is of course recognised that wider socio-linguistic 
constructions also exist, but where possible they should be acknowledged and 
perceptually bracketed, to enable a more scientifically orientated lens to be used.  
 
Although singularly small, nanoparticle products can contain millions or billions 
of nanoparticles per product, and can display unique and novel characteristics, 
offering new product potentials. Within any product, it is also possible that 
nanoparticles will be trapped within a solid or gel, or free to move about in a 
liquid of gaseous form. All may have different implications for how stable 
nanoparticles are, how safe they are, and if they change their size and shape, 
whether they change their toxicity. Figure 3.3 shows different nanoparticles with 
varying sizes and shapes.  
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Figure 3.3. Nanoparticle images ? showing different sizes and shapes (Eastoe, 
Hollamby and Hudson, 2006: 10). In this study, nm refers to nanometres. 
 
As can be seen in Figure 3.3, there are a variety of physicalities of nanoparticles, 
and it must not be assumed that nanoparticles are all the same. This is perhaps 
one of the big challenges for law, which is how to engage with a product that 
contains millions of smaller entities, each with a potentially different functional 
activity. Using a hypothetical example, one nanoparticle in the product causes 
cancer, and another cures it. This is arguably a new challenge for law, which has 
never had to deal with this physical variety of functionalities within a product 
before. More than this though, and as will be explored in the following section 
3.4.1. ?????????????? ?????????? ???? ?????????? ?????????? ???? physical shape of 
nanoparticles may change, alongside their physical activities with other entities, 
such as humans, which presents further challenges for engaging with these 
products.  
 
Utilising a scientific lens, the physical characteristics of nanoparticles such as 
size, shape and chemical composition etc. are pivotal. Using this lens, and 
examining size first, nanoparticles are a material class with all three dimensions 
between one million and one billion times smaller than a metre per nanoparticle 
(El-Shall and Edelstein, 1996). Compositionally, nanoparticles can be inorganic 
(metals), organic (carbon-based) or a combination of both, with it being possible 
to produce nanoparticles through scientifically and engineering based biological, 
chemical or physical processes. They can either be in the solid, liquid or gaseous 
state, which means that although a nanoparticle is less than one hundred 
nanometres in all three dimensions, the product may well be larger. This is 
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particularly the case where nanoparticles are incorporated into larger scale 
products such as deodorants, drinks, bandages etc. with these aspects being more 
fully considered in the following chapters.  
 
To understand nanoparticle properties, it is important to understand the physical 
characteristics, which are split into the three dimensional features related to their 
x-y-z axes, as well as the crystal structure (atomic arrangement within the three 
axes). Perhaps not surprisingly, the ability to measure these features has 
increased with advancements of scientific understanding and capabilities of more 
advanced equipment. Many measurements however, still require high-levels of 
scientific expertise, have high-costs with laborious measurement routines, 
meaning there is no quick route to product knowledge. Problematically, and 
when measuring nanoparticles for their physical characteristics, it cannot be 
assumed that one nanoparticle is necessarily the same as the next, resulting in 
statistical distributions of different parameters. Part of the difficulty is that within 
any sample of nanoparticles, x percent may cause cancer, where y percent will 
not. Determining the nanoparticle characteristics that are harmful or in a different 
example can be hugely problematic, resulting in statistical techniques to correlate 
averaged data with health and safety or beneficial data (personal communication 
with Dean, 2011). This is a challenge for law, as parts of any sample may for 
example be toxic to humans, with current tests not being routinely carried out 
with prolonged exposure to the phenomenon. This aspect will be considered in 
greater detail, later in this study in section 5.3.2. More than this though has been 
an assumption within science and law that nanoparticles are a predominantly 
static collection of products and physical entities, when they are often not. The 
next section on nanoparticle stability and Ostwald Ripening therefore explores 
this in more detail.  
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3.4.1. Nanoparticle Stability and Ostwald Ripening 
 
Within studies examining nanoparticle law there has been a propensity to regard 
nanoparticles as stable and physically static products. This is not to say that there 
has not been much debate and scholarship about nanoparticles interacting with 
biological entities (Domingo-Espin et al, 2011) or the wider environment (Yon 
and Lead, 2008) but more that irrespective of these interactions, nanoparticles 
themselves tend not to change. While it is acknowledged that viewing 
nanoparticles as static products provides a simpler view of physical reality, it is 
not one that should go unchallenged. As a brief starting point, nanoparticles have 
the potential to either dissolve into smaller non-nanoscale molecular constituents 
or aggregate into larger non-nanoscale structures, which confronts the notion that 
it is always nanoscale products that are being discussed or regulated within law. 
This process known as Ostwald Ripening (Ostwald, 1896, 1897) occurs in a 
solvent (liquid surrounding the nanoparticles). This is where the distribution of 
mean particle size increases as a result of smaller nanoparticles dissolving and 
larger nanoparticles growing (Liu et al, 2007). According to Binion (2008: 19), 
???????????????????????????????????????????????????????????????????????????????????
about the long term affects of these particles if they have accumulated in the 
body or conglomerated into larger particles???????????????????? ????????????????
where nanoparticles are changing size and morphology but this is not being 
recognised or captured within regulatory systems.  
 
While it may appear that such discussions are more fitting for the natural 
sciences, I argue that since size is used as a main demarcation point for whether a 
product is nanoscale and within the arena of nanotechnology, law must engage 
with this aspect as well. The question of course becomes, how should law do so? 
And what might it achieve? These points are discussed throughout this study 
where perceived pertinent, but as a starting point, a closer look at the physicality 
of the production of nanoparticles is considered.    
 
The production of nanoparticles by all manufacturing processes results in a 
distribution in size and morphology of nanoparticles, with different results being 
observed depending on the techniques and materials used for production (Dana, 
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2012). Law has showed little interest in this area, and to reiterate has 
?????????????? ?????? ?? ??????? ????? ????????????????????? ???? ???????? ???? ????????
??????????????? At some level I would argue that this is a consequence from the 
natural sciences, where and potentially for ease, this issue is not particularly 
discussed, with a preferred view that product size and shape does not change. An 
engagement with the physicality and complexity of this aspect does not have to 
be an overly problematic issue for regulation, which from a regulatory 
????????????????????????????? ??? ???????????? ????? ???????????At present though 
and as explored in the following section, a paucity of scientific data is arguably 
holding back any real potential to understand the physicality of nanoparticles and 
nanotechnology.   
 
 
3.4.2. Paucity of Scientific Data 
 
With so much discourse focussing on nanotechnology and nanoparticles, it is 
perhaps most surprising that there has in actuality been very little scientific 
testing of nanoscale products for as?????? ????? ??? ??????? ??? ?? ?????? ???????
environment (Yon and Lead, 2008). Caution must be taken when examining this 
comment, as it is not that that there has not been scientific testing of nanoscale 
phenomena, but more that much testing has been carried out for phenomena 
observed in laboratories, which may not necessarily correlate to how products 
????? ??????? ??? ?? ?????? ?????? ????????????? More simply, while much 
examination of nanoscience is on going, and for example within university 
laboratories, this is often focussed on nanoscience as opposed to nanotechnology 
products. This is not just a university issue, but also more one where there is 
???????????????????? ??????????????? ?????????? ??????????????? ??? ????????? ???????
and faster to carry out than for complex products.  
 
Using a hypothetical example of silver nanoparticles. It is in principle relatively 
straightforward to measure the size distribution of silver nanoparticles and how 
??????? ????? ????? ???? ???????????? ??? ??????? ????????g that there is access to 
equipment, knowledge to carry out the test, and interpret and resource to do so. 
??????????????????????????????????????????????????????????????????????????????????
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there is little else to influence the testing. However and more problematic is any 
requirement to move to a more complex system, where for example the same 
silver nanoparticles are put into a silver bandage or into a more complex mixture. 
Examining the bandage scenario first, there is no reason to assume that the silver 
nanoparticles will remain the same size and shape if incorporated into a bandage. 
This means that the toxicity and efficacy can change and may continue to do so 
with exposure to different environmental conditions. This leads to the question, 
of what an initial test of size distribution and stability was meant to show? It is 
unlikely to mirror how the ??????????????????????????????? world? setting. Moving 
onto look at a more complex liquid solution, with added silver nanoparticles, 
measuring the nanoparticles may well become much harder with other 
constituents present potentially masking the size and stability of the 
nanoparticles.  
 
Fundamental to the challenge of collecting data is the ability to produce results 
that are meaningful for application as nanotechnology and nanoparticle products. 
When nanoparticles are added to other liquids, solids or gases, there is a great 
potential for their physical features to change, so even if they have been shown to 
be safe before the addition, it cannot be assumed they will still be safe after the 
addition. This raises an important question about whether current regulatory 
systems might be able to address and capture this aspect. Reiterating Chapter 2 
Section 2.2.4, there is no specific requirement to assess nanoparticles as separate 
entities under current regulatory frameworks. In practicality, this means that 
there is very little incentive for product manufacturers to engage in assessing 
nanoparticle aspects such as size, shape, toxicity etc. and certainly no recording 
mechanism stipulated. Of course, depending on the product sector and 
application, aspects such as toxicity may well be assessed, as part of a product, 
???? ????? ?????????? ??? ??????????? ??? ???????? ???? ???????? ?nanoparticles with a 
cuboidal shape, and x nanometres in diameter increase the likelihood of y 
pathogenic state???????? ????? ?????? ??? ?????????????? ?????????????????????????????
only is there a lack of incentive to carry out more fit-for-purpose testing, but an 
arguable lack of operators and equipment to do so.  
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Drawing all of the aspects discussed so far in this chapter together, the next 
section produces an over viewing summary.  
 
 
3.5. Summary 
 
This chapter has highlighted that nanotechnology is a pervasive collection of 
technology products, with nanoparticles having penetrated numerous commercial 
sectors. Physically, nanoparticles are generally considered as having all three 
physical dimensions below one hundred nm and above one nm, but with many 
shapes and crystal structures being displayed by different products. Even within 
the one to one hundred nm size range, there is a potential of a ninety nine nm 
size difference for each of the three dimensions. All of these factors can result in 
different physical properties, which can be desirable but also negatively 
perceived. Beyond the scientific construction of nanoparticles there are often 
????? ???? ???? ?????????? ????????? ???? ????????????? ?????????? ?????? ???? further 
complicate discourses for the regulation of nanoparticle products.  
 
At present, there has been a predominant regulatory stance to classify 
nanomaterials as being the same as their bulk (above nano-?????? ???????????????
This is a problematic approach as for example; a silver nanoparticle could in 
principle be regarded as having the same health and safety concerns as a silver 
microparticle (one thousand nm) or much larger material (above one thousand 
nm) or a much larger structure (i.e. two metres). Clearly the toxicity of these 
differently sized silver entities cannot be the same, but are often regarded so 
from the current regulatory perspective, and is perhaps a consequence of no 
specific nanotechnology regulation. Thus simplicity is attained, but is at the 
expense of a system that in many ways poorly captures the physicality of these 
materials.  
 
It is of course relatively easy to be drawn into arguments, which overly simplify 
the phenomena of nanoparticles and nanotechnology, and how and why (if at all) 
they should be regulated. Competing social, commercial, environmental and 
legal drivers all potentially compete with different views being espoused for how 
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to regulate nanotechnology. With this in mind and following on from the 
comments raised in this section about the safety of nanoparticle products, the 
following chapter considers the commercial world of nanotechnology and 
nanoparticles. 
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Chapter 4. The Commercial use of Nanotechnology and 
Nanoparticles 
 
 
4.1. Introduction 
 
????? ???????? ??? ???????? ??????? ??? ???? ????????? ?????????? ?How are 
nanotechnology and nanoproducts used commercially, and what are the 
perceived negative and positive attributes potentially influencing their 
regulation???In this chapter, how nanotechnology can be used in commercialised 
products for the benefit of society is examined with two main areas, including 
the commercial world of nanotechnology and the application of nanoparticles 
being addressed. While nanotechnology is used in a wide variety of products, it 
is not feasible to cover all areas, and instead three main areas of food, medicine, 
and cosmetics, have been chosen as exemplars. These areas were chosen as areas 
where much discourse has been produced from multiple disciplines including 
science and law. As such these areas are more amenable for study based on 
current discourses. The attraction for businesses and consumers to use 
nanotechnology are examined throughout this section. For example persuasive 
elements from these areas include promising treatments for illnesses that 
conventional medicine cannot fulfil, food in areas where there is poor soil and 
cosmetics that can aid in age prevention on the skin. As a starting point, the next 
section examines the commercial world of nanotechnology.  
 
 
4.2. The Commercial World of Nanotechnology 
 
Over the past decades, advancements in science and technology have facilitated 
and enabled the creation of nanotechnology materials, which have been used as 
products and have generated great interest from numerous commercial sectors. 
This has resulted in the accelerated intentional creation and use of 
nanotechnology-based materials as products. While, this intentional creation has 
enabled a greater variety of products and commercial applications it has in part 
been driven by a convergence of the sciences and engineering towards the 
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production of nanotechnology products, with biology, chemistry and physics 
producing a wide range of materials. This has allowed new products to be used in 
areas such as medicine, environmental technology, electronics and the material 
sciences, while creating numerous challenges for law to engage with via these 
advances through regulation. In many ways, commercial nanotechnology has 
only been realised by the development of equipment allowing the production and 
measurement of nanoscale materials, allowing scientists to relate nanoscale 
structure to their function (Gray, 2012). Before a more in depth focus is made 
towards nanotechnology and nanoparticles, a background to product 
commercialisation is laid out in the following section, to construct a backdrop 
contextualisation for technology products.  
 
 
4.2.1. Product Commercialisation  
 
Scientific product commercialisation arguably starts with an inception stage, 
with products being driven through R&D into commercialisation. Conceptually, 
there are two types of market strategies that are broadly recognised for new 
technology products (Nemet, 2009): market pull (Schmookler, 1966) and 
technology push (Schumpeter, 1939). Market pull strategies are focused towards 
??????????????????????????????????????????????????????????????????????????????, 
1966), and is based on the concept that companies find and exploit perceived 
market opportunities (Kirzner, 1979). Technology push strategies are based on 
the idea that innovations are pushed through R&D, into sales and into the market, 
without a proper consideration of whether it satisfies a current user need (Martin, 
1994). Wonglimpiyarat and Yuberk (2005) have argued that these two market 
strategies are the driving force in the process of innovation and 
commercialisation. Technology push has been perceived as being greater during 
the initial stage of technology adoption; with market pull increasing as 
technology push decreases (Mowery and Rosenberg, 1979).  While there are 
multiple business models (Lux Research Inc, 2004) for R&D and 
commercialisation, there are numerous business and legal aspects that interact 
and influence the R&D and commercialisation stages, such as regulatory 
requirements to determine for example product toxicity for nanoparticle 
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cosmetics (Lux Research Inc, 2004). Other business processes such as marketing 
and sales are beyond the remit of this research.  
 
With any technology is the potential to draw out the reasons for constructed 
business drivers, including why certain products are put through R&D and 
commercialised. As might be expected, there are many drivers for 
commercialisation including, development of novel intellectual property (IP) 
(Correa, 2000), novel product functionality (Institute of Medicine, 2009) meeting 
consumer demand (Scrinis et al, 2007) and generating return-on-investment 
(ROI) etc. As an example of customer demand for novel functionality, in the 
defence sector (Crow and Sarewitz, 2001: 83) stated:  
 
?Nanotechnology offers a dizzying range of potential benefits for 
military application. Recent history suggests that some of the earliest 
applications of nanotechnologies will come in the military realm, 
where specific needs are well articulated and a customer ? The 
Department of Defence already exists.? 
 
The statement by Crow and Sarewitz (2001) is an example of some of the 
challenges borne out of high technology product R&D and commercialisation. 
????? ?????????????? ??? ????????? ??? ?????????? ????? ???????? ????? ????????? benefit, 
where all is clearly communicated. Unfortunately, there is a propensity of 
business discourse to be embedded within high-levels of positively based 
technical and functionality orientated language (Rogers, 2003). This can be 
problematic for the language constructed around sectors where nanotechnology 
is engaged with, and can create difficulties for different actors, including those 
within law to make sense and understand the product/technology (Beard and 
Easingwood, 1996). These aspects and others can create challenges and barriers 
to commercialisation of nanotechnology. With the majority of companies being 
engaged in nanotechnology R&D and commercialisation being within speciality 
chemicals, pharmaceuticals and semi-conductors, which all have their own 
stylised use of language, this problem has been further compounded (Lux 
Research Inc, 2004).  
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Nanotechnology and nanoparticle products are often poorly understood and as 
argued by Parent et al (1996), one of the greatest barriers to technology 
commercialisation is the lack of understanding of the technology itself, as well as 
respective uncertainties of risk and HSE considerations. Pecora et al (2003) 
found there was a gap between those with an in depth comprehension of the 
fundamental concepts of nanotechnology and those who believe they have an 
understanding. Castellini et al (2007: 183) demonstrated this point: 
 
?It is often that people can actually comprehend that elements are the 
building blocks of all matter if they know basic facts about atoms. 
Additionally, it is assumed that people familiar with the metric 
system can truly conceptualise the minute size of the nanoscale 
regime. These erroneous assumptions lead to a disappointing lack of 
communication.? 
 
Although there can be challenges to understand technology products, there is 
often a high level of attraction, with both of these aspects being more thoroughly 
examined in the following section.  
 
 
4.2.2. The Attraction and Challenges of Nanotechnology 
 
Nanotechnology and nanoparticles have created much scientific and 
consequently regulatory interest. Scientific interest has predominantly focussed 
on technical aspects of nanotechnology and nanoparticles, particularly novel 
properties displayed at the nanoscale. As such these entities are becoming key 
components in a wide variety of disciplines including physics, biology, 
chemistry and engineering, for product areas including optical components, 
cosmetics, food technology, polymer science and medicine etc. (International 
Journal of Nanoparticles, 2014). Importantly, nanoparticles are one of the most 
widely used types of nanomaterial in nanotechnology, and can be used alone as a 
product or incorporated into other products to enhance functionality or pave the 
way to new IP. As mentioned previously, nanoparticles can be defined as  
?ultrafine particle[s]  with lengths in two or three dimensions [between]  1 
	  	  	   	  	  	  	  	  61	  
nanometre and 1??? ??????????? (ASTM 2456-06). They can be composed of 
organics (carbon), inorganics (metal) or organometallics (a mixture of carbon 
and metals) giving great flexibility in product design. Nanoparticles are popular 
product choices for businesses due to the relative increase in surface area, as the 
materials are down sized to the nanoscale. This reduces the internal volume, 
which can be the non-profitable part of the product, but increases the surface area, 
which is more reactive and thus more profitable (Cientifica, 2003). The different 
sizes and shapes of nanoparticles and the ability to incorporate or bind them to 
other products have made them desirable commercial propositions.  
 
The unique characteristics of materials at the nanoscale has allowed for a wide 
variety of commercial claims for numerous applications to be made. These 
claims routinely promise a range of health and environmental benefits, and 
construct nanotechnology as the next advancement of science, where great 
commercial benefits can be enjoyed by all (Gray, 2012). An example of this can 
be seen within therapeutics and medical diagnostics where nanotechnology has 
been discursively framed as ??????????????????????????????? (Bosso, 2012). Yet, 
the risks to human health and the environment have still not been fully assessed 
enough for a regulatory framework to be considered which would protect the 
ecosystem and humanity from unknown consequences (Wiesner and Bottero, 
2007). Munshi et al (2007: 437) argue that:  
 
?For many investors the promise of nanotechnology looks real 
enough to interest them, but what keeps them back is a coherent 
translation of the scientific jargon behind much of the research being 
carried out in laboratories.? 
 
It is not just a problem of language that is creating difficulties for 
nanotechnology but is also the uncertainty about the difference between 
nanoparticles and larger scale products. This is coupled with the unknown nature 
of nanoparticle products, particularly for toxicity, regulatory compliance, 
environmental impact, and how the longer-term commercial aspects of 
nanotechnology products (Oberdörster, Oberdörster and Oberdörster, 2005; Beer 
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et al, 2012). Aspects such as these can result in the rejection of emerging 
technologies if the perception of risk is too high (Sjoberg, 2000).  
 
After considering some of the challenges and attractions of nanoparticles, the 
next section goes on to examine nanoparticle applications through a few 
examples.  
 
 
4.3. Applications of Nanoparticles  
 
Applications for nanoparticle-based products are of great interest to companies 
engaged in commercialisation. With increasing investment in this area (Lux 
Research, 2007; Gray, 2012), the question can be asked, what applications are 
nanoparticles used in? Looking back over the past decade, much discourse has 
focussed on the pervasive nature of nanoproducts targeting numerous sectors 
(Gray, 2012). The global market place for nanoparticle-based products has for 
some years been valued at tens of billions of dollars (USA) per annum 
(Woodrow Wilson, 2008). Suggestions from the Woodrow Wilson International 
Centre (2011) argued that 1,288 companies were producing 1,317 products in 30 
countries. This is a potentially misleading figure as it failed to take into account 
that nanomaterials are commonly incorporated into other products, which 
potentially increases the number of nanoparticle products being sold (depending 
on how a nanoparticle or nanotechnology product is defined).  
 
At present, it is difficult to find a sector in which nanotechnology, and 
nanoparticle products are not being sold into. This means that in practicality, 
there are a large variety of product functionalities, being used in a variety of 
product and sector based applications. Looking at nanoparticles, their greatest 
advantage for product use is the ability to increase product surface areas, while 
decreasing the cost-inefficient internal volume. Against limited attempts to 
regulate nanoparticle products based on their physicality as nanoparticles, it has 
made this collection of technologies an attractive commercial proposition for 
numerous companies. The pervasive use of nanoparticle products is shown in 
Figure 4.1.  
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xxxxxx  
Figure 4.1. Commercial scale production of inorganic nanoparticles  (IJNT, 2009)  
 
Figure 4.1, shows a variety of nanoparticle applications within several main 
sectors where nanoparticles are currently being used, with further segmentations 
and product uses indicated throughout this diagram. As might be expected, based 
on the ???????????????????????????????????????????????????????????????????????????????
may well view nanoparticles differently, and potentially as a consequence of the 
regulatory landscape (albeit not nanoparticle specific), be willing to engage in 
R&D and commercialisation more or less than other sectors. Importantly though, 
the number of applications and products shown in Figure 4.1, which is not 
exhaustive demonstrates the pervasive nature of nanoparticles, and their wide 
usage across numerous sectors.  
 
The following section draws on the application of nanoparticles and discusses 
some of the promises of nanotechnology demonstrating why the differences from 
the bulk make nanoparticles a preferential choice.  
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4.4. Applicative Differences from the Bulk 
 
Fundamental to nanoparticle regulation, is the intended use of these products. As 
previously mentioned, there are a variety of applications that nanotechnology 
products are used in, with this number appearing to grow year-on-year. Drawing 
on numerous sectors and applications, this section pulls together some of the how 
and why of the differences between nanoscale products and their bulk larger 
scale counterparts. This is critical to understanding that nanoscale products are 
not simply a smaller version of large products, but are better viewed as highly 
nuanced, and often more complex counterparts, with many physical differences 
played out in their manufacture and life cycle.  
 
The physical difference between nanoscale and bulk scale products is not always 
fully recognised in regulatory discourses, but importantly, authors such as 
Hansen et al (2003) argue that it is vital that regulations support this notion. This 
is not only a perceptive issue that supports the commercialisation of novel 
technologies, but one often grounded in physical studies. While smaller entities 
than their bulk counterparts, nanoparticles can create cosmetic benefits for their 
users, such as no white marks on the user (Nasir, 2011: WP), but can also create 
less well-known toxicological reactions, which must also be taken into account 
in their regulation. Nanotechnology is thus a physically distinct set of products 
and processes, and not simply a downsizing of previous products. On the one 
hand it can enhance old products, or create new products, all with potentially 
fundamental differences in physicality for the manufacturer and consumer. 
 
Developing and using nanoparticle products has much potential for numerous 
sectors, often based on the smaller size of nanoparticles in comparison to larger 
products. The commercial interest in developing new tools, new products and 
commercially exploiting them can perhaps be best summed up by Josef Kokoni, 
the director of the Center for Advanced Food Technology at Rutgers University 
(nanowerk, 2012) who commented that ??????? ?????? ????? ???????????? ???? ??
program in nanotechnology or is looking to develop one?? From this statement it 
is clear that nanotechnology is no new trend, but a new series of industries and 
products opening up, often through radically different technologies. Looking 
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further at food to demonstrate this point, the question can be asked what is nano 
food? The multifaceted nature of market penetration from a diverse range of 
research and commercialisation activities suggests that there are numerous 
aspects to be considered, including nanotechnology being a new way of making 
food, incorporating things into already existing food, packaging food, and 
labelling food. The perception of nanotechnology food has been cited as pivotal 
for commercial success (Hansen et al, 2003), and as such it is vital that 
regulations support this notion. Like many other nanoparticle applications, there 
are many commercial drivers that have facilitated a growing interest in food 
nanotechnology, which in part can be linked to the potential size of the global 
market, large potential market shares for new market entrants, IP protection and 
perceived profitability etc. (Helmut Kaiser Consultancy, 2005).  
 
The creation and commercial exploitation of nano-food is receiving much 
governmental and regulatory interest, particularly in the commercial sale of such 
products. According to the National Science Foundation, nanoparticles are being 
used for a wide variety of purposes, and for instance, to increase the absorption 
of nutrients contained in food and beverages such as fruit juice, tea and wine 
(Joseph and Morrison, 2006). Technological innovation has resulted in research 
??????????????????????????????????????????????????e body delivering nutrients to 
cells as and when needed. This is a paradigm shift from current nutrient delivery, 
which is by the controlled uptake of an individual, predominantly ingesting 
nutrients. These on demand nutrients have been designed for use in nanoscale 
capsules that will be incorporated into food with the addition of nanoparticles to 
better enable absorption (Joseph and Morrison, 2006). 
 
For high technology and in particular nanotechnology regulation, there is always 
the potential that what appears as science fiction today may very well become 
science fact tomorrow, with regulation having to potentially address these 
changes. ?????? ????????????????????????????? ?????????????Engines of Creation???
much of the focus of nanotechnology has been geared towards healing humans, 
but has at times been framed in science fiction terms rather than science fact 
(Davies, 2011). Health related nanotechnology exists within this paradigm, 
which can create opacity and challenges for non-technical specialists to engage 
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meaningfully with nanotechnology and the rapidity of change. Nanotechnology 
related to health creates even greater confusion due to a prerequisite for legal 
actors to not only engage with nanotechnology but with the complex areas of 
medicine and health, which also have their own specific discourses, meanings 
and regulation. 	  
 
With many socio-economic drivers for reducing disease and increasing public 
health, many countries are turning to the potential of nanoparticles and in a wider 
sense nanotechnology to reduce infections and to heal disease states, particularly 
in humans (Nanomedicine, 2012). Within the push for eradicating and limiting 
disease is the internal pressure within manufacturing companies for novel 
products to be commercialised that produce a high return-on-investment for the 
developing company (Nanomedicine, 2012).  
 
One of the many beneficial ways that nanoparticles are being applied is in the 
medical field, leading to novel means of imaging living systems and of 
delivering therapy (Provenzale and Silva, 2009).  Much of this research is 
focused on methods for imaging central nervous system functions and disease 
states. In addition to innovative forms of imaging, other therapeutic uses of 
nanoparticles include, drug delivery systems, neuroprotection devices, and 
methods for tissue regeneration. Research teams around the world are developing 
nanoparticles, which can be used in many ways to detect and treat different 
forms of cancer (Provenzale and Silva, 2009).  An example of this is gold 
nanoparticles being used to target brain tumours with the advantage of being able 
to cross the blood brain barrier and be target specific (Jain et al, 2012).	  
 
At present there are numerous health related and skin protecting agents, which 
utilise nanoparticles. Most simply they are a relatively inexpensive and simple 
???? ??? ??????? ???? ???????? ????? ????? ????????? ??????????? (Dana, 2012). 
Demonstrative of this point, the use of nanoparticles in suntan creams can be 
considered (Nasir, 2011: WP): 
 
?While widespread use of this technology is currently under 
evaluation, I think one of the main benefits of nanoparticles used in 
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sunscreens will be that the particles can fit into all the nooks and 
crannies of the skin, packing more protection and more even 
????????? ??? ???? ??????? ???????? ????? ??????????? ??????????????????
sunscreen formulations using nanoparticles may be more 
cosmetically appealing and seem to vanish when applied, consumers 
may be more inclined to use them on a regular basis.? 
 
In the arena of cosmetics, and in particular for numerous pharmaceutical and 
anti-aging products, nanoparticles have been seen to play an important role by 
delivering active ingredients to the skin by using time release application and 
patch delivery systems using nanospheres and nanoparticles. Thus, there is a 
cross over from drug delivery systems based on nanoparticles and cosmetics, 
which enables large companies to leverage their expertise in other areas and 
increase their exploitation of knowledge across products.   
 
According to Kaur and Agrawal, (2012) nanoparticles have triggered a 
?revolution? so that ??????????????????????????????????????????????????????????????
??? ??????????? ?????????????? ??? ????????? ???????????? By combining patented 
??????????????????????????????????????????????????????????????????????????????????
of fine cosmetics, a new type of product ???????????????? is set to bridge the gap 
in the market between cosmetics that ?????????????????????? and pharmaceuticals 
that ???????????????? The Freedonia Group Inc. Cleveland Ohio claim that there 
??? ????? ?? ?????? ??????? ???? ?????? ????????????????? ??? ???????? ?????????
appearance, that these products are projected to increase by approximately 12 
percent per year. This would make cosmeceuticals a dynamic sector in the 
personal care and cosmetic industry (Kaur and Agrawal, 2012). 
 
Finally, after the examination of different aspects and areas within this section, 
the next section, the summary draws this chapter together.  
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4.5. Summary  
 
This chapter has examined the use of nanoparticles in the commercial world of 
nanotechnology. Drawing on a collection of perceived benefits and challenges to 
companies in this area, a spectrum covering the drivers and difficulties for 
commercial activities have been explicated. This has been alongside an 
exploration of the applications and the commercial value of nanoparticles, as 
well as highlighting specific risks that will need to be addressed through 
regulation. Importantly, while the benefits and risks can at times be clear, yet 
??????? ???? ??????????????????????????????? ??????????? ???????????????? ????????????
collection of products is argued against as unhelpful.  
 
As argued in this chapter, there are clear commercial and social benefits for 
product commercialisation utilising nanoparticle-based technologies. While these 
benefits can routinely be drawn on to argue for a regulatory status quo to be 
maintained, this misses out much of the risk, and potential need to insure these 
products. Against a backdrop of uncertainty and what is frequently a low-level of 
knowledge about how nanoparticle products will act in the short, medium and 
long-term, the following chapter goes on to look at nanoparticle risk and 
insurance, which is a critical and inherently important aspect of nanoparticle 
commercialisation, and potentially regulation.  
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Chapter 5. Nanoparticle Risk and Insurance 
 
 
5.1. Introduction. 
 
????? ???????? ??? ???????? ??????? ??? ???? ????????? ????????? ????? ???? ?????????????
products perceived from a risk perspective, and how does this influence their 
??????????? The aim of this chapter is to examine risk and insurance for 
nanoparticles and in a wider context nanotechnology. These aspects are 
considered against a backdrop of the complexities of high technology products 
including the opaque arena of nanoparticles, where there is often much 
uncertainty and confusion over product physicality, in turn impeding decision-
making. Within this area, there is much debate regarding nanoparticle risk and 
insurance, particularly linked to inherent product uncertainties. While it is 
accepted that unknown and unregulated risk may influence and impact on the 
risk assessment and insurance of all high technology products, this chapter 
highlights why this is even more problematic for nanoparticles examining 
perceived pertinent risk management strategies as well as the precautionary 
principle, to assess their perceived effectiveness for nanoparticles as a collection 
of products, as opposed to being a single-entity. The future of these technologies 
as ever changing products is considered for risk and insurance. Section 5.3 
specifically addresses four regulatory issues raised from insuring products 
containing nanoparticles. The first issue to be considered will be the uncertainty 
of whether typical insurance policies currently do cover the risks from 
nanoparticles. The second issue is the risk that insurers might begin to withdraw 
cover from activities such as manufacturing or selling products that incorporate 
or are based on nanoparticles, and thus if the availability of insurance becomes a 
problem, how this might be addressed. The third issue is whether manufacturers 
are choosing to acquire sufficient insurance cover, assuming it is available, and if 
not, whether we should regulate for manufacturers to do so and the fourth issue is 
the challenge of insuring nanoparticle products.  
  
As a starting point to this chapter, the following section examines risk.   
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5.2. Risk  
 
To set up the consideration of nanoparticle and nanotechnology risk, this section 
sets out to briefly overview risk as a perceptual lens and practice. The term risk 
is commonly used in many disciplines, and in particular law and business to 
construct and describe realities that have known/unknown and 
expected/unexpected outcomes, with this aspect being engaged with more in 
Section 2.2.2. A predominantly negative lens is often used to categorise risk as 
being undesirable, which has led to numerous driving factors to understand and 
minimise risk. As an example of risk as a negative, Ball (2003) defined risk as 
??????? ?a situation involving exposure to danger??? ???????????? ????? the 
predominant view of risk is negative, risk can also provide beneficial but 
potentially unexpected results i.e. serendipitous business outcomes. It is however 
the negative aspects of risk that is pertinent to this study, as this is predominantly 
the lens used for legally examining risk, to mitigate this aspect (Marchant et al, 
2008).  
 
Risk management has received great interest from multiple disciplines including 
law, with numerous approaches being taken to examine, understand and mitigate 
risk. While various approaches to risk have been taken in different academic 
disciplines, law has been particularly active with regard to high technology 
products. Throughout this section, concepts within traditional risk management 
are considered, alongside whether they can be considered fit-for-purpose for 
complex and opaque high technology products. The traditional model of risk is 
predominantly based within a framework of cost-benefit analysis, where the risks 
of a product are weighed up against the precautionary principle. Simply, costs 
and benefits are considered against each other and within the shade of the 
precautionary principle, which promotes the view of being ???????? ????? ?????
??????? Models such as the cost-benefit model (neweconomy, 2015), have the 
advantage of potentially being relatively simple to facilitate decision-making, but 
can be ?????????????????????????????????????????????nuts and bolts???????????????? 
 
High technology products are arguably more difficult for risk management, 
which must be negotiated by all parties engaged with these products. This is 
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based upon different stakeholders and for instance, R&D companies, sales 
companies, buying companies, legal actors and insurers etc. having different 
levels of knowledge, using different styles of discourse and language to engage 
with products not easily understood. All of the decision-making processes 
required for risk management are against a backdrop of wider perceptions of 
high technology product risks, such as nanotechnology being constructed as a 
general panacea (Papazoglov and Parthasarathy, 2007) and at the same time 
being the greatest risk the world has ever faced (???????? 2007). Of pivotal 
importance to the ability to manage risk is the ability to understand what 
nanoparticles are as a product class, how they work, and how they are the 
same/different to other products, which have already undergone risk 
management. These aspects all feed into the ability for companies to make 
marketing claims about products, minimise their liability and communicate to the 
market and various stakeholders about products directly and through labelling. 
While all of these factors are important, it is how law views them that is of 
interest to this study. 
 
As a backdrop to risk, and in particular high technology products, the nature of 
commercialisation has risk weaved throughout it (2020 Science, 2012). Hodge et 
al (2010) has argued that risk is inherent throughout business practice, 
particularly product development and commercialisation, which thus necessitates 
involvement from law. Areas that law may engage with are shown in Table 5.1.  
 
Business Activity Description 
Breaching internal 
self-regulation 
Carrying out activities that breach internal guidelines and 
exposing the company to risk.  
Breaching network-
regulation 
Carrying out activities that breach network guidelines and 
????????????????????????????????????????????????????????????? 
Breaching 
governmental 
regulation 
Carrying out activities that breach governmental regulation, 
such as failing to disclose product toxicity, and exposing the 
???????????? ???????? ??? ??????? ????? ?? ??????????? ???
regulatory bodies.  
Competitor action Action from competitor companies or networks that result in 
known or unknown risks to a company.  
Table 5.1. Business practice, law and risk.  
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Although demonstrative of the areas that law may engage with, Table 5.1. has 
not produced a totality of legal risk but more highlighted key macro areas. 
Within these or other macro areas, is the need for law to dig deeper into the 
minutiae of business practice, particularly for high technology. Importantly, there 
??? ???? ???????????? ?? ???????? ??????? ???? ???? ??????????? ??? ???? ????? ?????
technology product risk, as the notion of risk often changes. Drawing on the 
thoughts of Slovic (2011: WP), ?man learns by trial, error and subsequent 
corrective actions to arrive at a reasonably optimal balance between the benefit 
from an activity and its risk???While this might be considered a luxury, as 
disasters such as Thalidomide are to be avoided, in practicality, no matter what 
the system used, the practicality of risk regulation is that it is an adaptive and 
evolving process.  
 
Within any strategy that ??????????? ??? ????????? ??? ???????????????????? ?????? ?????
balancing act that must take place between perceived risk and benefit, which 
must be negotiated. This may flow into what factors need to be mitigated as well 
as what is acceptable from many different perspectives by the introduction of 
new policies to mitigate the risk and advance the commercialisation of perceived 
beneficial technologies (Starr, 1972). Looking at this further, Starr (1972) 
claimed that, (1) the public seems willing to accept voluntary risks roughly 1,000 
times greater than involuntary risks at a given level of benefit, (2) the 
acceptability of a risk is roughly proportional to the real and perceived benefits, 
and (3) the acceptable level of risk is inversely related to the number of persons 
participating in an activity. This is potentially a complex mixture of factors, but 
does suggest that knowing the acceptable risk level for each activity is 
paramount, as is the perceived risk. Eliminating uncertainty may also mean 
eliminating the technology and losing the benefits or by trying to eliminate the 
uncertainty, the technology could be altered. Thus some risk may at the same 
time be inevitable and also desirable (Slovic, 2011) as a consequence of 
commercialisation. These may be important considerations for nanotechnology 
products, particularly in light of the confusion and uncertainty currently 
surrounding them.  
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Cost has been linked to high technology product decision-making when making 
risk assessments (HSE, 2001). Slovic (2011) has claimed that there are four main 
areas when carrying out risk analysis on a new technology, which include, if; (1) 
the benefits outweigh the cost; (2) the risks are no greater than those of currently 
tolerated technologies with equivalent benefit; (3) the public accept the risks; and 
(4) the risks are no greater than those accompanying the development of the 
human species. Within this range of requirements is the backdrop of public 
perceptions that are constructed for new products, often based within the shadow 
of prior and potentially unrelated products, which can either facilitate the sale 
and adoption of new products, or negatively stigmatise them. Regulators are 
often keen to keep abreast of public perceptions for risk with claims being made 
????? ????????? ??????????? ??????? ??? ?????-?????? ?????????? ??? ??????????? ??????????
risks (Abraham and Lewis, 1999). While this is perhaps an over-statement, there 
is a need for regulators to be perceived as being attentive to current social 
perceptions of products.  
 
Importantly, the actual risk can be very different from the perceived risk, and an 
example of this is bovine milk containing bovine growth hormone (BGH), which 
was rejected due to negative public perception of the product. This led to 
numerous supermarket chains refusing to buy or sell any milk products from 
cows treated with BGH (Elmer-Dewitt, 1994). Importantly, even though WHO 
(1999), FDA (1999), and NIH (1990), all stated that meat and milk from BGH 
cows were safe, issues were still raised about the dangers of BGH, including to 
animal welfare (Doohoo, 2003) and human health (Collier and Bauman, 2014). 
This makes risk management particularly problematic, when there are competing 
narratives about the risk of products, which is arguably compounded by the 
challenges of understanding high technology and the language used. 
Speculatively, it is worth considering that as the technology becomes more 
opaque and complex as in the case of nanotechnology, the more difficulty there 
is in predicting the risks. Nanoparticles are well known for being ambiguous and 
poorly understood technologies, and the next section explores nanotechnology 
risk to explicitly consider perceived and physical risks from nanoparticles.  
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5.2.1. Nanotechnology Risk  
 
Nanotechnology is a highly pervasive collection of technologies, with it having 
been speculated that there are over 116,000 products within the global 
marketplace (CPI, 2014). With this number being expected to increase there is a 
clear driver to more deeply understand nanotechnology and nanoparticle risk, as 
well as how to manage and regulate this risk. According to Marchant et al, 
(2008: 3) ???????????????? ????????? ????? ??? ?????????????? ?????????? ???? ???
?????????????????????????????????????????????. Perhaps most problematically is 
the notion that ?????????????????????????????????? about nanoparticle products 
and nanotechnology. While speculative offerings can be produced, little 
information is grounded within scientific testing, hindering test-driven 
knowledge. Even though there are multiple shortcomings, Table 5.2 details some 
of the key perceived nanoparticle risks.  
 
Nanoparticle Risk Examination 
Size. Arguably the perceptive lens of risk changed with nano, and 
raised small size as risk-laden. Prior technologies such as 
????????? ??? ???????? ???? ???????? ???? ????? ???? ????? ?????
narrative.  
Distribution of 
nanoscale 
phenomena. 
?????? ??? ?? ???????????????????? that nanoparticles are all the 
same size and shape etc. This is not the case, and it is 
possible that a variety of sizes and shapes of nanoparticle 
products may have their own toxicities. Little is being done 
to address this issue.  
Socio-cultural 
discourse. 
???????? ??????????? ???????? ??? ????????? ??????? ???? ??????
stories about nanoparticles. Similar technologies, such as 
GMO have faced the same challenge. This issue sits in and 
outside of law and is arguably the most challenging aspect.  
Definition. Nanotechnology suffers from a lack of legal definition, 
particularly for whether it is an incorporated material into a 
larger product, it is a nano-entity on a larger product etc.  
 
Table 5.2. Nanoparticle risk (Marchant et al, 2008: 3) 
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Within the multitude of Risk management strategies are traditional risk 
management principles, which include acceptable risk, risk analyses, and a 
feasibility aspect often known as best available technology, which includes the 
precautionary principle (Grunwald, 2008). An argument has been made that 
these strategies are potentially inadequate for high technology products (Phoenix 
and Treder, 2003), with suggestions that new strategies are needed.  
 
The perception of nanotechnology is an important issue particularly when 
assessing risk. Satterfield et al (2009: 752-758) stated that it is essential that 
?????????? ??????? ???????????????????????????????????????be critically examined 
?????????????????????????????. Public perception may jeopardise the development 
of nanotechnology as demonstrated with GMO, recombinant DNA technology 
and nuclear power. Sheetz et al, (2005: 335) states ??????? ??? ???? ?????????
challenges facing nanotechnology is avoiding a backlash from the public that 
slows or even halts the progress of research and development?? The ways that 
individuals engage with risk is however complex and is shown in Table 5.3.  
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Vehicle What it is and how it works 
Heuristics  ?????????????????????????????????????Heuristics serve people well in 
many circumstances, but they also create vulnerabilities to the 
predations of advertisers, political spin doctors, trial attorneys and 
ordinary con artists?????????????, 2003: 1165). 
Heuristics 
(Affect) 
The ???????? heuristic is most applicable for nanotechnology and 
????????????????????????????????????????????????????????????????????????
or negative feelings when confronted with a certain word, concept or 
?????? ?????????? (Mandel, 2005: 161). If an individual perceives 
benefits to a technology, the risks of that technology are believed to be 
low, which is conversely true for high-risk technology (Slovic, 2000). 
Heuristics 
(Availability) 
????? ????????????? ?????????? ????????? ???? ??????? ???????? ??? ??????
people assume that events more easily recalled are more likely to 
recur? (Sylvester and Lohr, 2005; in Marchant et al, 2008: 18). If an 
individual recalls a memory linked to harm, they will be predisposed 
towards the over estimation of the probability that it will recur.  
Temporality 
 
The risk of an event is coloured by when it occurred. Something fresh 
??????? ?????????????????????????????????????????? 
Stigmatisation 
 
Media coverage and discourse as well as stakeholder communication 
can create an imbalance of information i.e. ?????????????????? ??? ???? ??
far-reaching effect beyond perception of risk attached to a technology 
(Slovic, 2000). As Sunstein (2003b: ????? ???????? ? ?representative 
anecdotes and gripping examples can move rapidly from one person 
to another. Once several people start to take an example as probative, 
many people may come to be influenced by their opinion, giving rise 
??? ???????? ???????????? ???????? ????????????? ????? ??? ??????????? ???
certain media and new technologies???? 
 
Table 5.3. Ways We Engage with Risk.   
 
While this study is embedded within a legal paradigm, it is important to engage 
with the driving social forces for the way that nanotechnology risks are perceived 
as shown in Table 5.3. This may be critical for nanotechnology, as it has become 
susceptible to cascade effects from these social aspects, which negatively 
impacted prior technologies such as GMOs. Against a backdrop where some 
believe that ???????????? ??????????? ??? ???????? ??????? ????? ??????????? ?????????
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and the climate necessary for product?????????????????????????? (Mandel, 2005: 
117), is a requirement for risk management to deal with this aspect. Without 
critical engagement with this area, the negative publicity surrounding 
nanotechnology, may well create a bleak outlook due to the over estimated 
probability of risk. Yet this bleak picture is not the only way forward for 
nanotechnology. The heuristic processes have the potential to over estimate the 
risks but it is possible that the benefits are seen to outweigh any risk. This is 
because ??????????? attitudes could also create perceptions of desirable benefits 
produced by ?????????????? cascades. This reasoning could offset any reasoning 
that is risk based. It is not known at this stage whether the risks of 
nanotechnology outweigh the benefits (Sheetz et al, 2006). It is necessary 
therefore for action to be taken to reassure the stakeholders, individuals and 
organisations in some form. This can be challenging though when the wider 
aspects of prior high technology commercialisation is considered, particularly the 
more problematic technologies. Thus, the following section considers prior 
technologies and nanotechnology risks to explore this aspect further.  
 
 
5.2.2. Prior Technologies and Nanotechnology Risks - Asbestos 
 
The commercialisation of prior high technology products has resulted in multiple 
??????????? ?????? ????????? ???????? ????? ??????? ??? ??????? ???? ????? ??? ??????
echoed into the launch of new technology products. Thus nanotechnology and 
nanoparticle products exist in a sea of discourse, where reasons for framing a 
product as safe or risk-laden are to varying degrees rational. In this section, 
asbestos is considered as an exemplar of a material class widely used in many 
technolo????? ????? ???? ??? ??????????? ?????????? ?????? ???????? ?? more understood 
physical risks.  
 
Asbestos is a naturally occurring crystalline fibrous silicate material, mainly used 
in heat insulation among other areas, which is frequently highlighted ??? ??????
????????????????????????????????????????????et al, 2008). At present asbestos 
is known to cause disease states (asbestosis) and is the main cause of malignant 
mesothelioma cancer in humans (asbestosvictimadvice, 2013). Problematically 
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for determining adverse effects, it has a long latency period but once manifested 
death can often occur within a year (UNESCO, 2006). Health experts from the 
EU predict that deaths from mesothelioma, lung cancer and asbestos could reach 
between 250,000 ? 4000,000 over the next 35 years due to exposure from 
asbestos.  
 
Importantly, asbestos has been used for over two thousand years, where there 
have been over 3,000 commercial products containing asbestos including, 
clothing, floor tiles, textiles, roofing and cement piping (Manning, Vallyathan 
and Mossman, 2002). Arguments have been made for hundreds of years about 
the potential risks from asbestos that might necessitate regulation (similarly to 
the use of certain non-asbestos nanotechnology products today). It has been 
stated that in 1879 when industrial scale mining of asbestos was started, the 
dangers from asbestos were relatively unknown. Using hindsight, it could be 
??????? ????? ??? ??? ????????? ??? ????????????? ???????????? ??????????? ??? ?????????????
with a need for such claims to undergo some level of validation. Clearly, with 
???????????? ??????? ???????? ????????? ???? ??????? ??????? ????? ?????? ?????? ????? ?????
?????????????? ????? ??? ??? ????? ?????? ?????????????? ??? ????????? ?????????? ????????
signs, as in the case of asbestos can and were missed. This is not to say that 
concerns were not raised, as examining Table 5.4, a detailed timeline of asbestos 
related health issues, has been put together potentially acting to show adverse 
effects from this material used in many products (UNESCO, 2006: 10).  
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Year ????????????????? 
1898 Lucy Deane, a factory inspector, first warns that asbestos dust has a 
potential to cause harm to workers and those exposed to it. 
1906 50 deaths amongst female asbestos textile workers were reported by a 
French factory. A recommendation for controls was made. 
1911  Experiments on rats demonstrate ???????????????????? to believe that 
asbestos dust is harmful. 
1911 and 
1917 
The UK Factory Dept. decides that there is insufficient evidence to 
validate any action to be taken. 
1930 ??????????????r R???????????????????????????????cent of workers in 
Rochdale show signs of asbestosis. 
1931 Asbestos Regulations (UK) stipulated asbestos dust control but only 
in the manufacturing process. Compensation to be awarded for 
asbestosis but this is poorly implemented. 
1935-1949 Asbestos manufacturing workers report high incidences of lung 
cancer. 
1955 Research carried out by Richard Doll (UK) found a high risk of lung 
cancer in Rochdale asbestos workers. 
1959-1964 ????????????? ??????? ???? ??????????? ??? ????????? ?????????
neighbourhood in South Africa, USA and the UK. 
1998-1999 The EU and France ban asbestos in all forms. 
2000-2001 Canada appeals the EU and French ban but the WTO upholds it. 
 
Table 5.4. A ????????????????????????????????? 
 
It is potentially easy to look at Table 5.4 and inquire why more was not done to 
limit the impact of asbestos on human health. The ?evidence???????????????????? 
might appear to have indicated there was a problem decades before anything was 
carried out to limit the negative impact of this material. While it can be argued 
that not enough was known, the backdrop of positive promotional narratives 
from vested commercial parties cannot be ignored. Examples of quotes, taken 
from the Chillicothe Constitution Tribune (1936: 9) highlight this with the 
advert: ?[p] ink asbestos aprons for careless ladies who lean on stoves sizzled 
into the International Fashion Market today from Great Britain????????????????
also advertised as a material to be worn by young children.  
 
	  	  	   	  	  	  	  	  80	  
?For little girls anything is good that even has a suggestion of the 
Shirley Temple styles. Fine broad ? cloths and silk prints are the 
most popular materials. For little boys there are [ two]  ? piece knits 
and for boys just a little older there are worsteds in a tailored coat 
and short trousers.? 
 
Beyond positive commercial narratives, the main reason for delay in action 
against risk associated with asbestos was due to the length of time between 
exposure and symptoms being displayed, and a lack of a reporting system legally 
mandated that would pick up on adverse effects. With no reporting system, the 
burden of demonstrating scientific proof that asbestos has adverse effects 
significantly delayed any risk reduction regulation being put in place. All of the 
early warnings from 1898 ? 1906 were ?ignored? and little precautionary action 
undertaken. Further to this, no surveys were carried out to monitor long-term 
dust exposure (EEA, 2001). Highlighting the problems that may ensue from 
asbestos exposure and adverse effects, the following has been argued (Canadian 
asbestos: a Global Concern, 2003: WP): 
 
?The asbestos cancer epidemic may take as many as 10 million lives 
before asbestos is banned worldwide and exposure is brought to an 
end. The battle against asbestos is in danger of being lost where the 
human cost may be the greatest in developing countries desperate for 
industry.? 
 
In 1979, a potential scapegoat for asbestos was provided by Sells (1994) 
claiming that asbestos workers who smoked were fifty times more likely to 
contract lung cancer from tobacco than from asbestos. This prompted the tobacco 
industry to take refuge in government mandated warnings that served them as a 
defence against product liability claims. This highlights a very difficult issue 
with unpicking adverse effects, in that even within statistically large populations, 
lifestyle choices can make it challenging to understand what is causing the 
adverse effect. This is shown in the pharmaceutical sector, where a 
?????????????????? ???????? ?????? ?????????? ??????? ??? ????? ?????????????? ????
?????????????????????????????????????????????????????????????????????????????????????
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(Amery, 1999). In the pharmaceutical sector, the reporting system has been 
underused with little incentives for stakeholders to provide data that there is a 
problem, which may also be the case with areas like asbestos, and maybe even 
nanotechnology.  
 
Looking at asbestos, it appears that there was a culture of denial with the 
companies involved (Sells, 1994). Lessons should be learned from the ???????
regulation of asbestos and the denial by both governments and companies of the 
dangers associated with asbestos products, when dealing with nanotechnology 
products until they have been proven to be safe. The misuse of asbestos has 
caused thousands of deaths, destroyed an industry as well as wiping out a huge 
percentage of stockholder equity (Sells, 1994). The severity of asbestos and the 
damage it did should not be underestimated, particularly for harm to humans, but 
also for casting a shadow over future technologies, where risks might be weighed 
against asbestos.  
 
Within the UK, it took until 1985 for asbestos materials (blue and brown) to be 
banned, and until 1999 for the import, sale and second hand reuse to be 
prohibited, arguably meaning there was a fourteen year period with a potential 
for adverse effects from asbestos sale and use. Finally, the 2012 Control of 
Asbestos Regulations was enacted to stipulate the management of asbestos 
currently in buildings, with a requirement for employee training in specific 
handling of this material. More than this though, control limits for asbestos in 
working environments were set out alongside particle sizes, that are not 
??????????? ??????? ???? ??????? ?????? ???????? ???????? ??? ?????????? ??????????????
????????????? ??????????? ??????????????? ????? ?????? ?????????? ??? ??? ???????????????
???????? ????? ??? ???????? ???? ???????? ??????? ??????? ??? ?????????? ?????? ???? ????
material to be ???????????? ??????????????????????????????????????????????? 
 
Asbestos is not just an abstract prior technology unrelated to nanotechnology 
products other than through a vague concept, as carbon nanotubes (CNTs) are 
currently being argued as physically similar in nature to asbestos (RSC, 2008). 
CNTs are cylindrical carbon based tubes, that are long, thin, and approximately 1 
- 3 nms in diameter by 100s ? 1,000s of nms long (azonano, 2014). Applications 
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include fuel, solar cells, electronic and optical devices, and batteries, amongst 
others (azonano, 2014). According to the Royal Society of Chemistry (2008), 
carbon nanotubes have similar qualities to asbestos fibres in that they are long 
and straight and of a comparable size and have been shown to cause cancer in 
lung cells in mice (Poland et al, 2008). For this reason toxicologists have 
indicated that those working in the production and disposal of CNTs are at risk 
of asbestos like illnesses particularly if exposure is from inhalation (Greenemeier, 
2008). Donaldson from the University of Edinburgh (2008: WP) stated:  
 
?We need more research on the toxicology of these materials, and the 
????????? ??? ????? ??? ???????????? ????????? ??????? ?????? ????? ????
???????? ????????? ??? ????? ??????? ???? ???? ??? ????? ?????? ????????n as 
behaving like asbestos?? 
 
Caution when working with CNTs first gained prominence in 2006 (Van 
Noorden, 2008: WP) when it was stated: 
 
?tubes that resemble asbestos should be treated as though they were 
asbestos and regulated accordingly. In this way, workers involved in 
their manufacture, use and ultimate disposal will be protected??? 
 
The chief science advisor with the US based project on Emerging Technologies, 
Andrew Maynard claimed: ?????????????????????????????????????????????????????
UK and the US that not too many companies have signed up to? (Van Noorden, 
2008: WP). Thus there is the potential for monitoring, even if it is limited in 
practicality. It is expected that nanotechnology will suffer if the public as well as 
stakeholders lose faith through linking CNTs and asbestos, with the argument 
that ?It is up to governments to give industry as much guidance as possible???Van 
Noorden, 2008: WP). The next section moves on to consider existing risk 
management principles that can potentially be used for such materials.  
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5.2.3. Existing Risk Management Principles ? Acceptable Risk 
 
Arguably, risk is inherent with all social and physical activities, with there being 
a notion of acceptable risk, which can vary for what is acceptable. While it is not 
possible in this study, or desirable to go through numerous accounts of 
acceptability within existing risk management strategies, a broader approach of 
examining the macro concepts of these aspects is considered in this section.   
 
Determining risk can be argued as a mix of subjective and objective elements, 
depending on how it is carried out, where acceptability is often determined 
through cultural notions at any point in time. Thus what is acceptable today 
might not have been yesterday, and may not be tomorrow. Practically, and 
????????????????????????????????????????????????????????????and set an acceptable 
level of product or technology risk at a certain time point. The nature of the 
qualitative and quantitative aspects of risk assessments is beyond the remit of 
this study, where it is important to understand that many approaches to 
determining risk and acceptability can be used, but the minutiae of how they 
work is beyond this study.  
 
Current discourses regarding the understanding of nanotechnology places risk as 
being too uncertain to permit meaningful risk assessments, which are hindering 
meaningful methods to address this area, and thus reduce risk, or even determine 
what is an acceptable risk. This situation is likely to remain relatively static for 
some time, until there are sufficient, social, business, scientific and legal drivers 
to more adequately tackle this area and a more strategic examination of 
supporting knowledge of the physicality of nanotechnology and risk (Oberdörster 
et al, 2005; Lin, 2007). An example of the lack of knowledge and testing regimes 
to understand nanotechnology-based products is shown from the lack of 
acceptable test methods and validated data available to allow credible 
quantitative and fit-for-purpose estimates of the potential risks that are specific to 
nanotechnology (Sweet and Strohm, 2006; SCENIHR, 2007). This is further 
demonstrated from studies that have been carried out but have been at best 
preliminary and exploratory, but unfortunately framed as being confirmatory and 
fit-for-purpose (Sweet and Strohm, 2006; Nel et al, 2006). Such studies highlight 
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the complexity of nanotechnology risk assessments, but also the often 
unsupportable claims made from reports, which leads to further opacity in 
communicating, creating and facilitating the toxicological risks of 
nanotechnology products to better regulate these areas. Of pivotal importance 
from these studies, is the repeatedly echoing discourse that it is at the moment 
not possible to provide over-arching themes for product safety, and that a case-
by-case basis for product safety testing must be carried out instead, which is no 
small task (Florini et al, 2006; SCENIHR, 2007; Greenwood, 2007). This is a 
daunting prospect for companies engaged in R&D, sales, marketing, risk 
management and regulation.  
 
Current testing proposals by Florini et al (2006) to create a platform for risk 
management have been criticised as being unlikely to be carried out by scientists 
due to the cost and time associated with these activities. Marchant et al (2008) 
have stated that this issue is crucial to risk management due to the high number 
of products that contain nanomaterials already in the market, and where there is 
an indication that a high number of workers and consumers, have already been 
exposed to nanoparticles and are still being exposed. Thus, regulators are 
perceived as operating with a lack of sufficient information to make decisions 
that would facilitate regulation (Florini et al, 2006). In 2007, the EPA issued a 
white paper providing a time line for oversight stating that it would take 
approximately four to five years for the agency to have sufficient risk knowledge 
to develop a risk strategy to develop for managing nanotechnology risks (U.S. 
EPA, 2007: 112). By this time the majority of all citizens globally will have been 
exposed to nanomaterials in some form or another. New generations of products 
will be entering the market with their new risks and uncertainties, and with 
seemingly little to stop or regulate this aspect.  As stated by David Rajeski of the 
Woodrow Wilson Centre (2004: 45), ?????????????????????????????????????????????
?????????? ???? ????? ????? ????? ????? ????? ??? ???????? ?????? ??????. Discourse 
regarding nanotechnology risk assessments has been predominantly negative 
towards risk management and as argued by Morrisey (2007 In: Marchant et al, 
2008: WP). ?We are in this awkward middle territory where we have just enough 
information to think that there is an issue, but not enough information to really 
inform policy makers about what to do about it???????? ????? ????? ??????? ??? ????
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??????????????????????????????????????????????????????????????????????? any risk 
assessment development (Renn and Roco, 2006).  
 
Finally, the development of risk assessments for nanotechnology is arguably 
needed, current risk based approaches are only providing a primary risk 
management solution for the short term due to the rapidity of technological 
innovation. Acceptable risk strategies suffer from certain structural 
disadvantages. For example, if only the acceptability of risk is considered, then 
other factors such as the importance of nanotechnology is disregarded. These 
factors include the cost of reducing any risk as well as any benefits and are 
important for when making any decision about nanotechnology. 
 
Following on from the aspects discussed in this section, is the examination in the 
next section of risk analyses, which considers the vehicles, used to analyse 
nanoparticle risk.  
 
 
5.2.4. Risk Analyses 
 
Within risk management studies for high technology products is the ability to use 
several types of analyses, to determine risk, which can be compared against 
potential benefits. These analyses include cost-effectiveness analyses (Bleichrodt 
and Quiggin, 1999), cost-utility analyses (Black, 2002), risk-benefit analyses and 
cost-benefit analyses (Boardman, 2006) amongst others. Arguably the most 
popular choice for carrying this out is cost-benefit analyses, which is a collection 
of processes and models used to (1) determine if there is justification i.e. a sound 
basis for carrying out an activity/endeavour, and (2) to provide a basis for 
comparing outputs and projects (Boardman, 2006). The second model of 
particular importance is that of risk-benefit analyses, which seeks to quantify risk 
against benefits to facilitate decision-making. For businesses, both of these 
models are important to understand the relationship of cost and risk to benefits.  
 
Models have a lot to offer regulation, to better determine how nanotechnology 
should be regulated and as a way ??? ?????????????? ????????????????? for example. 
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As Gwinn and Vallyathan (2006: WP) highlighted for instance, current potential 
models ??????ill ? equipped for managing nanotechnology at this time, given the 
immense uncertainties about its risks and benefit??. Looking beyond this 
statement, Marchant et al (2008: WP) claim that prior models are ???????????? 
due to the ?????????????? benefit balancing for nanotechnology as a whole would 
mask the significant cost ? benefit variance that likely exists between different 
?????????????. The narrative constructed by such academics suggests that when 
looking at the total number of potential applications of nanotechnology and 
specifically products, the notion of performing a specific cost-benefit or risk-
benefit analysis for each product could overwhelm any available resource given 
over to risk management. The suggestion appears to imply that while a useful 
?paper exercise?, in practicality the resource and cost to do so would be 
prohibitive. Such tools may therefore inform decision-making and produce a 
more in-depth understanding of products, but may also be limited in scope and 
capability.  
 
???????????????? ?????????????????????????????????????????????????????????????????
????????????????????? model. Here the risk is reduced to the lowest possible level 
that is economically or technologically feasible. This approach is very popular 
amongst policy makers as it potentially allows any controversies arising from 
risk analysis to be circumvented, thus allowing potential risks to be reduced 
(Shapiro and McGarity, 1991; Wagner, 2000; Babich, 2003; Drieson, 2005). This 
can be appealing for technologies such as nanoparticles, however it is not 
without weakness as it often ignores risk information. Utilising this approach can 
result in an either an under or over regulation, and raises the question of how it 
can be used for complex products as found within nanotechnology and 
nanoparticles? Arguably none of the traditional risk management models and 
analyses has the capacity to manage risks from nanotechnology effectively due to 
the amount of existing uncertainties surrounding this varied collection of 
technologies. This has precipitated an application of the precautionary principle 
to nanotechnology, which leads to the next section, which considers risk and the 
precautionary principle.  
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5.2.5. Risk and The Precautionary Principle 
 
In recent years the precautionary principle has emerged as an alternative 
?????????????????????????????????????????????????????????????????????????????? 
The precautionary principle is based on a recognition that decision-making often 
occurs in situations of uncertainty, where decision-makers can be required to err 
on the side of caution. This often means that new technologies are delayed until 
their safety can be ?proven? or ?ensured?, and can require a demonstration of 
product safety, which is a well-debated concept in other high technology areas of 
medical devices and pharmaceuticals etc. (Mann and Andrews, 2014). As there 
are arguably many unknown risks and uncertainties surrounding nanotechnology, 
there is often an assumption that the precautionary principle is an ideal solution 
to aid decision-making. Yet there are limitations, which are detailed in Table 5.5. 
 
Limitation Description 
Poor definition The precautionary principle is too poorly defined to be used as a 
decision-making vehicle, which can be particularly problematic 
where there is also a lack of understanding about the product it is 
being applied to (Sandin, 1999).  
Lack of text There is no standard text available for the rule, and conflicting text 
about nanotechnology and nanoparticles (Sandin, 1999).  
Unable to 
answer 
questions 
The precautionary principle is unable to answer questions that are 
imperative for regulatory decisions. These include the level of 
harm/risk that will trigger the precautionary principle, as well as 
which data is needed by the producer to satisfy the precautionary 
principle, and how benefits can be weighed against risk 
(Marchant, 2003).  
 
Table 5.5. Nanotechnology Precautionary Principle Limitations.  
 
The precautionary principle needs guidelines or criteria to resolve these 
questions, and arguably from well informed expert decision-makers within the 
legal nanotechnology paradigm. Without these, it can be used for mischief 
making (Marchant and Mossman, 2004) and can also suffer from being ?biased 
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towards the status quo?? This has the potential to impede new technologies, even 
those that may prove beneficial (Cross, 1996; Holm and Harris, 1999).  
 
The precautionary principle may be particularly beneficial where there is 
????????????? ?????????? ??? ??????????? ??? ?????????? ?????? ???? ???????? ?? ????-for-
????????? ????? ?????????????????? ?????? ??? ????????????? ??? ????????? ??? ?????? ????
burden of proof from needing scientific evidence, which due to potential 
limitations in testing could be used to reduce the impact of a product suspected 
of potentially causing unacceptable harm. Importantly, the precautionary 
principle cannot necessarily make anything safe, but more mitigate the risk from 
???? ??????????????????????????????????????????????????????????????????????????????
as might be expected can be open to abuse to limit commercialisation of products, 
based more on psychological concerns than scientific fact.  
 
Given that nanotechnology offers many potential environmental and human 
health benefits, there are drivers to promote this technology rather than hindering 
it, as long as risk can be mitigated and adequately managed. However, as with 
any promising technology with associated risk, and according to Sunstein (2003), 
the precautionary principle does not provide sufficient guidance on which 
direction to choose i.e. risk or benefit. Wiedermann and Shutz (2005) have also 
argued that the precautionary principle actually increases the concerns of the 
public rather than addressing it, therefore creating a greater anxiety about this 
technology (Wiedermann and Shutz, 2005). This is because it alerts the public 
that there is potential risk, which is often sensationalised by the media creating a 
negative perception and unease. 
 
The examination in this section so far suggests that neither the precautionary 
principle nor traditional risk management approaches provide sufficient 
strategies for mitigating risk. Technologies in the past have had their risk 
regulation postponed until proof of evidence could be confirmed (Wilson, 2006; 
Florini et al, 2006; Lin, 2007). Other risk management tools such as liability, 
self-regulation, and risk communication can be used as an interim measure 
(Baram, 1984; IRGC, 2006). With this in mind, it is not surprising therefore that 
nanotechnology is still relatively unregulated with numerous governments 
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showing concern about regulating nanotechnology products as nanotechnology 
products (Bowman and Hodge, 2007). With the demonstration that the current 
models of anticipatory regulation appear to be ill advised and inappropriate, it 
does not mean that there are not substantive drivers for pursuing regulation. 
Arguably, it is inevitable that nanotechnology will eventually be regulated and 
this could be brought about by public and/or political pressure, necessitating a 
regulatory response (Marchant and Sylvester, 2006) or due to economic, 
environmental or ethical concerns. As a way of dealing with this challenge, the 
next section considers a new risk management model.    
 
 
5.2.6. A New Risk Management Model 
 
There are many challenges facing the management of risks concerning 
nanotechnology. The risk management models that are currently in place, 
including the precautionary principle are arguably not sufficient in their present 
state for nanotechnology. There is an urgency to develop a successful risk 
management strategy so that commercialisation of nanotechnology can go ahead 
safely and at a rapid pace, where risk is more adequately considered against 
potential benefits.  
 
Suggestions have been made that any new risk management model should 
incorporate a flexible and evolutionary approach towards nanotechnology 
regulation (Marchant, 2003). Coupled with this it should draw on a range of 
different stakeholders to better inform decision-making. Within such a 
framework, some scholars have argued that a ?????? ???? ????????? ????? ??? ?????
traditional? should be implemented giving an incremental and reflexive 
management of nanotechnology risks (Forrest, 1998; Fiedler and Reynolds, 
1994; Reynolds, 2003; Wejnert, 2004; Segal, 2004; Bowman and Hodge, 2007; 
Breggin and Carothers, 2006; Paddock, 2006; Wilson, 2006; Lin, 2007; Bowman 
and Hodge, 2007; Kuzma, 2007). Drawing on the participation of public and 
private stakeholders, as well as researchers and those already commercialising 
???????????????? ?????? ??????? ?? ????????? ??????? ??? ??? ?????? ????? ???? ?????
closely mirror the reality of these products. It would also have the potential to 
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assist in gaining a clearer understanding of benefits or risks of any particular 
nanotechnology product or process and thus communicating that understanding 
to the public, and regulators enabling multiple risk aspects to be managed. 
Through experience iterative procedures can allow the gradual development of 
cost effective and appropriate regulatory systems, Marchant et al  (2008: 23) 
argues that this approach is the best way forward as it takes into account most of 
the major issues.  
 
Risk is problematic when dealing with nanotechnology, as at present it is 
inherently uncertain. There are potential risks in the areas of environment, health 
and safety threshold levels of exposure, as well as variations amongst processes 
and products that are closely related. The heuristics influencing the individual 
view of risk cannot easily be negated but transparency and dissemination of all 
risk information as it becomes available, can create a higher level of trust by 
?????????????????????????????????????????????????????????????????? 
 
When examining traditional approaches to risk regulation, they may appear 
inappropriate for nanotechnology due to the reasons discussed previously. 
According to Marchant et al (2008: 4) Ayres and ?????????????? Responsive 
Regulation (1992) provides a comprehensive theoretical approach arguing that 
the choice given ??? ???????? ?regulation?? ???? ?????????????? stating that 
regulation involves a relationship that is symbiotic between private and public 
actions that are able to be managed and can respond to variations in behaviour 
and conditions in industry that will obtain a better regulatory outcome. It could 
be argued with such rapid rates of R&D and manufacturing of nanotechnology 
products, that strategy is needed that will reduce any potential risks, even if they 
are merely perceived.  
 
Finally, any new risk management strategy should encompass the challenge of 
stipulative and lexical definitions, which echo into the most basic question of 
?what is nanotechnology???????????? et al, 2008: 23) or more pertinently for this 
??????? ?what is a nanoparticle??? ?????? ??????? ????? ??? ????? ?????????????
hampering efforts in identification of risks linked to the research, technologies 
and application process. Even with this uncertainty surrounding nanotechnology 
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as political pressure continues to grow, the need for a regulatory response 
becomes essential for the future.  
 
After discussing many elements of risk, the next section moves onto explore 
insurance as it relates to high technology and particularly nanotechnology risk.  
 
 
5.3. Insurance 
 
As detailed in the prior part of this chapter on nanoparticle risk, there are 
numerous commercial drivers for high technology product insurance, for 
multiple stakeholders. As a starting point, it is perhaps most helpful to examine 
what is meant by insurance. ??????????????????????????????????????????????????????
the foundations being within the practices adopted by Italian merchants from the 
fourteenth century, although it is likely that insurance practices existed before 
that time. While a thorough examination of the foundations of insurance are 
beyond the remit of this study, it is worth briefly stating that many of the 
principles developed for maritime insurance have been adopted for more modern 
insurance endeavours. At present it is possible to insure almost every 
conceivable event or thing, against risk of loss or damage through first and/or 
third party insurance (Birds, 2013). Although the term insurance is commonly 
spoken about, defining the phenomenon from a legal standpoint is problematic 
(Purves [2001] J.B.L 623).  The statutes dealing with the regulation of business 
insurance do not contain a definition of insurance, as there is a perception that 
any attempt to define might misconstruct the phenomenon of insurance and may 
produce negative consequences for insurance contracts. Within itself, this is an 
important aspect but more generally is an important aspect for the construction of 
any definition, its perceived meaning(s) and wider echoes into the practice of law. 
Birds (2013: 9) however argued that: 
 
?It is suggested that a contract of insurance is any contract having as 
its principle object (Re Digital Satellite Warranty Cover Ltd [2011] 
EWHC 122 (Ch) at {84} to {86}) one party (the insurer) assuming 
the risk of an uncertain event (Gould v Curtis [1913] 3 K.B. 84), 
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which is not within its control, happening at a further time, in which 
event the other party (the insured) has an interest, and under which 
contract the insurer is bound to pay money or provide its equivalent 
if the uncertain event occurs??? 
 
More simply however and drawing on a lexical definition from the Oxford 
English Dictionary (2014: WP) the definition of insurance is:  
 
?An arrangement by which a company or the state undertakes to 
provide a guarantee of compensation for specified loss, damage, 
illness, or death in return for payment of a specified premium??? 
 
Investor Words 2510 Insurance (2014: WP), utilised a descriptive definition of 
insurance as: 
 
?A promise of compensation for specific potential future losses in 
exchange for a periodic payment.  Insurance is designed to protect 
the financial well?being of an individual, company or entity in the 
case of unexpected loss. Some forms of insurance are required by 
law, while others are optional. Agreeing to the terms of an insurance 
policy creates a contract between the insured and the insurer. In 
exchange for payments from the insured (called premiums), the 
insurer agrees to pay the policyholder a sum of money upon the 
occurrence of a specific event. In most cases, the policyholder pays 
part of the loss (called the deductible), and the insurer pays the rest. 
Examples include car insurance, health insurance, disability 
insurance, life insurance and business insurance??? 
 
Within the practice of insurance law, are several requirements for something to 
be insured as detailed in Table 5.6. 
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Requirement Meaning 
Legal entitlement There must be a legally binding contract where the insurer 
must be bound to pay.  
Uncertainty There must be uncertainty to whether the event being insured 
will occur, as opposed to life insurance when the uncertainty is 
when.  
Insurable interest The insured party must have an interest in the thing insured.  
Control The uncertainty related to the thing being insured must be 
outside of the control of the insurer, although this has not been 
directly considered.  
Payment does not 
have to be money 
The insurer does not need to be obligated to pay money.  
Stipulated premium 
and policy 
The provision of a clearly stipulated premium and policy has 
been argued as being necessary.  
Utmost good faith The party seeking insurance must act in the utmost good faith 
for the insurance policy to be valid.  
 
Table 5.6. Requirements for Insurance.  
 
As might be expected, these requirements will have different levels of 
importance for different elements being insured, but can be taken as a foundation 
for setting an insurance contract. In the following section and moving on to 
examine insurance in this study, companies engaged with nanotechnology 
insurance are examined.  
 
 
5.3.1. Companies Engaged with Nanotechnology Insurance 
 
The integration of nanotechnology into an insurance framework has proved 
challenging and is an on going process, with much debate at how it should be 
carried out. Embedded within an insurance perspective, there is a composite 
mixture of overt and unknown risk associated with the use of nanomaterials 
creating many challenges for how companies wanting insurance and those 
providing insurance should proceed. Some of these insurance difficulties are 
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based within risks associated with (1) employers liability, (2) product liability, 
?????????????????????????????????????????????????????????????????????????? 
 
As a starting point and at present, the majority of commercial insurance policies 
do not mention or contain any kind of definition of nanoproducts. Some 
companies such as Continental Western Group are actively trying to exclude 
losses that are related to nanoproducts, and in particular CNTs, as they can be 
linked being similar in nature to asbestos. With growing debates surrounding 
nanotechnology, ???????? ??? ??????? ???????? 2008) has hypothesised several 
possible risk scenarios as shown in Table 5.7. 
 
Risk Scenario Details 
Pollution spill Potentially caused by spills or leaks at a nanomaterial 
production facility.  
Chronic illness Workers and/or end-users developing chronic illness from 
nanoparticle exposure. 
Nanoparticle 
accumulation 
Nanoparticle leaching into the environment, resulting in 
increased levels over time.  
Future findings Development of new techniques and equipment that may 
find problems in materials currently not assessed or 
deemed safe.  
Incorrect analysis Intentional or unintentional incorrect analysis producing 
results suggesting dangerous products are safe.  
 
Table 5.7. Potential nanoparticle risk scenarios.  
 
As was stated by ?????????????????????????? 2008: WP). 
 
?The insurer can accept that nanotechnology risks are included 
within the overall set of risks that the insurance policy covers and 
therefore may not need to mention nanotechnology specifically. The 
additional risk introduced is then reflected in the price of premium 
for the insurance???? 
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The insurance company Allianz claim that they are insuring many commercial 
and industrial clients from the arena of nanotechnology (Allianz, 2014). This 
ranges from manufacturers of consumer products to chemical companies 
producing nanoparticles. As their insurance portfolios grow, an increasing 
number will contain policies associated with commercial activities relating to 
nanotechnologies. This would suggest that the insurance industry is therefore 
contributing to an early commercial phase of nanotechnology. Adequate 
insurance coverage is paramount particularly for SMEs who wish to engage in 
commercial and entrepreneurial activity. According to Allianz (2014: WP??? ?A 
balance needs to be kept between managing a sustainable insurance portfolio 
with adequate returns and maintaining a responsible approach towards 
?????????????????????? The insurance industry, ???????????????????????????????????
always an enabler of new technologies?? Allianz have stated that ?currently, there 
are no specific policy exclusions or terms in regular use that are tailored to 
address risks from nanotechnologies? (Allianz, 2005). GenRe states, ????????????
?????????????????????????????????????????????????????????? These are commercial 
general liability policies (Allianz, 2005: WP). By not excluding 
nanotechnologies from their policies, Allianz are promoting that 
nanotechnologies ???? ???? ????? ?????? ??? ?? ????????? ??????? ??? ?????? ??????? ??????
nanotechnologies are proven to be hazardous they are not treated as such 
therefore the burden of proof lies with the science companies to prove risk or 
with regulators to provide regulations for nanotechnology companies to work 
inside. Problems will occur if nanoparticles are acknowledged as being different 
to their bulk state and potential toxicities surrounding their physicalities are 
proven. This could have serious affects on insurance policies by raising 
premiums, or by insurance companies refusing to insure products that contain 
nanomaterials. Many SMEs could also be affected due to increased premiums 
rendering them unable to continue to produce or sell products containing 
nanoparticles. As manufacturers of nanoparticle products are liable for any health, 
safety or environmental issues or damage caused by their products, it should be 
mandatory for all companies to take out adequate insurance. This could be 
problematic when dealing with nanoparticle products, as many of the risks are 
unknown due to lack of data surrounding nanotechnology. Therefore I would 
suggest that it should be a prerequisite of any company manufacturing 
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nanoparticle products that they not only insure their products but also insure their 
employees as it has been suggested that nanoparticle toxicity has the potential to 
cause chronic illnesses in the long term (Marchant, 2008). 
 
????????????????????????? ?????????????????? ????????? ??????? ?????????????????????
????????????????? and that risks from nanotechnology have the potential to require 
the insurer to pay for a host of different aspects. These aspects have been 
summarised in Table 5.8 
 
Number Insurer requirement 
1 Clean up costs of land and water contamination.  
2 Medical costs of treatment of human exposure.  
3 Liability claims from persons directly affected, environmental groups and 
shareholders.  
4 Latent liability claims of persons affected.  
5 Business interruption while facility is investigated.  
6 Cost of product retail.  
 
Table 5.8.  Potential insurer cost requirements 
 
This section has highlighted some of the challenges of nanotechnology insurance, 
but a more fundamental claim can be made towards the challenge, which is 
discussed in the following section of research paucity and insurance.  
 
 
5.3.2. Research Paucity and Insurance 
 
There has been a lack of a coherent research strategy to understand the risks 
facing businesses engaged with nanotechnology commercialisation, which 
echoes into the challenges facing insurance. A major concern about nanoparticles 
is their toxicity, which can be variable and difficult to determine. Auty (2014: 
WP) stated that:  
 
?The risks associated with nanoparticles are not well known outside 
of specialist sciences and this is a problem. Most people have an 
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intuitive sense of risk, based on precedent, analogy, trusted sources 
and meaning. With engineered nanomaterials, there is little 
meaningful precedence, and trusted sources are hard to find. 
Regulators, insurers and other risk managers are thus unable to 
produce simple generally applicable messages on engineered 
??????????????????.  
 
A further difficulty is that many products and processes include nanoparticles 
without the knowledge of the producer or the user. This leads to a major problem 
of causality and what a company seeking insurance can report in good faith. 
There are no standardised common reporting documents identifying the exact 
type of nanoparticle contained in each product, which is a critical aspect to 
weighing up a risk, as there is insufficient knowledge to determine effective 
controls. This is something that regulation should address, as there are thousands 
of products on the market containing nanoparticles with the potential to be 
hazardous. A standardised common reporting document or checklist should be 
created for manufacturers/producers/importers, which could be handed to an 
insurer, allowing for more transparency when assessing risk. While this may 
mean that companies seeking insurance act in good faith in reporting what they 
know, this might result in insurance companies not wanting to insure. Further to 
this, with nanotechnology being such a highly specialised field, it raises 
challenges for communication of technological aspects about products and 
understanding taken away by the insurer and insured. Arguably more research is 
needed into risks pertaining to nanomaterials and the controls necessary to 
reduce potential risks to public health and to the environment. According to Auty 
(2014: WP):  
 
?My biggest concern is retrospective risk, closely followed by rapidly 
????????? ????????????????? ????????????? ???? ??? ????? ???????????
and the risks largely unknown. At some point a loss will be identified 
and the change in liability exposure resulting from this change in 
knowledge could be very significant. With rapidly changing risk, you 
??????????????????????????????????????????????????????????????????????
years and implied liability exposure goes from none to maximum in 
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the same time scale. Risk management measures may find it hard to 
keep up. Of particular interest under rapidly changing risk are 
carbon nanotubes and silica?? 
 
Traditional laws that govern compensation and liability are based on a ????-to-
one ????????????????????????????????????????? It may be extremely difficult to 
clarify whether the exposure to nanoparticles is the cause or a contributing cause 
to an illness. Experts in industry as well as insurers, are having to tread carefully 
due to the potentially adverse effects on human health, which could be caused by 
a wide variety of products containing nanomaterials, such as cosmetics, 
lubricants and fuels, construction materials, surgical implants, pharmaceuticals, 
food ingredients and food wrappings. Binion (2008: WP) stated that:  
 
?In ?????? ???? ???????? ??????? ???????? ???? ???????? ??? ??????? ??????
reports of users suffering breathing problems, some requiring 
hospitalisation. While it was subsequently determined this product 
did not incorporate true nanoparticles or nanotechnology, insurers 
??????? ????? ????? ??? ???? ????? ????? ???????????? ?????????? ???? ????????
rallying round a potential new source of tort claims and plaintiffs??? 
 
There is also the impact of nanotechnology on the environment where there is a 
continued debate regarding the extent that commercial and industrial use of 
nanomaterials has on the affect of organisms and ecosystems. When examining 
the risks, it is easy to see why nanotechnology has been compared to asbestos, 
welding fumes and silica, and has the potential to become a source of ??? ????
?????????????????(Binion, 2008). 
 
It has been argued that so far the insurance industry is becoming aware of the 
risks associated to nanotechnology, but until the risks manifest themselves 
through thorough risk assessment demonstrating actual harm caused, insurance 
for that harm may not be possible (Binion, 2008). As Marchant et al (2008: WP) 
?????????Underwriters and risk experts at Zurich will be monitoring this area with 
????? ????????? ???? ???? ????????? ???? ???? ????? ?? ????????? ????????The next section 
therefore examines underwriting and nanotechnology.  
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5.3.3.  Underwriting and Nanotechnology 
 
Underwriting is the process and end point where an insurer, signs and accepts 
liability, along with payment should loss or damage occur to a contractually 
bound insured party. Within underwriting, one of the greatest challenges facing 
nanotechnology insurance is the lack of definition, or highly variable definition 
of nanotechnology. While there are common and lexical definitions, they are 
often too broad and can capture ?almost anything?, and have created a problem 
for insurers for where to draw demarcation points. Importantly, insurers have not 
sought to create a definition, and have relied on other, non-uniform sources. At 
the present time (2015), nanotechnology from a scientific perspective is a blanket 
term used to cover the manipulation of matter with at least one dimension sized 
from 1?100 nanometres (Royal Society and Royal Academy of Engineering, 
2004). With so much potential variability between what this might mean (see 
section 2.3.1), insuring is not without challenge, as mischievous or unintended 
linguistic constructions may miss the physicality of nanotechnology. Ideally, 
specific enquiries and disclosures of size and nature of the material, plus any 
processes involved are necessary for the underwriting to be more effective and 
fit-for-purpose.  
 
There is difficulty when predicting the influence that nanotechnology will have 
on the tort system. Any effect could have subsequent effects on insurers and 
policy?holders with the potential to bring significant problems if coverage 
litigation occurs. For example, if nanomaterials are involved in a coverage issue, 
determining exactly when the injury or damage occurred and by whom (if 
appropriate) and also if it occurred during the policy period. The Swiss 
Reinsurance Company have predicted that, ?????????????????????????????????????
likely to be chronic, rather than acute, with periods of latency before 
???????????????(Binion, 2008). Therefore trigger issues ? those that initially cause 
the damage/injury, will be the greatest cause for concern by the policy holders 
????????? ??? ???????? ????????? ???? ???? ??????? ???????? ???????? ???? ??? ???? ??????
numbers of nanomaterials currently being used in an array of products, insurers 
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may find that they become involved in an insurance battle, trying to prove the 
initial trigger to the damage/injury. 
Currently the language used in a standard nanotechnology policy excludes 
coverage for property damage and bodily injury, ?expected or intended from the 
standpoint of the insured??(Binion, 2008: WP). The legal standard can vary from 
authority to authority but with the current lack of research into the safety and 
risks of nanomaterials, insurers may find it difficult to win a nanotechnology tort 
claim. The major problem for any claimant would be, with the large amount of 
products containing nanomaterials, which single product caused the 
damage/injury or was it a collective issue, where each nanomaterial is said to be 
safe but mixed together can cause a damaging effect (Binion, 2008).  
 
According to Binion (2008: WP), there is an exclusion policy for coverage of 
????????? ???????? ??? ?????????? ???????? ???????? ???? ??? ???? ???????? ???????? ???
threatened discharge, dispersal, seepage, migration, release or escape of 
???????????????? ??????? ??????? ?????????? ?? ?pollutant?? ??? ????? ??????? ????????
gaseous or thermal irritant or contaminant, including smoke, vapor, soot, fumes, 
acids, alkalis, chemicals and waste???For example, in the following scenario, an 
individual uses a body cream that contains fullerenes, which in this case has not 
been classed as a traditional pollutant (this is what the exclusion is meant to 
????????????????????????????????????????????????????????????????????????bodily 
??????? ??? ??????????????? ??????? from normal usage of the product was not 
caused from ???????????? ????????of any pollutant. Whereas the insurer is more 
likely to claim that the damage/injury was caused from waste, which is subject to 
the pollution exclusion. In both instances, the pollution exclusion could be 
applied, demonstrating difficulties when dealing with this emerging technology 
(Am. States Ins. Co. v. Koloms, 1997). 
 
Another problem that arises concerning exclusion is that of coverage for property 
damage. Standard CGL (commercial general liability) policies exclude coverage 
for property damage to the pol??????????????????? and ???????????The definition 
of ?????????????? is: 
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??????????????????????????????????????? ?????? ?????????????????????
or disposed of by the policyholder and the containers and the 
materials, furnished in connection with such goods and products?? 
 
????????????????????????????? refers to ???????????????????? that are performed 
by the policyholder or on his behalf. This also includes any materials used in 
connection with this work. A company could argue that neither of the two 
exclusions would apply, stating that bodily injury and property damage claims do 
not reflect or constitute damage to their product or work (Binion, 2008). Again 
lack of information on nanotechnology risks influences CGL policies (Binion, 
2008: WP).  
  
????? ??? ???? ???? of clear information on nanotechnology risks, the 
risk of significant third ? party claims for bodily injury or property 
damage, and the fact that the current standard CGL policy terms 
might not account for nanotechnology ? related claims, insurers 
should consider the options available to them now for effective risk 
????????. 
 
The Swiss Reinsurance Company (2007) suggest that some policies that are 
claims based should be restricted until the risks of nanotechnology are more 
clearly identified. Also it may be necessary for insurers to consider excluding 
individual products until nanotechnology has more fit-for-purpose regulation and 
the risks are more fully understood. If exclusion were to be made, then an 
extensive disclosure would be necessary about the product and the 
nanotechnology used and any nanomaterials contained in the product. All 
dangers and risks must be researched and documented meticulously making 
exclusions increasingly more complicated. Problematically however, Auty 
(2014: WP) from Liability (Oxford) Ltd. claimed that, ?????? ???????????
measures which should be adequate for one engineered nanomaterial may not be 
?????????????????????????????????????.  
 
There are many unquantifiable risks when looking at nanomaterials from an 
insurance perspective, as many risks may not be ap???????? ???????? ??? ???????
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(2007: WP) claim in a paper describing options that insurers face when dealing 
with nanotechnology risks: 
 
???????????????????????? ????????????????????????????????????????????
the overall set of risks that the insurance policy covers and therefore 
may not need to mention nanotechnology specifically. The additional 
risk introduced is then reflected in the price of premium for the 
??????????.  
 
There are different types of policy, which can cover risks involving 
nanotechnologies. In a policy known as an ?????????? policy, nanoparticle 
products do not have to be listed by the insured to be covered. According to Re 
Katrina Canal Breaches Litigation (2007: WP), this type of policy: 
 
??????????????????????????????????????????????????????????????????????
under an all ? risk policy will be allowed for all fortuitous losses not 
resulting from misconduct or fraud, unless the policy contains a 
specific prov?????????????????????????????????????????????????.  
 
This type of policy only necessitates the policy-holder to show loss or damage to 
the property that is covered, meeting any responsibility needed to demonstrate 
coverage, while the insurer must prove ?????????? ???????? ???? ??? ???? ??????????
?????????????? ?????????????p. v. Commercial Union Ins. Co, 2002). 
 
It has been argued that insurers like to focus on a common exclusion. This is 
often the pollution exclusion where all?risk and named?risk policies in standard - 
form property policies profess to exclude all losses that are caused by, ????????????
??????????? ????????? ??????????? ???????? ??? ??????? ??? ????????????? (Insurance 
Services Office, 1990). In this case a ??????????? is defined as ?????????????????d, 
gaseous, or thermal irritant or contaminant, including smoke, vapour, soot, 
fumes, acids, alkalis, chemical and waste? (Insurance Services Office, 1990: WP). 
Nanoproducts do not fit in with any of the above listed items (although soot 
contains natural nanoparticles) but insurers may argue that they are 
?????????????? or ?????????????These terms are not usually explicitly defined in 
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insurance policies therefore courts typically rely on definitions that are set out in 
dictionaries (Werbach, 1994). Yet, nanoparticles contained in products have the 
potential to be ??????????? or ??????????????? The problem lies with the insurer to 
prove that the nanoparticle fits within the description and definition of ?????????? 
or ?????????????? In many cases courts will limit pollution exclusions to 
conventional ????????????????????????? (Carpenter and Zeng, 2015). The reason 
for this is because the term ?????????? could then be extended to include common 
dust as a pollutant (Parks Real Estate Purchasing Group v. St. Paul Fire and 
Marine Ins. Co, 2006). The common pollution exclusion is a point for debate as 
it is not broad enough to encompass nanoparticles. This argument is supported by 
the presence of a separate exclusion policy for the majority of modern properties. 
This is following losses that were incurred from asbestos after courts maintained 
that asbestos was ????? a pollutant. When examining a Commercial General 
Liability (CGL) policy, a policyholder must demonstrate that losses suffered are 
based on liability for bodily injury or property damage which has been caused by 
an ?occurrence??? A typical definition of an ???????????? is ???? ??????????
including continuous or repeated exposure to substantially the same harmful 
???????????? ????????, 2007). Insurers are likely to dispute the pollution 
exclusions in CGL policies, arguing that they prohibit coverage for any losses 
that have been caused by nanoproducts. The language used for the standard 
pollution exclusion which is contained in the CGL policies is very similar to that 
of other CGL policies in that it applies to ????????? ???????? ??? ???????????
???????????????????????????????????????????????????????????????????????????as well 
as having the same definition of the word ???????????? (Kimber Petroleum Corp. v. 
Travellers Indem.Co, 1997). 
 
 
5.3.4. Commercial Insurance Coverage 
 
The challenges that nanotechnology bring to the commercial world of insurance 
are not small, particularly for whether nanoparticles should be or are covered by 
insurance. While the problem of how to insure products that have potential health 
risks and uncertain exposure rates is not new to insurance law (Hull and Bowman, 
2010) the complexity, uncertainty and opacity related to nanotechnology 
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arguably is. More simply put, it is difficult to find a collection of products that in 
any way mirror the potential challenges that nanotechnology displays. Looking 
for how to deal with this, Blaunstein (2006) believes that insurance coverage for 
nanotechnology issues will occur in three phases, as shown in Table 5.9.  
 
Phase Description 
1 A period where nanotechnology is studied and risks and exposures 
assessed. These potential risks are covered within existing policies with no 
separate definition.  
2 An apprehensive period where the insurance industry may attempt a 
reduction in coverage exposure.  
3 The final period where insurance companies may offer customised and 
specialised solutions for nanotechnology coverage.  
 
Table 5.9. The three predicted stages of nanotechnology insurance.  
 
Blaunstein (2006) believes that currently we are in the first phase, with an 
unknown timescale existing for the move into the following second and third 
?????????????????????????????????????????????????? in 2008 claimed that insurers 
of nanotechnology products have several options when issuing commercial 
insurance coverage (Baxter, 2008). They noted that complete exclusion of 
nanotechnology products by insurers could be undertaken, or a separate limited 
coverage for nanotechnology risks with full coverage for other aspects of the 
policy, or insurers may only allow a fixed period of time where claims can be 
????????? ?????? ???? ??????? ???? ?????????????? ???????? ????? ?????? ????? ????? ??? ???
insurance group will continue to research and monitor any potential risks linked 
????????????????????????????????????????? view on the situation (Germano, 2008). 
 
Continental Western Insurance Group was the first insurance company in the US 
in 2008, to issue a ???????specific commercial insurance exclusion?? ????? and 
Bowman, 2008: 305). Monica (2008, in Hull and Bowman, 2008: 305) explained 
that:  
 
??????ntent of this exclusion is to remove coverage for the, as of yet, 
unknown and unknowable risks created by ? products and processes 
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that involves nanotubes. The exclusion is being added to make you 
and your customers explicitly aware of our intent not to cover injury 
and / or damage arising from nanotubes, as used in products and 
??????????.  
 
The reasoning behind this decision was due to the comparison of carbon 
nanotubes to asbestos. Continental made a specific exclusion covering (Monica, 
2008; in Hull and Bowman, 2008: 305):  
 
?bodily injury, property damage, and personal and advertising injury 
related to the exposure of nanotubes and nanotechnology in any form. 
This includes the use of, contact with, existence of, presence of, 
proliferation of, discharge of, dispersal of, seepage of, migration of, 
???????????????????????????????????????????????????????????????????? 
 
It is not known whether Continental Western Insurance Group have actually 
implemented this exclusion as these documents were hastily removed from 
?????????????? ??????e on the publication of an article by the BNA which 
discussed nano specific exclusion. As with much of nanotechnology, this 
potentially creates further difficulties for decision-making within insurance law. 
Thus, the following section considers the future of insurance and nanotechnology.  
 
 
5.3.5. The Future of Insurance and Nanotechnology 
 
At present, most insurance policies do not explicitly exclude nanomaterial risks, 
which raises the question of whether current policies cover nanotechnology, or 
whether they are excluded? The opinion over whether there will be a 
nanotechnology exclusion policy is not agreed on, as L??????? ?????? WP) 
claimed that:  
 
?Insurers could, theoretically exclude any liability related to losses 
caused directly by nanotechnology. As long as exclusions are well 
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worded and enforceable this reduces the risk to the insurer to near 
?????? 
 
However, Allianz and OECD (2010: WP) wrote: ???? ?????????????? ?????????????
appropriate to start a debate about a general exclusion of nanotechnologies from 
??????????????????? ??????????? ????????????????????????????????????. If there is 
to be no debate as suggested by Allianz and OECD, perhaps this suggests a move 
for insurers to ??????????????????????????????????????????????????????????????????
applicable to nanotechnology within regulations and statutes so that there is no 
confusion about coverage or exclusion. Although this type of regulation is still in 
its infancy, insurers still need to link their definitions and coverage to 
governmental definitions and regulations. Policyholders must also work 
alongside the insurance brokers by paying attention to exclusions and coverage 
limitations particularly at the time of policy renewal. This may mean that 
insurers may increase specialized coverage once there has been better assessment 
of risks regarding nanotechnology. This would come with an increased premium. 
If these policies mirror other specialised policies that are already in place, they 
would most likely be single risk coverage that would provide low coverage limits 
but would demand a high premium.  
 
Finding out potential risks from nanotechnology may bring a higher cost per 
premium for a company wanting insurance as well as potentially creating other 
problems. For those companies that invest in safety testing and monitoring, they 
may find that they have become liable for risks to the environment, health and 
human safety through that testing. To be unaware of the risks from a lack of 
company research would mean that the company would avoid liability. Therefore 
there is a suggestion that companies would avoid testing for risks to avoid 
liability (Wagner, 2008).  
 
 
5.3.6. Possible Future Insurance Scenarios 
 
It is difficult to predict how insurance coverage will evolve for nanotechnology 
and nanoparticle products and whether it will be in a similar way to other 
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emerging technologies. Broadly speaking and according to Hull and Bowman 
(2008), there are three phases that insurance coverage evolves through, which 
include (1) the early study phase, (2) the fear phase, and (3) the mature phase. 
Hull and Bowman (2008: 175) argued that the first phase, which is the early 
study phase: 
 
?typifies the current state of nanotechnology, is characterised by 
continuance of existing policy coverages and efforts by insurers and 
reinsurers to become more familiar with those special exposures and 
risks posed by nanotechnology? 
 
Initially underwriters may make a positive response to applications due to 
increased premiums for such technologies, but as there are no verified risks, 
there is no definitive decision to exclude nanomaterial coverage from policies. 
Hull and Bowman (2010) have stated their reasons that this strategy may be 
adopted including, a minimal risk of exposure to the public, a variety of different 
nanoparticle properties and products with different risk potentials, and the 
zeitgeist of insurance portfolios, where the diverse nature of technologies and 
unfavourable single effects of products are considered.  
 
Presently there is a lack of data validating risks associated with nanomaterials 
and nanotechnologies, but with global efforts by governments to seek 
information on health, safety and the environment (HSE), insurance companies 
need to be vigilant when creating policies that cover nanotechnologies and 
products containing nanomaterials. In the UK, The National Industries 
Association (NIA) is attempting to develop a roadmap, which will set out 
Responsible Technology Development, in order to set out a programme for 
health, governance and the environment (Hull and Bowman, 2010). Once an 
improved and stable regulatory landscape has been devised, insurers will have a 
clearer vision of any potential risk.  
 
Insurers are also collecting information themselves concerning risks pertaining to 
nanotechnologies and nanomaterials. This information includes how businesses 
that are involved with nanotechnologies dispose of, store or produce 
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nanomaterials. Insurance companies are assessing any potential bodily injury to 
the public or workers, property damage, or environmental damage or liabilities 
associated with businesses using or handling nanomaterials (Hull and Bowman, 
2010). 
 
The second phase, which is ???? ?????? phase, occurs when there is increasing 
anxiety about any future liability. The suggestion that carbon nanotubes behave 
in a similar way to asbestos coupled with other suggestions to stop the progress 
of nanoscale research, indicate that this phase has already arrived or if not is 
imminent (Poland et al, 2008; ETC Group, 2003). Insurance companies 
alongside reinsurers have already begun to believe that the risks associated with 
nanotechnologies might be greater than anticipated. With increasing media 
coverage, doubts are beginning to be raised within insurance companies about 
current policies causing them to reconsider coverage and limits. The ?????? stage 
may be unpredictable as there are conflicting research results which are being 
published on a daily basis. If insurers decide that the risks are too great, they will 
pull out of the market ?????????????????????????????????????????????????????????????
scenario were to take place, it is possible that governments, who want to push 
forward the positives of nanotechnology, may propose alternate solutions for 
high-risk activities connected with nanotechnology.  
 
One of these solutions could involve the initialisation of pools of insurance 
companies who take on the most unpredictable aspects of this technology. It 
would be mutualised and the funding exposure balanced across companies 
insured for nanotechnology, therefore allowing premiums to be lower (Hull and 
Bowman, 2010).  
 
Another solution may be for governments to step in, backing up any liability on 
the part of the nanotechnology industry. There is precedent for this in the US 
when Congress enacted the 1957 Price Anderson Act, limiting the liability ????????
nuclear industry in the event of a nuc????? ????????? ??? ??????????????????? (Hull 
and Bowman, 2010: WP). Further to this, Hull and Bowman (2010: WP) 
suggested that insurers might need:  
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???? ?????????? ?? ??? ? fault system in which the nanotechnology 
industry funds the first layer of insurance according to a 
predetermined scheme and any claims above that amount would be 
???????????????????????????????.  
 
This type of regulation can be seen as rigid, slow, cumbersome and incurring 
high costs (Moran, 1995; Sinclair, 1997). Although due to their compulsory 
nature, and strong accountability they possess characteristics that appeal to voters. 
Ludlow et al., (2009; In Hull and Bowman, 2008: 316) have suggested that: 
 
??????? ???? ??????????? ?????? ? based regulation provides many 
advantages compared with no regulation. In many instances industry 
prefers this form of regulation because it provides a level playing 
field, as well as providing protection against short ? cutting 
competitors. It also provides certainty, assisting in securing capital 
finance and ins????????? 
 
The third phase, the ?mature? phase is when insurers know the exact type, 
severity and frequency of losses that could occur as a result of nanotechnologies. 
Insurers will be able to predict with more accuracy the types of losses due to 
more information being readily available from research, allowing for a better 
understanding of potential risks. Customised solutions at reasonable rates should 
therefore become available.  
 
It is necessary for governments, the legal community, manufacturers and 
scientists to work together to quantify and identify nanotechnology risks. Both 
the legal climate and public response are critical for this industry to continue to 
be healthy but this is under pinned by the accuracy of risk related data provided 
(Hull and Bowman, 2010). 
 
After examining multiple aspects of nanoparticle risks and i?????????? ???? ?????
section draws multiple aspects together in a summary.  
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5.4. Summary 
 
This chapter has examined nanotechnology and particular nanoparticle risk and 
insurance. While the arenas of risk and insurance have frequently dealt with 
complex, uncertain and opaque products, the speed, technological complexity 
and opacity of nanotechnology products have created an unprecedented 
challenge. Coupled with a paucity of scientific data to back up claims being 
made about the risk and safety of nanotechnology and nanoparticle products, it is 
unlikely that a fit-for-purpose solution will be found that meets all stakeholder 
criteria. The examination of nanotechnology products is often linked to concerns 
?????? ?????? ????????? ????? ?????????? ?????? ?he shadow of the past for prior 
technologies such as asbestos has been argued as creating a shadow over the 
future for nanotechnology products such as CNTs, which has impacted on both 
risk and insurance of products. It is suggested that the complexity and paucity of 
technical data for nanoparticle products is hindering more adequate assessments 
of risk and insurance for specific concerns, and that this factor must be a priority 
for these areas to advance in a meaningful way. Without meaningful data, it will 
be difficult to use many of the risk assessment systems, in turn creating 
challenges for insuring products. Through physical scrutiny of these products, 
there is a potential for nanoparticle products to be assessed as their own entities, 
and limit socially constructed arguments being made from prior technologies.  
 
????????????????????????????????????????????????????????????????????????????????????-
for-????????? ????????? ?????with a compilation into an industry database. The 
collection and utilisation of this data, although itself potentially problematic, has 
the potential to enable more appropriate risk based calculations and decisions. 
Practically, the construction of perceived and actual risks must be in conjunction 
with key stakeholders who have a high level understanding of the physicality of 
these materials and products, as well as limitations of testing methodologies and 
how this relates to risk. Thus, the suggestion at this point is not necessarily to 
state how nanoparticles should be regulated, but more to indicate a roadmap to 
enable regulation of risk.  
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The next chapter goes on to look at health, safety and the environment, which is 
an area often debated and contested for the impact that nanotechnology and 
nanoparticles will have, as well as the potential for regulation.  
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Chapter 6. Health, Safety and the Environment. 
 
 
6.1. Introduction 
 
????? ???????? ??? ???????? ??????? ??? ???? ????????? ????????? ?What are the health, 
safety and environmental implications of nanoparticle products, and how might 
regulation be used to address this issue???Nanotechnology products exist within 
an arena of commercial promise and inherent risk. Underlying many concerns 
about risk is the aspect of health, safety and the environment, which this chapter 
examines. Aspects concerning health, safety and the environment start at product 
inception, and span through R&D, usage and end with disposal. Engaging with 
this regulatory journey, this chapter explores issues including the concept of 
health, safety and the environment in different contexts, difficulties with 
addressing and regulating health, safety and the environment and regulation as a 
commercial barrier.  
 
With any examination of health, safety and the environment is the way in which 
a product may create harm, and which for simplicity is split into two forms. The 
first is the harm that may come from a product being used 
intentionally/unintentionally and resulting in harm to the user, others or the 
environment, which at some level can be controlled by a user. The second, which 
is much harder to control, is the unintended exposure to others, and for example, 
silver nanoparticles being washed out of clothing into drinking water, which 
many people are potentially exposed to. The examination of health, safety and 
the environment is therefore a complex mix, and often with great difficulties to 
unpick the important underlying aspects most pertinent for regulation. As a 
starting point to set up the rest of this chapter, the following section considers the 
concept of health and safety.  
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6.2. The Concept of Health and Safety 
 
Health and safety is a much-discussed aspect of personal and organisational life, 
with regulation being a vehicle to engage with a multitude of often-conflicting 
drivers. While there is a growing background narrative about challenges facing 
health and safety (HSE, 2014) it has been argued that there are very real needs to 
better regulate aspects of high technologies such as nanotechnology to reduce 
risk for the individual, society and the environment etc. (HSE, 1974). In the UK 
for example, the main regulatory body driving this goal is the Health and Safety 
?????????? ??????? ?????? ???? ???? ???????? ???? ?regulations and procedures 
????????? ??? ???????? ????????? ??? ??????? ??? ??????????? ??? ??????? ????????????? 
(CompactLaw, 2015: WP). Thus HSE has been involved in the creation of 
legislation to set in place systems and procedures through regulation to minimise 
injuries and accidents as well as creating safer environments. This is 
demonstrated from the HSE statement about workplace safety (HSE, 2014):  
 
??????????????????a right to work in places where risks to their health 
and safety are properly controlled. Health and safety is about 
stopping you getting hurt at work or ill through work. Your employer 
???????????????????????????????????????????????????????. 
 
This is arguably a powerful statement as it sets out that workers have a right for 
this to be the case, but also creates responsibility for the individual to adhere to 
workplace systems put in place by the employer. This chapter considers what this 
means for nanotechnology products in and outside of the workplace. An 
examination is made of the workplace, due to the availability of numerous legal 
discourses surrounding nanotechnology. The prevalence of discourse is much 
higher regarding the workplace, in comparison to personal use, but is often 
demonstrative of shared challenges arising from nanotechnology.  
 
Looking more at the HSE, it is responsible for regulating, promoting and 
enforcing health, safety and welfare in the workplace. It also has the 
responsibility for researching into occupational risks and hazards in England, 
Scotland and Wales, (Northern Ireland has its own HSE). HSE arose out of the 
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Health and Safety at Work Act 1974, absorbing the Railway and Factory 
Inspectorate (although the Railway Inspectorate has since been transferred to the 
Office of Rail Regulation in April 2006). The Department of Work and Pensions 
funds HSE, investigating major incidents and industrial accidents, and in 2008, 
merged with the Health and Safety Commission.  
 
The variety of areas that HSE engages in is vast, including agriculture, 
construction industries, chemical manufacture and storage industries, and food 
and drink manufacture, pesticides and recycling and waste management 
industries amongst others. According to HSE (HSE, 2014: WP): 
 
?????????????????????????????????????????????????????????????????????
their health and / or safety arising out of work activities, and, HSE, 
has responsibility for the occupational / worker protection aspect of 
???????????????????????????.  
 
New technologies present potentially unique challenges for HSE, based on the 
possibility of unique, unusual, and unknowable risks that may arise as 
technologies are developed and used in the workplace and beyond. Nanoscale 
materials may react differently to their bulk form and what is known about the 
characteristics at the bulk may not apply at the nanoscale (as previously 
discussed in Chapter 3). Not surprisingly, there are many potential health 
concerns relating to nanomaterials as discussed in this chapter. Importantly 
though, the HSE has still not actively sought or produced specific regulation 
concerning nanotechnology. While buried within so many conflicting drivers, it 
??? ????????????????????? ???? ???? ???? ????????? ??? ???????? ??? ???? ????? ????????
with nanotechnology. The approach taken by the HSE is demonstrative of wider 
discourses that have also argued that it is better to wait and see what happens for 
nanotechnology products being used by consumers.  
 
In the following section monitoring nanoparticles in the workplace is examined 
to better understand the dangers from nanoparticles and also challenges for 
regulating their use.   
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6.3. Monitoring Nanoparticles in the Workplace 
 
The pervasive nature of nanoparticle commercialisation has resulted in 
nanoparticle products being used in multiple supply chains and from product use. 
The wide use of nanoparticles has created risk for potential worker exposure 
from products containing nanoparticles. It is important that risks should be 
examined, and where necessary regulatory tools composed and utilised to ensure 
fit-for-purpose worker and end user protection (Boucher, 2008). It is thus 
important to examine the life cycle of nanoparticles, from their creation, use and 
end of life, which can give a fuller view of potential nanoparticle toxicity. This 
steps away from a propensity for regulations requiring scientific evidence from 
the R&D stage, and which is often at the expense of monitoring products in more 
??????? ?????? ????????????? ???????? ??? ?? ??????????? (Hull and Bowman, 2010). 
Arguments have been made that nanoparticle monitoring should be more 
orientated towards understanding risks in non-laboratory environments (although 
in practicality, tested in a laboratory). For example the Parma Declaration on 
Environment and Health (2010) led to government ministers pledging to 
implement improved assessment methods to examine health and environmental 
risks associated with nanoparticles and in a wider context, nanotechnology. The 
???????????????????????????? ?????????? also been reviewing relatively recent 
research to clarify links between nanoparticles and health risks with findings 
focusing on a more pragmatic approach on risk regulation.  
 
Within any workplace, there are three possible routes where workers may be 
exposed to nanoparticles, which may also be the same for the end user i.e. the 
consumer. The three main routes of nanoparticle exposure are (1) ingestion, (2) 
inhalation, and (3) dermal contact i.e. the skin (Hansen, 2012; Poland, 2012). 
These routes are all based on an individual coming into physical contact with 
nanoparticles, with nanoparticles being too small to see with the naked eye. This 
creates problems for workers, as they will be unable to see the nanoparticles in 
their environment, potentially creating a false perception of there not being any 
danger due to exposure, which is again similar for product users. With an 
increased use of nanoparticles in many work and home places, there is arguably 
an urgent need to examine the exposure of workers to nanoparticles, as well as 
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customers, and track this impact over time. Coupled with this is a need to 
identify worker subgroups that are more vulnerable to nanoparticle exposure, to 
adequately deal with any associated risk. Although children are unlikely to be 
within a workplace (unless in a crèche etc.), alongside the elderly they are known 
to be higher risk groups (WHO, 2008; Chaudhry, 2012). This of course may well 
be different for consumers, where higher risk classes might specifically use 
products. Examining the life cycle of a product and associated risk can be 
beneficial to higher risk groups (as long as this is factored into the examination) 
as nanoparticles may be specifically utilised in the creation of products for these 
groups. An example of this is the use of silver nanoparticles, which are beneficial 
????????????????????????????????????????????????????????????????????????????????????
baby bottles and a variety of other health care products, but may result in greater 
exposure levels (Chaudhry, 2012). 
 
At present there is a dearth of scientific data for almost every type of 
nanoparticle, making decision-making for risk within the workplace challenging 
(Hansen, 2012). For information to be acquired, there is a technical and financial 
cost of measuring nanoparticles in the workplace, where there appears to be little 
desired on the part of businesses to carry this out (Hansen, 2012). Although, 
??????????????????????????????????????????????????????????????????????????????????
(CST) Nanotechnology have been meeting regularly since 2006 with the HSE to 
discuss the manufacture, use and disposal of nanoparticles in the workplace. 
Carrying out accurate and routine measurements has been cited as a current 
barrier from the CST Secretariat (2006), with problems including, (1) high cost 
of equipment to carry out routine measurements in workplaces and a (2) lack of 
skilled operators for such equipment. Stepping beyond this, there is also a third 
barrier, which is the difficulty of analysis and contextualisation of measured data 
into a meaningful format on a large scale, where sense can be made to better 
regulate such environments. Pivotally, there is a lack of equipment to provide 
accurate monitoring of nanoparticles in complex work places. In an attempt to 
address this, a Nanoparticle Occupational Safety and Health Consortium 
(NOSH) led by DuPont (USA) in 2006 set out to look at the specifications 
required for an instrument that would detect airborne nanoparticles in a working 
environment. These specifications included the monitoring of each different type 
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of nanoparticle that an individual would be exposed to, as well as the length of 
time and dosage of exposure (CST Secretariat, 2006). Although it has been 
argued that a guaranteed market would exist for any company that could meet 
those specifications, at present, no such machine capable of all requirements 
exists (Bosso, 2010). Bosso (2010: xiii) has stated that the U.S. government is 
spending $1.5 billion annually on nanotechnology R&D but less than 3 percent 
of this is allotted towards identifying health, safety and environmental issues. 
Only limited discussions are occurring focussed towards customer use of 
products, highlighting the challenge facing this area.   
 
The difficulty for any machine to measure workplace exposure is the wide 
variety of environments that may need examining, where exposure to 
nanoparticles can occur, which is also the same for customer use, albeit with 
different environments. Looking at workplace environments, they can include 
laboratories, transport areas, storage and sales facilities, cleaning areas, waste 
management and maintenance etc. In any of these or other areas is a possibility 
for nanoparticles to be liberated into the environment, with potential profound 
difficulties in measuring their release and effects. Importantly, current safety 
procedures are insufficient and protection measures inadequate (ETUC, 2008). 
As a minimum, this demonstrates a necessity for increased training, education 
and research in health and safety concerning nanoparticles, as well as other 
nanomaterials (ETUC, 2008). 
 
Examining what occurs when nanoparticles are released into the workplace, 
either by deliberate action or by leakage, is beneficial to understand the 
difficulties facing this area. Upon nanoparticle release they will rapidly mix with 
the air and disperse quickly through the gaseous environment (HSE, 2004). The 
concentration of nanoparticles does not remain localised, allowing the level of 
exposure at the site to drop rapidly. This can be demonstrated by the use of 
nanoparticle aerosols that behave in a different manner to larger particle aerosols 
due to the ??????? ??? ????????? ??????????? ??????????????? ????????????? ????
deposition?? ????? 2004: WP). This can have an adverse affect due to the 
nanoparticles then being spread over a larger area causing greater levels of 
worker exposure. According to HSE (2004) workers are more at risk from 
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aerosols that contain a smaller particle size that can be inhaled.  HSE claim that 
at the micrometre scale, behaviour of nanoparticles in aerosols is governed by, 
?inertial, gravitational and diffusional forces? (HSE, 2004: WP). As particle size 
decreases to the nanoscale, diffusional forces become dominant allowing 
behaviour that is similar to gas or vapour, and thus, increasing the spread. HSE 
therefore believes that it is necessary to examine the differences between large 
?????????? and small ????????????? particles in relation to aspects of exposure and 
control (HSE, 2004). This further increases the potential measurement 
requirements in a workplace, and raises questions about the practicability of such 
an approach.  
 
Although a discussion of nanoparticle liberation into the air has been discussed, 
nanoparticles may also enter the workplace from leaks (thus in a liquid form). In 
such cases, nanoparticle accumulations on surfaces are more likely to enter the 
body through the skin. Surface based nanoparticle contamination raises further 
problems as the collection methods for examining nanoparticles are different to 
air-based contamination, and swabbing may miss or highlight un-representative 
areas of contamination (HSE, 2004). Decontamination of nanoparticles is 
problematic as normal cleaning processes are not always effective, creating a 
possibility that workers could suffer chronic exposure from dermal and ingestion 
routes if the nanoparticles remain in a contaminated workplace for any length of 
time.  
 
Although numerous difficulties have been highlighted in this section, moves are 
being made towards addressing some concerns, although arguably at a limited 
rate. For example, ETUC are encouraging Member States to set up a register of 
????????? ????????? ??? ?????????????? ??? ???????????? ????? ??????? ?????????????
programmes. As a starting point, valuable information for future studies can be 
collected and examined for the prevention of occupational diseases, such as 
chronic effects of engineered nanoparticles in the human body, which might only 
become noticeable in the longer term (ETUC, 2011). 
 
Drawing on concepts raised in this section, the next section focuses on the 
dangers of working with nanoparticles.  
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6.3.1. Dangers of Working with Nanoparticles 
 
Workers may be exposed to nanoparticles in the workplace at various times, in 
different environments, and either inhaled, ingested or absorbed through the skin, 
which may also occur for customers, but through potentially different 
mechanisms. Considering the numerous workplace activities that are carried out 
in any sector using nanoparticles, the events causing unintended or undesired 
nanoparticle release into the workplace are numerous, and can for example 
include procedures such as cutting and grinding, as well as cleaning etc. 
(NIOSH, 2009). To more fully understand the phenomenon of workplace 
nanoparticle toxicity and risk, it is arguably necessary to identify the hazards 
from different nanoparticles, with current strategies to do this being at an early 
stage. Importantly, current information points to bulk scale products having 
different properties to their counterparts at the nanoscale, which creates unique 
challenges for addressing nanoparticles in the workplace. This is being 
compounded by conventional sampling and detection methods for carrying out 
occupational safety monitoring not being adequate for nanoparticles. Current 
occupational exposure limit values (OELVs) may not be relevant for 
nanoparticles, according to the Chemical Agents Code of Practice (HSA, 2010). 
All of these aspects are against a backdrop of a relative paucity of data to show 
the toxicity of nanoparticles in different workplaces (NIOSH, 2009). This has in 
turn resulted in the Health and Safety Authority (HSA, 2010) recommending a 
???????????????????????? using control measures to include engineering controls 
that involve a total enclosure of a process and containment control, so that any 
dust will go through a ventilation extraction allowing only purified air to be 
recirculated (HSA, 2010). Providing that the nanoparticles are in the air, and can 
be cycled through a fit-for-purpose ventilation system, this may go someway to 
resolving part of the risk of nanoparticles, but raises a further question about the 
maintenance of a ??????????????????????????????????????????.  
 
Importantly, the HSA has stated that at present there have been no specific health 
effects that have been explicitly associated with nanoparticle exposure in the 
workplace. This is due to the lack of any scientific and medical evidence, which 
is arguably from a current lack of adequate methods to measure exposure to 
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nanoparticles. This appears a somewhat circular argument by the HSA, where an 
inability to measure something has resulted in a lack of evidence, thus making it 
safe. Based on this ????????????????????????? recommended occupational health 
screening (HSA, 2010). Looking beyond workplace detection and screening, 
which as already argued is challenging, there is laboratory evidence albeit not 
from the workplace, that nanoparticles can be toxic, as shown in Table 6.1. 
 
Method of Risk Risk 
Inhalation Evidence exists that certain nanoparticles may be deposited in 
the respiratory tract if inhaled. This can cause inflammation and 
potentially damage cells (NIOSH, 2013). 
Skin absorption 
and inhalation 
Titanium dioxide commonly used in sunscreen and other 
commercial applications including paint, paper, cosmetics and 
food, can be produced in a varying size of particles including 
nanoparticles. NIOSH has determined that nanoscale titanium 
dioxide particles have a higher mass ? based potency than larger 
particles. This suggests that occupational exposure to nanoscale 
titanium dioxide by inhalation could be a potential occupational 
carcinogen (NIOSH, 2013). 
Skin absorption There is a possibility that certain nanoparticles have the ability 
to penetrate cell membranes causing damage to intra cellular 
structures and cellular functions (NIOSH, 2009). 
Environmental Nanoparticle dusts may be combustible and could ignite easier 
than larger dust particles creating a risk of explosions and fires. 
Examples of this are wood and sugar (NIOSH, 2009).  
 
Table 6.1. Nanoparticle risks to humans and the environment.  
 
Within the workplace, there are only a few current occupational exposure limits 
specifically set for nanoparticles. This is an area that should be addressed due to 
certain nanoparticles having the potential to be more hazardous than their 
counterparts in the bulk state (NIOSH, 2009). Thus any existing occupational 
exposure limits for a substance may not give adequate protection for substances 
at the nanoscale, and is in need of reform. This is not to suggest that no moves 
have been made to set occupational limits, but more that they are the exception 
rather than the rule. An example of an existing limit recommended by the OSHA, 
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is for worker exposure to nanoscale titanium dioxide, which should not exceed 
???????? ???? ??????????? ???? ?????? ??????? ????? ??? ??? ???trast to fine scale 
particles of titanium dioxide (particle size of greater than 100 nm) is 2.4 mg/m3 
(NIOSH, 2009). Exposure limits for other nanoparticles have not been set yet, 
therefore NIOSH recommend that safety measures should be put in place by 
minimising exposure using hazard control and best practice measures. These 
include, (1) assessing worker exposure to nanoparticles to control and identify all 
measures needed to determine if controls in place are effective, (2) tasks where 
workers could be exposed to nanoparticles should be detailed, identified and 
described, (3) identifying the state of the nanoparticle i.e. dust, powder, droplets 
or spray, (4) identifying exposure routes i.e. inhalation, ingestion or physical 
contact, and (5) determining an appropriate sampling method to measure 
quantities of exposure such as airborne concentrations and duration of exposure. 
As NIOSH (2009) explicated, it is important that companies determine what 
??????????? ????????? ???? ??????? ??? ?????? ????????? ????????? ???? ?????? ???? ?????
affective strategies. Importantly, NIOSH are proposing an inventory of tasks that 
will include information on the duration and frequency of anything that could 
result in exposure as well as the quantity of material being handled, the physical 
form of the nanoparticle and its dustiness. This exposure assessment has the 
ability to help with the understanding of exposure potential and could provide 
guidance for controls for exposure mitigation (NIOSH, 2012). 
 
A set of strategies for decreasing and potentially eliminating worker exposure are 
required as a way of exposure control. For example, workers can limit their 
exposure by job rotation and good housekeeping procedures such as spill 
prevention, correct labelling and proper storage. Exposure sources during the life 
cycle of the nanoparticle need to be evaluated with its disposal at the end of life 
stage following regulations as for contaminated refuse. It is interesting to note 
that many products containing nanoparticles may change their exposure potential 
during their life cycle. An example of this is liquid paint when applied changes to 
a solid form once dried. The dried surface suffers abrasion and weathering that 
could lead to further exposure (Hansen, 2009). This should raise the level of 
concern due to the challenges of measuring nanoparticles in the work and home 
place.  
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As Howard (2012) posed, what are the properties that may influence or 
determine the inherent hazards of nanoparticles? Questions are also being raised 
about the appropriateness of current H&S legislation, guidelines, test protocols 
and animal models that are being used to assess risks to humans due to doubts of 
suitability of the models being used to identify low dose and long-term effects 
(Howard, 2012; Kearns, 2012; Loft, 2012).   
 
A management tool used for protecting workers from potentially hazardous 
working conditions is Prevention through Design (PtD). This tool allows 
occupational health and safety issues to be addressed by eliminating hazards and 
minimising risks during the whole life cycle process. PtD is also used as a cost 
effective method in many nanotechnology research laboratories to enhance 
occupational health and safety within their facilities (Murashov and Howard, 
2009).  
 
A pertinent question that needs to be raised when dealing with nanoparticles in 
the workplace is; can the protection equipment that is currently available today 
be effective enough to protect workers from the potential hazards including 
inhalation, dermal contact and ingestion? An examination will be made of this 
aspect, with the next section exploring inhalation of nanoparticles.  
 
 
6.3.2.1. Inhalation 
 
One of the commonest ways a worker may be exposed to engineered 
nanoparticles is through inhalation via the mouth or nose (Hoet et al, 2004). The 
greatest risk of exposure of inhalation is from nanoparticles in a dry powder 
form. Liquids containing nanoparticles present less of a risk, while the least risk 
being from nanoparticles that are incorporated into a solid, due to their limited 
mobility (NIOSH, 2009). Dusty materials present a particularly large problem 
due to their propensity to liberate nanoparticles into the environment. During the 
manufacturing process, synthesis and material handing can potentially increase 
exposure to an employee. Other ways of increased exposure can be through open 
manual handling of bulk amounts of nanoparticles, high energy processes 
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including sonication, grinding, blending and milling, all of which can potentially 
cause the release of nanoparticles (Gohler et al, 2010; Johnson et al, 2010). 
 
The European Centre for Ecotoxicology and Toxicology of Chemicals 
(ECETOC, 2006) believes the inhalation of nanoparticles to be one of the main 
areas of concern, due to potential negative effects of nanoparticles that may 
occur in the human body. The first site of major concern in the human body is 
the respiratory tract, which aims to filter unwanted materials but may itself be 
damaged by the presence of nanoparticles (Hoet et al, 2004). Smaller 
nanoparticles have a greater potential to penetrate the lining of the lung, due to 
their relatively small size (ECETOC, 2006). Different nanoparticle sizes can thus 
damage the respiratory system at different levels. Beyond direct physical 
damage, nanoparticles can reduce the ability of the respiratory system to function 
correctly, and in particular inhibit its ability to clean itself, which can facilitate 
the creation of disease states. Hoet (2004) has argued that this problem is 
independent of the toxicity of the material at the nanoscale but is more related to 
size and shape of the nanoparticles. Work carried out by Wilson et al (2002) and 
Donaldson et al (2003) have shown that inhaled nanoparticles can result in 
airway inflammation, triggering of asthma, blood clotting, and cellular death. 
Beyond direct damage to the respiratory system, ECETOC (2006) has reported 
that where insoluble or slowly dissolving nanoparticles are deposited on the 
walls of the respiratory tract, they are only partially moved by mucus or 
coughing and are instead swallowed, which can create problems in the digestive 
systems, where damage can be done to the intestines, liver and kidneys (Behrens 
et al, 2002; HSE, 2004). Perhaps more worrying are the animal studies carried 
out in medical research, that have shown that nanoparticles can change their 
chemical composition, crystal structure and particle size, all of which can alter 
their toxicity. This creates a great potential difficulty of assessing nanoparticle 
toxicity, if the interaction with a living host changes nanoparticle size, shape, 
crystal structure and toxicity upon entering a host body (NIOSH, 2009).  
 
The new ISO 10808 standard (2010) contains new guidelines in a bid to help 
industry assess the possible risks in the growth of nanoscale - based products by 
increasing safety for workers and consumers. ISO has attempted to take into 
	  	  	   	  	  	  	  	  124	  
account particular characteristics and potential risks of nanoparticles thus it may 
be an important step towards regulation (ETUC, 2011). 
 
For workers handling nanoparticles and being exposed to them on a regular 
basis, it is important for their health and safety that regulations for the control of 
airborne particle pollution are set in place. Uncertainties and research gaps have 
a propensity to create difficulties for management decision-making about health 
risks (NIOSH, 2009). More research is needed so that exposure limits can be set, 
preventing dangerous doses from being reached during the lifetime of those 
exposed. As of yet, no data is available to determine a critical dose of 
nanoparticles that initiates disease states in humans (Bosso, 2010). This can be 
coupled with a lack of data in this area for humans in general (ICON, 2006). 
Methods to monitor worker exposure are hindered by a lack of universal 
sampling equipment that can be used to measure exposure (NIOSH, 2006; 
Maynard and Aitken, 2007). Many methods of measurement are simply not fit-
for-purpose and cannot differentiate between different nanoparticles and whether 
they are toxic or safe (NIOSH, 2006; Fujitani et al, 2008). If measurement of 
nanoparticles in the workplace is currently unachievable due to lack of 
knowledge and technology, it may present an insurmountable challenge for 
constructing fit-for-purpose legislation (Hansen, 2009), or at least regulation 
based on sound scientific evidence. This is no small challenge, and arguably 
there is little suggestion for how to advance this area, and seems to suggest that 
while a rapid state of commercial exploitation of nanotechnology products has 
been sought, the predominant focus has been on manufacturing rather than 
technological innovation to assess product safety.  
 
Moving on from inhalation, the next section examines the ingestion of 
nanoparticles.  
 
 
6.3.2.2. Ingestion 
 
Ingestion of nanoparticles involves an individual directly or indirectly eating or 
drinking nanoparticles, or food and liquid contaminated with nanoparticles. 
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Practically, this is far less likely to happen in comparison to inhalation, as the 
opportunities for ingestion are arguably lesser (NIOSH, 2009). Importantly, and 
according to HSE (2004) guidelines on the health and safety of nanoparticles, 
relatively little work has been carried out to understand nanoparticle ingestion. 
Studies have so far been limited to food contamination from hand to mouth 
including sources such as lead nanoparticles from paint. Although from a non-
nanoparticle study, Sen et al (2002) showed that scaffolders working with pipes 
containing lead had high levels of lead poisoning from penetration of lead 
through the skin, and eating practices. This suggests that the risk of 
contamination from potentially toxic materials must be considered with more 
nuanced thinking to more fully capture the risk.  
 
If using the lens of risk, there is a potential to misconstruct the ingestion of 
nanoparticles to that of accidental ingestion, which potentially misses out 
intentional ingestion, as would be the case of nanoparticle pharmaceutical 
products. These products, take advantage of the small size of nanoparticles to 
enhance product activity and to more accurately target desired parts of the body, 
such as a tumour. However and irrespective of the intentionality of ingested 
nanoparticles, there is still risk with their ingestion (including pharmaceutical 
nanoparticles). A document presented to the House of Lords in 2009 
(publications.parliament.uk, May 2009: WP) examined evidence into known risk 
factors associated with the exposure of nanoparticles. It claimed that current 
research has indicated that nanoparticles are able to penetrate cell membranes in 
the lining of the stomach wall, potentially passing through the epithelium into the 
lymphatic vessels or the bloodstream. Chaudhry (2009: 113) argued that there is 
excellent mobility both inside and outside of the cells potentially accessing ?????
??????????????????????????????????????????????????????????????????????????????????.  
If this is the case, and bearing in mind this is a wide-ranging claim, it would 
suggest caution in the use of nanoparticles that may be ingested. Stepping back 
to look at the physicality of nanoparticles within a human body (although the 
argument could be extended to other animals), do nanoparticles remain as 
nanoparticles once digested? It is certainly possible that nanoparticles may 
undergo processes that result in their breaking into smaller parts or aggregating 
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into larger scale particles, which may influence their toxicity. Chaudhry (2010: 
36) argued that: 
 
??f nanomaterials are solubilised, digested or degraded within the gut 
????? ????? ???? ??? ?????? ???????????? ????? ???????? ??? ??? ???????????
indigestible, non ? degradable nanoparticles that can survive 
??????????????????????. 
 
While informative and insightful regarding the dangers of insoluble 
nanoparticles, which may interact with the body beyond digestion in a negative 
way, it is perhaps limited in its scope. For example, the dissolution of lead 
??????????????????????????????????????????????????????????????????????????????????
It has however been argued that insoluble nanoparticles present the most risk, 
which was stated by SCENIHR (2009: WP): 
 
??oxicologists agree that the persistent nanoparticles, especially 
those that are non ? biologically degradable, inorganic, the 
inorganic metal oxides and metals, are the particles that pose the 
??????????.   
 
Importantly, the potential health impact on humans and other animals from 
nanoparticles is still predominantly unknown. With an increasing use of 
nanoparticles in a greater number of products that interact with food and liquids, 
including for instance fridge-freezers (Donaldson, 2008), this is not a small 
problem and I believe is an area worthy of much greater study, to elucidate the 
risks and to work towards more fit-for-purpose regulation.  
 
Building on this and the prior section, which have examined nanoparticle 
ingestion and inhalation respectively, the next section considers dermal exposure.  
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6.3.2.3. Dermal Exposure 
 
Dermal exposure to nanoparticles typically refers to physical contact of 
nanoparticles with the skin and hair follicles (Tinkle et al, 2003), where the 
nanoparticles may remain or further penetrate into the body. Evidence based risk 
is currently lacking in this area, and HSE (2000) have claimed that there is no 
evidence to suggest that there is any specific health problems associated with 
dermal penetration by nanoparticles. Arguably, it might be more fitting to 
reframe this as there is insufficient evidence based on a lack of studies, rather 
than no evidence from a lack of risk, which potentially suggests examination, 
which failed to show risk. Unfortunately, little work has been carried out in this 
area, meaning that much discourse is speculative.  
 
Schneider et al (2000) highlighted perhaps the greatest problem for assessing 
nanoparticle related dermal toxicity, is the technical challenge of monitoring. 
Currently, although this is likely to change, the equipment to measure 
nanoparticle dermal toxicity is limited, resulting in many claims being made 
about bulk scale rather than nanoscale materials. Further to this, is the use of 
animal models rather than skin on a human, with the former being informative 
for the latter, and raising the question of validity to humans? Importantly, where 
animal models have been used, dermal exposure to nanoparticles has a potential 
to cause harmful effects locally either on the skin, within the skin or if the 
substance is absorbed, by dissemination throughout the bloodstream causing 
systemic effects. These effects are more pronounced in areas of high exposure, 
more susceptible areas of the body such as the inner thighs, and with an 
increased length of exposure (Schneider et al, 2000). Although attempts have 
been made to more fully understand this area, the scientific link between claims 
being made and risk management is thus largely unknown, which hampers not 
only management but also the potential for fit-for-purpose nanoparticle 
regulation.  
 
As with ingestion of nanoparticles, pharmaceutical companies have shown an 
increasing interest in the potential to exploit the ability of nanoparticles to 
penetrate the dermal layer as a delivery system for their products. Particular areas 
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of interest to the pharmaceutical industry include drug delivery and anti-aging 
cosmetics. Friends of the Earth (2006), has raised concerns about the use of such 
products, which are currently being sold globally, which in fish models have 
shown the potential of such products to penetrate the brain and cause gene and 
brain damage. ?????????????????? WP) showcased the problem by stating:  
 
????????????????????????????????????????????????????????????????????????
and assess the risks and benefits of this new technology before use 
?????????????????????????????. 
 
This raises the question as to whether nanoparticles used dermally are able to 
penetrate the human skin layer and travel through the bloodstream to major 
organs, and if so, what damage can they do? When considering the increasing 
use of nanoparticles in products, (for example sunscreens that contain 
nanoparticles of titanium dioxide and/or zinc oxide), this is potentially not a 
small problem (IARC, 2006; The Friends of the Earth report, 2006; Benninghoff 
and Hessler, 2008). Again the issue arises for how to address a lack of 
technology to suitably address these concerns, whereby at present it is potentially 
hugely problematic to detect and elucidate damage being done to the body by 
these products. This is not simply an issue relating to a lack of technology to do 
this but also a lack of skilled operators as well as recognised and potentially 
???????????? ??????????????????????????????????? 
 
Although this particular section has arguably raised more questions than it has 
answered, and examined the direct risks of exposing the human body to 
nanoparticles, the next section explores environmental issues of nanoparticle 
release and contamination.  
 
 
6.4. Environmental Issues 
 
?????? ???? ????? ???????? ??????????????? ??? ????????? ???????? ??????? ?????????
intentionally and unintentionally released nanoparticles in two specific 
environments, nanoparticles can be released in many other environments, which 
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may fill the demand for various societal drivers, but may also produce long-term 
negative societal and health impacts, particularly in the wider environment. This 
section therefore focuses on nanotechnology, with attention being paid towards 
nanoparticles in what has been terme???????????????????????????????? 2010).  
 
As a general backdrop to this section, it is worth emphasising that non-human 
?????????????????????????????????????????????????????????????????????????????????
years, if not longer. Simply, natural nanoparticles can be found in ocean spray, 
volcanic ash, clouds, forest fire smoke and clays etc. (Hutchison and Malone, 
2011). These nanoparticles are usually believed to be harmless to the 
environment unless an environmental incident occurs i.e. a volcanic eruption, 
where an excess of nano and other scale particles can result in the damage to 
human, animal and wider environmental health. This could however be just a 
simple discursive framing, as little academic attention has been paid towards 
naturally occurring nanoparticles and their health and safety impact, in 
comparison to their human made nanoparticle counterparts.  
 
Looking at the intended use of nanoparticles within the environment, examples 
can be found for global projects, such as providing clean water for the 1.1 billion 
people without access to clean water (Prentice and Reinders, 2007). Non-
nanoparticle products, while somewhat effective for cleaning water are often cost 
prohibitive i.e. too expensive and can create environmental damage (Bernhardt et 
al, 2010), whereas nanoparticle products offer a potentially cheaper and more 
scalable solution. While nanoparticle products may offer a lot commercially and 
for cleaning water at a relatively low cost, the long-term effect is simply not 
known. Coupled with this has been a lack of research into longer-term effects to 
understand the ecological effects of such products (Bhattacharya, 2012). 
Titanium dioxide nanoparticles, which are currently being used in this area, have 
been shown and as already argued within this study, to create potential toxic 
effects  (Bhattacharya, 2012).  
 
The promises of nanotechnology for environmental scientists have become a 
double edged sword. There are positive and negative aspects that need 
investigating, as there has been little research into the key areas. There are those 
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who believe that nanotechnology holds the key to the future by being the saviour 
of the planet due to novel pollution prevention methods and remediation 
????????????????????????????????????????????????????????????????????????? 2010). 
With this in mind it is important to examine the evidence presented by HSE 
posed to human health and the environment that unfortunately has often been 
contradictory. Some policy makers and environmental scientists conclude that 
the risk posed is incredibly small whereas others such as Oberdörster (2004) 
believe that the risk is great to both human health and the wider environment. 
Currently the safety and danger of nanoparticles is very difficult to evaluate due 
to a lack of knowledge of their fate and toxicology posing the question of how to 
regulate. Concern has been expressed about the risk of silver nanoparticles 
destroying microbial communities, due to silver being an antimicrobial. 
According to Oberdörster, (2004) they have also been found inside the brains of 
large mouthed sea bass.  
 
There is a growing dilemma posed by nanoparticles to understand the potential 
risks that they can cause to human health and the environment. Different 
individuals and organisations interpret the same information in very different 
ways often taking into account their own interests that may colour their 
judgement. There are three different approaches when examining governance of 
these novel materials. 
 
The first approach is one of optimism. It claims that no regulatory attention 
should be necessary unless there is proof or at least a clear indication that harm 
has been or could be caused. This approach is seen to prevent the suppression of 
innovation as regulation is often claimed to stifle it. The second approach is a 
less optimistic one, and argues that any attempt to regulate nanoparticles should 
??? ?????? ???????? ??? ????? legislation would only be enforced when there is 
?????????????????????? ????????? ???????????????????????????????????????????????????
that science is able to detect risks at an early enough stage to prevent damage. 
Currently much science is contradictory when examining nanotechnology. The 
third approach is the view that nanoparticles should not be used in products until 
they have been proven to be safe not only to human health but in the 
environment. This creates the problem that consumers may be denied health 
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benefits and technologies that have the potential to generate a positive lifestyle 
effect.  
 
There have been many instances in history where substances have been used 
???????? ????????? ?????? ??????? ????????? ?????? ???????? ????????????? ???? ????
asbestos (Carman, 2008). Therefore it is important to avoid assumptions that 
have the potential to create serious consequences. Currently it is not feasible to 
answer questions on the impacts of nanotechnologies without using traditional 
regulatory frameworks that are risk based. Collingridge (1980: 16) described this 
problem as the ?technology control dilemma?????????????????? 
 
???? ???? ?????? ??????? ??? ?? ??????????? ??? ??? ???? ????? ??????? ???
establish the most appropriate controls for managing it. But by the 
time problems emerge, the technology is too entrenched to be 
??????????????????????????????????.   
 
This suggests nanoparticles, like other emerging technologies ?require an 
adaptive governance regime capable of monitoring technologies and materials 
as they are developed and incorporated into processes and products? 
(Collingridge, 1980: 32). Adaptive management systems more capable of 
responding to new information are needed to look beyond the traditional 
regulation solutions. This is a substantial challenge that moves towards the 
governance of innovation and away from the governance of risk, striving towards 
an adaptive and open system to encourage innovation but capable of preventing 
harm to human health or the environment (Jasanoff, 2005). Moving on from 
these areas, the following section considers nanowaste and nanopollution.   
 
 
6.4.1. Nanowaste and Nanopollution 
 
While attempts have been made to catalogue nanomaterials regarded as waste or 
??????????????????????????????anomaterials? at Nanowerk lists 25 nanomaterials, 
which is a very low number when considering the number of commercialised 
nanotechnology products (nanowerk, 2015: WP). This is not a complete list, and 
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for the nanomaterials listed, there is very little known about the behaviour of 
nanomaterials when they enter waste streams or their various end of life cycles. 
More information is needed to give a better understanding of the risks at the end 
of their product life. This would suggest that better disposal pathways plus 
potential transformation processes for nanomaterials are needed for 
nanomaterials in waste treatment plants (nanowerk, 2015: WP). This is due to 
little consideration having been shown for what are often unique properties of 
nanomaterials in the recovery or recycling stage. 
 
At present, there is no legal framework for separate treatment of waste 
containing nanomaterials. As there are no monitoring procedures, a prerequisite 
obtaining the exact knowledge about the nanomaterials being used such as the 
type, composition, potential transformation, amounts and concentration is needed. 
This information is currently unavailable due to the lack of studies on the end of 
a product life phase of nanomaterial products. One reason for this is that there is 
very little known about nanomaterial wastes and their behaviour in biological, 
thermal or mechanical waste treatment plants or landfills.  
 
Nanomaterials can be released into the environment at any stage during the life 
cycle of a product due to chemical or mechanical effects (nanowerk, 2015: WP). 
Boldrin et al (2014) argued that nanomaterials entering the environment diffuse 
into different sources and should be classed as ?nanopollutants?? Nanowaste can 
be defined as applicable when nanomaterials come into contact with solid wastes 
and collected separately. Nanoparticles only become waste after their elimination 
from wastewater treatment plants after the biological purification phase. 
Therefore sludge containing nanomaterials requiring further treatment can be 
classed as nanowaste. Wastes containing nanomaterials that are from production 
processes and households are also classed as nanowastes. Figure 6.1, shows the 
difference between nanopollutants and nanowastes.  
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Figure 6.1?? ???????????????? ???????? ???????????????? ???? ???????????? ????? ?????? ??????
that contains nanomaterials (Bodrin et al, 2014). 
 
It can be asked, why is the differentiation between nanowaste and nanopollutants 
important? The reason behind the necessary distinction is due to the Waste 
Management Laws (UK) (1996), the Hazardous Waste Laws (EU) (2009) and 
the Duty of Care Regulations transposed into the Waste (England and Wales) 
Regulations (2011) (gov.uk/waste-legislation, 2015). Nanowaste is therefore 
subject to these regulations although there is still no legislation specific to 
nanomaterials or mention of the term nanowaste. 
 
At the present there is too little known about the behaviour of nanomaterials in 
waste incineration plants posing several questions about the disposal of large 
amounts from industrial facilities and viable alternatives such as chemo?physical 
treatment methods. There are issues surrounding collection due to the diverse 
amount of products containing them. Recycled products that contain 
nanomaterials often release nanoparticles during the recycling process. Swiss 
studies have shown that on average 0.00079 percent by weight of filter dust in 
the incineration plant present in the form as nanomaterials, making up less than 
10 percent of the total amount (nanowerk, 2015: WP). This theme of uncertainty 
is considered in greater depth in the following section. 
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6.5. Uncertainties of Environmental Exposure to Nanoparticles 
 
With an increasing number of commercially available products containing or 
based on nanoparticle technology, there is a growing need to understand the 
consequence of environmental risk from these products. There are several routes 
to nanoparticles being released into the wider environment, including (1) 
manufacturing processes, (2) transportation, (3) product usage and disposal, and 
(4) product degradation amongst others (Biswas and Wu, 2005; RS and RAE, 
2004; Boxall et al, 2008). According to Christian et al (2008: 326-343) the 
environment may be impacted by nanoparticles in four different ways as shown 
in Table 6.2. 
 
Effect Consequence 
Toxicity Damages or kills natural biota. 
Trojan horse effect Negatively impacts the ability of natural 
biota to uptake and utilise nutrients.  
Oxidation of natural organ material 
(NOM) 
Indirect effect on an ecosystem that 
changes it negatively in some way. 
Changing environmental microstructures Addition of nanoparticles changes the 
physical structure of microenvironments.  
 
Table 6.2. Negative Aspects of Nanoparticles in the Environment.  
 
Currently there are no official figures for the total load of nanoparticles in the 
environment due to a lack of available monitoring equipment, fit-for-purpose 
analytical methods, and an incentive to detect and quantify nanoparticles (Muller 
and Nowack, 2008). According to Nowack and Bucheli, (2007: 5) part of the 
physical challenge of measurement is based on ?the lack of analytical methods to 
quantify nanomaterial effects in environmental matrices due to the complexity of 
both environmental conditions and nanomaterial physico ? chemical properties?. 
This is coupled with different levels of nanoparticles being released from 
products at different times in a product?s life cycle. An example of this is paint, 
where nanoparticles are initially in a liquid form during application but as the 
paint dries they are encapsulated in a solid form once the paint has been applied. 
In this example, initial consumer exposure comes from the liquid paint but then 
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changes as the paint dries, becomes weathered and if physical abrasion of the 
surface takes place thus allowing nanoparticles to re-enter the wider 
environment. With such uncertainty, concerns must be raised about the lack of 
information from potential hazards not only to the environment but also to the 
consumer (Hansen, 2008). 
 
There is a potential that manufactured nanoparticles can interact with ecosystems 
due to their small size and increased mobility, in comparison to bulk scale 
materials. Penetration into waste streams, water, soil, microorganisms, aquatic 
and land-based life could disrupt numerous ecosystems (AZoNanotechnology, 
2008). It is important to recognise that risk assessments made for the release of 
nanoparticles into the ecosystem is done with great uncertainty. This uncertainty 
is magnified by the challenge of it potentially taking years to scientifically 
demonstrate nanoparticle toxicity in such env?????????? ??????????? ???? ??????? 
2010). Life cycle notions and end of life of these materials are all under question 
as it is unknown what makes a nanoparticle relinquish its reactive properties or 
how or what could reactivate them (Zhu et al, 2007). It would appear that there is 
a very real issue for humans and the environment being exposed to an unknown 
risk without strategies being developed to mitigate this uncertainty and risk. The 
current research zeitgeist is orientated towards finding lethal effects from 
nanoparticles, which has been at the expense of building an understanding of 
sub-lethal exposure and ecosystem damage, which could also bring other 
perturbations such as climate change or species invasion (Lyon et al, 2007). 
 
It is necessary for governments to be aware of how and in what quantities 
manufactured nanoparticles from nanoscale products could potentially be 
released into the environment (EMPA, 2010). This poses the question as to what 
level of contamination can be expected in river or soil samples. It will be 
necessary for analytical methods that are suitable for investigating environmental 
samples of nanoparticle concentrations be established. This may be problematic 
due to some of the samples being at an undetectable level and therefore almost 
untraceable, leading to concern over the lack of standard or reliable equipment or 
methods to measure nanoparticles in the environment, including investigation 
into their potential risk (EMPA, 2010). It has prompted the Department for 
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Environment Food and Rural Affairs (Defra) alongside other global governments 
including many state governments in the United States, to set up special 
????????????????????????????????????????????????????????????????nanoecotoxicology, 
which the following section examines.  
 
 
6.5.1. Nanoecotoxicology 
 
Numerous studies have clearly highlighted the potential commercial advantages 
and opportunities of utilising nanoparticle technology in products. This must 
however be tempered against nanoecotoxicology, which is the damaging and 
lethal effect nanoparticles may have on the environment and ecosystems. One of 
the most challenging aspects of nanoparticles argued by Hansen (2009) and 
Migliore et al (2009) is that over time, nanoparticle properties have the potential 
to change. This can include oxidisation, changing surface coatings, and overall 
size and shape of the nanoparticles. Importantly, nanoparticle ???????? ??????
natural environmental conditions has been limited to examining the phenomenon 
in laboratory conditions, at the expense of a plethora of environmental conditions 
??? ???? ??????? ??????? ??? ??????????? ????? ??????? ?????? ?????? ????? ??? ?? ????????
examination of nanoparticles during the aging process under natural 
environmental conditions, taking into account these effects, which can be used to 
better inform regulatory systems.  
 
With much positive exposure of the perceived benefits of nanoparticle 
technology, entities such as The World Bank (the United Nations Food and 
Agricultural Organisation) UNFAO are looking at using nanoparticle 
applications to feed a growing world population where natural food production is 
under strain (Suppan, 2013). These agricultural applications particularly for 
crops have the potential to decrease the volume of pesticides by using silver 
nanoparticles and nanoscale metallic oxides that would target soil pathogens (but 
may also kill beneficial microorganisms). This is arguably a reductionist view of 
targeting one problem, while ignoring the wider implications and detriments of 
such technology.  
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In 2006, Oberdörster et al (WP) published a document in the Environmental Law 
Review advising: ?it would be prudent to examine and address environmental 
and human health concerns before the wide-spread adoption of nanotechnology.? 
So far, only some medical arenas of nanotechnology have heeded this advice. 
Thus, many governments have allowed thousands of consumer products to be 
marketed that have nanoparticles incorporated into them to be commercialised 
before any pre-market safety assessment has taken place. 
 
European Commission Directorate General for the Environment, (February 2010: 
WP) claimed: 
 
???? ?????? ??? ???????????? ??? ??????????? ??????? ????? ??? ?????????????
targeted at soil biodiversity, whether at international, EU, national 
or regional level. This reflects the lack of awareness for soil 
biodiversity and its value, as well as the complexity of the subject. 
Several areas of policy directly affect and could address soil 
biodiversity, including soil, water, climate, agricultural and nature 
policies.? 
 
Consumer products containing nanoparticles continue to be developed and 
commercialised without governmental regulation (Rizzuto, 2009: WP). ?As 
agri-nanotechnology rapidly enters the market, can soil health and everything 
that depends on it be sustained without regulation?? asks Suppan (2013: WP) 
?????????????????????????????????????????????????????????????????????????????
system should be asking themselves.? 
 
Without a regulatory system in place for the production or sale of fertilizers 
containing nanoparticles, soil scientists, farmers, biological engineers and 
public health professionals need to request governments to make robust 
assessments before allowing such products to be indiscriminately used by 
industry. To showcase this problem in greater depth the following section 
considers nanosilver and its use in the environment.  
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6.5.1.1. Nanosilver 
 
Nanosilver is a collection of products based solely on or using nanoscale silver, 
usually in a nanoparticle form. It has become a popular product for killing 
undesired microorganisms such as bacteria, as it has inherent antibacterial 
properties. Examples of product usage include swimming pools, washing 
machines, socks, deodorant, Elastoplast and toothpaste. Luoma (2008) estimated 
that between 10 - 30 percent of USA households use silver as a biocide, 
potentially in a nanoscale form. This has the potential to create a mass release of 
silver nanoparticles into the environment. The estimate by Luoma is based on the 
release of silver nanoparticles from three products; swimming pools, washing 
machines and socks. Looking more in depth at this issue, the contribution from 
socks containing silver nanoparticles depends on the amount of silver contained 
inside the product. The lower end estimate was between 6 - 930 kg and the 
higher end estimate was between 180 ? 2790 kg (Luoma, 2008). The estimate for 
the discharge from washing machines containing silver was 2850 kg with the 
contribution from swimming pools being approximately 30 tonnes. Luoma 
(2008) also estimated that in the future, 457 tonnes of silver could be discharged 
into wastewater. This figure has the potential to be reduced by waste treatment to 
approximately 128 tonnes if 80 percent of the discharge is treated and 90 percent 
of the silver is removed from these products or if an after stage silver removal 
treatment. There is little evidence to suggest there is any serious move to address 
either potential strategy for silver removal at this time.   
 
It has been estimated that over 300 tonnes of nanoscale silver are used globally 
per annum (Kaegi et al, 2013), which is not necessarily surprising as silver is 
effective as an antibacterial agent against over 650 disease causing 
microorganisms (ETUC, 2011). Cost is also an important factor due to the 
increased surface area of nanoparticles where one cubic centimetre of nanosilver 
has the equivalent surface area of two football fields.  Thus less silver is used 
when in a nanomaterial form. Although less silver has the potential to be less 
harmful to the environment, in a nanoscale form, lower levels can be more potent 
than their bulk forms, which can be more damaging to the environment. 
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Nel (2012) carried out research into the potential dangers of silver nanoparticles 
on aquatic life. They found that the geometries of these particles are the essential 
determinant in the toxicity of aquatic life (nanowerk, 2012: WP). The importance 
of this study and those similar is due to the concern over the amount of products 
currently on the market containing silver nanoparticles, with unknown 
geometries and associated toxicities. Nel (2012) found that the environmental 
toxicity from the silver nanoparticles was due to the defects on their surface 
capable of damaging cells. This is an important point, as prior to this research, it 
had been believed that the toxicity was from the release of silver ions. Therefore 
this study has revealed that silver nanoparticles have a potential to damage 
aquatic organisms prompting the need for safety questions to be asked about 
their impact not only on aquatic life but also on human cells.  
 
Tracking the life cycle of nanoparticles in the environment has also received 
much attention. The Lake Ecosystem Nanosilver (LENS) project examined the 
disposal of nanoparticles and in particular nanoscale silver (nanowerk, 2012: 
WP). The pathway these particles travelled throughout the waterways into rivers 
and lakes showed similar results to that of Nel (2012) in that nanoscale silver has 
the potential to damage aquatic organisms and particularly algae, zooplankton 
and bacteria, which are at the bottom of the food chain.  
 
The importance of the results from studies such as LENS is that they can be used 
to help policy makers decide whether and to what extent nanoparticles are toxic 
to aquatic life and ecosystems and whether regulatory action is required to 
protect and control their release into the environment. With the Nanowerk (2012: 
WP) estimate that 30 percent of nanoproducts contain silver nanoparticles, it is 
important that this area is elucidated. To date there is no evidence that 
nanoparticles have caused actual harm from their current applications to larger 
organisms such as humans, but due to the uncertainty of their behaviour in the 
environment and lack of adequate testing, adverse effects may still occur (Porter 
et al, 2012). 
 
In the UK, a collaborative research group from DEFRA, the Natural 
Environment Research Council (NERC), the Engineering Physical Sciences 
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Research Council (EPSRC) and the Environment Agency was formed in 2006 to 
investigate the behaviour and life cycle of manufactured nanoparticles in the 
environment.  This group is known as the UK Environmental Nanoscience 
Initiative (ENI). As nanotechnology is in many ways still in its infancy, the 
environmental unknown risks associated with manufactured nanoparticles remain 
high. The ENI (2010) has highlighted areas for concern being the need to 
understand sources, pathways, fate and persistence, outputs of nanoparticles, 
bioavailability and environmental exposure. There is a fundamental need to 
understand the behaviour of nanoparticles in the environment plus any potential 
interaction with other chemicals that have the potential to influence 
bioavailability.  
 
Finally, and as hinted at throughout this chapter so far, health and safety risks 
can act as a commercial barrier for companies engaged in nanoparticle R&D and 
commercialisation. Thus, the following section explores health and safety risks 
as a commercial barrier.  
 
 
6.6. Health and Safety Risks as a Commercial Barrier  
 
With many varied perspectives and conflicting discourses on nanoparticles and 
nanotechnology, it is not surprising that such products are perceived as being 
risk-laden by numerous stakeholder groups. According to Davies (2010), there is 
a large majority of the population that has little knowledge of nanotechnology, 
but this does not mean that they do not have an opinion on the subject. Many 
people obtain these opinions from dissemination of information from different 
communication channels such as the mass media, which widely disseminates 
quite different views. These views, which can often misconstruct nanotechnology 
into positive and negative stories, should not be dismissed lightly. Perceived risk 
is a real barrier that can only be overcome with the production of information 
that allows the public to properly understand the technology. Arguably, this is 
the same for the development of regulatory systems based on fit-for-purpose 
scientific research rather than story telling.  
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There are many examples of prior commercial technologies that have suffered 
from the media. An example of negative publicity is genetically modified food, 
which has been more hype than product (Greenpeace, 2010). The challenge for 
interested stakeholders is to be able to engage with nanotechnology and cut 
through the pervasive misconstructions of the technology that shroud its 
capabilities and risk. Looking briefly at genetically modified foods, the growth of 
this technology was slowed down due to the high level of public fear that was 
perceived, particularly in Europe (Sandler and Kay, 2006). The fate of GM foods 
demonstrates the fickleness of the public who can quickly change their opinions 
on emerging technologies if they believe they can be detrimental to their health 
and safety or to the environment (Landy, 2010). This can have disastrous 
consequences for commercial entities engaged in R&D and commercialisation. 
Generally, and for high technology products, public concern has often prompted 
governments to take action by selecting investigating panels and regulatory 
institutions to determine new laws and policies to prevent environmental effects 
and protect human health (Bosso, 1987). The public has come to expect 
government to protect them at some level from risks that individuals cannot 
understand or control (Landy, 2010). 
 
Risk assessment is a process that can assess impact of exposure, identify hazards 
and set regulations to correspond to findings. A constant feature of risk 
assessment is uncertainty. Ruckelshaus (1983: 1026) describes risk assessment as 
a ??????un wedding between science and the law.? He claims that, ?science 
thrives on uncertainty? but ????? often assume, indeed demand, a certainty of 
protection greater than science can provide with the current state of knowledge?. 
There is also a fundamental question associated with risk assessment of 
nanotechnology, which is; are theoretical and demonstrable assumptions about 
the bulk operable at the nanoscale? As stated by Tostoshev (2006: 21) 
 
?The unique properties and extremely small size of nanomaterials are 
such that even determining the full extent of the risks to human health 
and environment is currently beyond the means of existing risk 
??????????? ???????????? ??? ?????? ????? ????? ???? ??????? ??? ???
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acceptable response should public concerns about the safety of 
nanomaterials be aroused.? 
 
This poses the question as to whether all nanoparticles and nanoproducts 
carry an equal risk. The answer to this question is simply no. For example a 
sticky bandage containing silver nanoparticles placed over a small cut is 
likely to be less toxic and harmful than nanodiamonds being placed into an 
oral cavity where a root canal filling is being carried out. An argument can 
be made that governments need to be transparent, effective and responsive 
to the perceived risks of nanoparticles on behalf of the public so that trust 
is maintained. ???? ?????????? ?????????? ???????? 2000) as seen in the 
?????? ????? ???? ??????? ??????????? ??????????????? ?????? ??? ????? ?????
disease, can persuade the public to mistrust policy makers and their claims 
that new technologies may pose little risk. The promises of nanotechnology 
should not be constrained or rejected due to public anxiety from potential 
risk. Therefore it may be necessary for the public to trade off any potential 
risks in order to receive any potential benefits (Bosso and Kay, 2010). 
Commercial entities are not exempt from the discourse and physical 
activity in this area, as it directly feeds into their R&D, funding streams 
and ability to commercialise their products.  
 
Risk assessment of nanoparticles need to be performed on a case-by-case basis, 
due to their unique properties (Kobe, 2012). Counter commercial arguments can 
be made that such a task might be cost prohibitive, demanding and impractical. 
Chaudhry (2012: WP) has suggested that there might be as many as: 
 
???????? ?????????? ????????????? ??? ??????? ??????? ??????? ??????????
(SWCNTs), depending on structural types, length, manufacturing and 
purification processes, and surface coatings. Each one of these 
SWCNTs has different chemical, physical and biological properties 
that may determine their overall hazard.? 
 
From a scientific perspective, testing is no small task and may well create 
additional costs for R&D as well as for companies with products already being 
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sold into the marketplace. However, specific case-by-case reporting of 
nanoparticle properties and their implication for environmental and toxicological 
behaviour is at some level necessary if a deeper understanding is required to 
facilitate description, recognition and evaluation of applications of families of 
nanomaterials (Chaudhry, 2012). It has been suggested that with so many gaps in 
scientific data, ambiguity and uncertainty, traditional risk analysis may lead to a 
??????????????????????? (EEA, 2001, 2013). This can be caused if too much time is 
spent waiting for the completion and results of the risk assessments with a loss of 
focus on the implementing of measures that have the potential to reduce or 
prevent possible risks. A framework of communication is needed from 
manufacture to end of lifecycle of nanoscale products (Grobe, 2012). The 
International Risk Governance Council (IRGC) noted in 2006 (14) that a: 
 
??? ????? ??? ?????????????? ???? ?????????????? ?????? ???? ?????????
application and regulation of nanotechnology among all 
stakeholders may have negative effects on societal impressions and 
political / regulatory decision making.? 
 
Thus more informed communication could be considered a vital part of the 
commercial journey of products to market, and their longer-term acceptance and 
adoption (Rogers, 2003). Communication allows stakeholders to make better-
informed choices about risk and facilitate commercial activities (IRGC, 2006). 
Regulation can be an important part of elucidating information regarding product 
safety, but as previously mentioned, can also add additional costs, which 
manufacturers do not wish to pay.  
 
Finally, and after much discussion in this chapter, the following section makes a 
summary of the themes so far considered.  
 
 
6.7. Summary 
 
This chapter has provided an in depth examination of health, safety and the 
environmental issues as they pertain to nanotechnology and nanoparticles. 
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Building on an understanding of what the HSE often aims to achieve, the 
difficulties for using this framework to engage with nanoparticle products has 
been highlighted. More specifically, it was noted how a lack of scientific data 
and monitoring of products from the R&D stage and in commercial use has 
reduced the potential to use scientifically based knowledge to better inform 
health and safety regulation. This is particularly worrying considering the high 
number of products commercialised and number of workers being exposed as 
well as users to these products. With potential risks being present from product 
inception through to and including the disposal stage, the lack of engagement by 
bodies such as HSE may not best suit the users and workers engaging with these 
products. More than this, there is at present little focus being paid towards 
developing technologies and methods to assess this area, meaning it is unlikely 
that anything will change any time soon. Thus we are left with a system focussed 
towards rapid commercialisation, with limited attention being paid towards 
unpicking and highlighting aspects relevant to health, safety and the environment.  
 
While this chapter focussed on workplace health and safety aspects related to 
nanoparticles, it is also possible to view much of this discourse as being relevant 
to end users, who may also be exposed. Drawing on the more frequently 
discussed arena of the workplace, it should also be noted that there are arguably 
also a great number of health and safety risks from using nanoparticle products, 
which at present is not receiving enough attention. Discussions for how to 
regulate this aspect are thus limited.  
 
The following chapter goes on to consider the regulatory landscape that risk 
mitigation exists within for nanotechnology and nanoparticles.   
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Chapter 7. Regulatory Approaches to Nanotechnology 
 
 
7.1. Introduction 
 
????? ???????? ??? ??????? ??? ???? ????????? ?????????? ?????? ???? ???? ???????????
approaches to nanotechnology and nanoparticles that might best result in 
regulation promoting innovative commercialisation while addressing needs to 
????????? ??????? This chapter sets out to examine the regulatory approaches to 
nanotechnology which are situated between a driver to mitigate risk, while 
promoting commercial activities, which benefit numerous economies and 
societies through revenue, employment and utility from products. It is accepted 
that any approach to regulation is in essence a balancing act where different 
stakeholder drivers must be weighed up, and consideration is made about what 
regulation is striving to achieve and how it should be carried out. Problematically 
for nanotechnology, regulation is complicated by the complex nature of the 
technology, as well as wider social constructions that confuse and complicate 
many issues. This is as well as a general difficulty with a lack of scientific data to 
support regulatory decision-making and recommendations. This is not to position 
scientific data as prime, but more to highlight the difficulties where data can be 
pivotal for areas such as product safety, and problems that ensue when it does not 
at present, often exist. Thus the ability to engage with nanotechnology as a high 
technology product class is severely limited, and is acknowledged throughout 
this chapter.  
 
As a starting point from which key themes and ideas are drawn out and built on, 
the next section considers regulating high technology.  
 
 
7.2.  Regulating High Technology  
 
Novel high-technology products present many opportunities and challenges for 
businesses and the regulatory structures engaged with commercialisation-based 
activities. Through the broadest lens, regulatory structures can either help or 
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hinder commercialisation and safeguard or damage the marketplace and 
environment. Depending on the scope of legal regulation, it can shape the R&D 
landscape, commercialisation, as well as other socio-economic and physical 
environments. Regulating any technology is arguably a double-edged sword in 
that it can protect societal interests, but at the same time stifle innovation and 
increase barriers to commercialisation. The challenge for regulators is to 
understand the phenomenon they seek to regulate in an in depth enough way to 
engage meaningfully with potential outcomes, which is no small undertaking. If 
regulations are too strict, or are based on information that is incomplete or with 
an excessive precautionary principle, they have the potential to distort the market 
and delay technological benefits to society. Alternatively, if regulation is too lax, 
this can also result in the commercialisation of toxic products.  
 
Within these socio-organisational and regulated structures are different 
stakeholders including individuals, companies, and interest groups that all 
produce their own narratives and can make the environment of 
commercialisation opaque for individuals carrying out decision-making. This can 
be even more pronounced in high technology areas such as nanotechnology, 
where the commercial environment is complex and often uncertain (Falkner et al, 
2012). Importantly, regulatory barriers can arguably be segmented into the real 
and the perceived. Although a blunt segmentation, real regulatory barriers might 
for example seek to obligate manufacturers to health and safety testing, which 
can delay the commercialisation of a product, and increase the cost.  
 
Regulation can be carried out from the micro-scale i.e. self-regulation (micro) 
and at the other end of the spectrum at the macroscale via top-down external 
regulation (macro), including regulatory bodies, with both being examined in this 
study. Simplistically, it has been argued that with no or limited regulation, a 
????????? ?????? ???? ????? ???? ??? ???????? ?????? ?????????? ???? ???????????? ???? ???
commercialised irrespective of the consequences (Jones and Hunziker, 1994). 
Thus there is a balancing act between regulating between competing aspects such 
as safety, while enabling commercial activities to meet societal and economic 
demands, that benefits companies, society. The question of who should construct 
and operate a governance system is wide ranging, and in this study, there is an 
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examination of different regulatory systems, which include many types of 
organisations including governments, interest groups and self-regulation.  
 
To further understand these aspects in light of nanotechnology, the next section 
explores regulating nanotechnology.  
 
 
7.3. Regulating Nanotechnology 
 
This study has discussed some of the most important challenges of the 
physicality and socially constructed aspects of nanotechnology, with this section 
exploring the regulation of this area, and in particular nanoparticles. This is no 
small task due to the complexity and opacity of the subject matter. Importantly, 
this is being carried out in over sixty countries, where politicians, academics, 
regulators and members of the public have been asked questions about the long 
and short-term adequacy of existing nanotechnology regulation to better inform 
decision-makers about how nanotechnology should be regulated, if at all (RS and 
RAE, 2004; Macoubrie, 2005; Chaundry et al, 2006; Gavelin et al, 2007; 
Hansen, 2009). 
 
There are multiple views on nanotechnology-based regulation, and how existing 
principles may apply, if at all, which in part can be linked to difficulties for 
stakeholders to actively engage with nanotechnology and make sense of it. More 
than being a nanotechnology problem, this is an issue potentially experienced 
with any new technology, but is arguably more pronounced with 
nanotechnology. This has resulted in a broad spectrum of approaches being 
??????????? ?????? ?????? ????? ?? ??????ez-??????? ????????? ???? ???? ???? ???????? ???
?overhaul????? ?????????? ??????????? ????????? More broadly though, there are 
concerns about the capacity of governments and regulators to respond to and 
address the challenges that nanoscale substances and innovations may bring 
(Bosso, 2010). This is based on there not being a clear understanding of how 
regulation will affect or indeed is affected by nanotechnology, or more 
pertinently, what exactly nanotechnology is, thus how to regulate it.  
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Arguably, the regulation of nanotechnology will be in an arena of much 
uncertainty (Bosso, 2010). Regulators may need to be flexible and adaptive, 
taking evidence based approaches so that innovation and trade is not hindered 
but human health and safety, and the environment is protected. Nanotechnology 
should not be thought of as harmful or benign unless there is supporting 
scientific evidence. Therefore problematically, any nanotechnology regulation 
will not only be made against a backdrop of uncertainty, but also against ?a 
reasonable level of [unknown] risk? creating challenges for decision-making. It is 
foreseeable that due to a lack of understanding and information available on 
nanoscale substances, regulation may need to be created before all the evidence 
can be provided (Eisner and Coglianese, 2010). This is due to the 
nanotechnology market developing at a faster rate than science testing can 
elucidate risks, and a lack of a coherent strategy within science to understand the 
risks hereafter (Bosso, 2010). Eisner (2010) has argued that the lack of specific 
information from science is the greatest problem for regulation. This may hinder 
regulators in their quest to understand the consequences of health and 
environmental exposure or the key contributory mechanisms that could prevent 
the ?correct? regulatory response.  
 
Discourse on nanotechnology regulation has often stated a need to produce a 
???????? ????????? ??? ?? ??????? ??? ????????? ????????? ?????? ????????? ?????? ????
however been little suggested for how to achieve this (Macnaghten et al, 2005). 
Fundamentally, one of the greatest challenges facing nanotechnology regulation 
?????????????? ?????????????????????? ??????????????????????? ????????????????????or 
functionally different. If simply smaller, nanotechnology may sit easily within 
current regulations, which potentially cover this collection of products. If 
functionally different, current regulations may need modification.  
 
Importantly the argument has been made that: ?Despite some earlier concerns 
that the use of nanomaterials in food was essentially unregulated, it is clear that 
nanotechnologies in food are ?????????? (Sanderson, 2013: WP). Looking at this 
comment, it is worth pointing out that it is not that nanotechnology sits outside of 
all regulatory systems, but more that the physicality of the phenomenon of 
nanotechnology is not well captured by current regulations. Drawing on the work 
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of Davies (2006), it was argued that there are so many combinations from the 
physicality of nanomaterials (including size, shape, chemical reactivity and 
material composition), the need for deeper examination is clear, particularly for 
toxicity. For example there are up to 50,000 different permutations possible just 
from one single-walled carbon nanotube which points to regulation being a 
daunting task, but never the less, an essential one. Davies (2006: 14) also makes 
the pragmatic claim that there are regulatory implications for difficulties in 
detecting nanomaterials: ?if these nanomaterials cannot be detected, the 
provisions of the environmental laws are inoperable?. Thus, an argument can be 
made that regulation may well need to be linked with further exploration and 
exploitation of technologies to more adequately interrogate nanomaterials.   
 
Suggestions for nanotechnology regulations were made by Kimbrell (2009) who 
claimed that nanotechnology has highlighted how ?out-dated? our current 
regulatory systems are for high technology and how ill equipped they are to deal 
with high technology issues of the twenty first century. Although specifically 
orientated towards high technology, it must be remembered that regulatory 
systems are in a temporal state of flux, where what is desirable and fit-for-
purpose today may not be tomorrow. More than this, technology, and particularly 
high technology, creates challenges for the way that stakeholders perceive 
specific aspects ???????????????????????????????????????????????????????????????????
so potentially their narratives, necessitate different regulations, built upon 
different foundations. 
 
Looking at the suggestions by Kimbrell (2009), eight principles for developing 
regulations were put forward and are shown in Table 7.1.  
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Number Principle 
1 A precautionary foundation. 
2 Mandatory nano-specific regulations.  
3 Health and safety of the public and workers.  
4 Environmental protection.  
5 Transparency 
6 Public participation 
7 Inclusion of broader impacts ? ethical and social.  
8 Manufacturer liability.  
 
Table 7.1. Suggested eight principles for good governance.  
 
These principles discussed in the above table 7.1 potentially make a good basis 
for taking the first steps towards nanotechnology regulation although it must be 
remembered that nanoparticles potentially can change their physicalities making 
strict regulatory systems highly challenging.  
 
An ?ideal?? ????????? ?? a foundation for the regulation of nanoparticles and 
nanotechnology would be to use the precautionary principle as a basis, so that 
any threat to human health and/or the environment can be minimalised. This 
???????????????????????????????????????????????????????????????????????yet been 
fully established by the scientific community due to the lack of data in this area 
(Kimbrell, 2009). The precautionary principle is often viewed as part of or an 
alternative to risk management strategies, where the burden of proof for safety 
falls upon the product manufacturers and distributors with lack of evidence of 
specific harm or data not being a substitute for reasonable certainty of safety. 
Unfortunately no version of the precautionary principle answers the critical 
questions that need to be considered in moving forward with regulatory decisions 
for nanotechnology, such as; what level of harm is required to trigger the 
principle, what level of risk is acceptable, and how should risks and benefits of a 
new technology be weighed up (Marchant, 2003). Guidance in these areas is not 
provided by the principle (Sunstein, 2003). Yet the precautionary principle can 
be useful as a regulatory tool for nanotechnology if used as a precautionary 
foundation. This approach can be implemented by making it a pre-requisite for 
market approval that independent health and safety data reviews are carried out 
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with all information recorded for future reference in a data-base or registry, by 
the monitoring and recording of results over time, particularly data associated 
with worker exposure.                                                                                                        
 
For any nanotechnology regulatory regime to be effective the legal authorities 
must be modified and adaptable so that the different properties and challenges 
presented by the nanoparticles can be effectively and adequately addressed. 
Unfortunately any regulatory system would still be inadequately equipped to 
oversee future processes and products such as nano structures and active nano 
systems currently under development (Kimbrell, 2009), but as a starting point to 
build future regulatory regimes upon, this can be seen as a step forward in the 
right direction. In other words, it might be argued that some regulation is better 
than no regulation, particularly if that regulation is flexible and adaptive. Part of 
this regime would be that nanoparticles would be treated as separate substances 
to their bulk counter parts, allowing them to be regulated under nano-specific 
mechanisms, which require specific testing and data requirements. This should 
be mandatory as voluntary initiatives are often insufficient due to lack of 
compliance and therefore create data gaps, which often delay mandatory 
measures (Brazell, 2012).  
 
When setting out a regulatory regime for nanotechnology and nanoparticles the 
health and safety of humans and the environment should be paramount. 
Therefore it could be argued that any nanomaterial that has not been proven safe 
to humans or the environment should be removed from the market place, 
although this would no doubt be much criticised by manufacturers. As I believe 
that the precautionary p????????? ??????? ??? ???? ?????? ???? ???????????? ???? ?????????
????????????????????????????????????????????????????????????????????????????????????
in section 7.3.1.3, allowing the benefits of nanoparticles and nanotechnology to 
be further considered until proven unsafe. The issues of health, safety and the 
environment are discussed in more detail in Chapter 6. 
 
So far products containing nanoparticles have been commercialised without their 
full life cycle analysis being fully investigated. This could lead to unknown 
environmental impacts from inception at the manufacturing stage through to 
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usage and disposal and into the waste stream. To protect the environment from 
possible nanoparticle toxicity, a full life cycle analysis should be completed prior 
to commercialisation of a nanoparticle product. To help with this, government 
funding must be increased for environmental impact research, which should 
couple laboratory and ?????? ?????? ??????????? ??? ????????? ????? ?????? ?????????
environmental protection laws, assessments and metrics must be adjusted and 
made adaptable to address the new challenges brought by the potentially 
changing physicalities of nanoparticles. These issues are discussed in more detail 
in sections ?6.4. Environmental Issues? and ?6.5. Uncertainties of Environmental 
Exposure?. 
 
A key feature when installing a regulatory system for nanotechnology is 
transparency to ensure that measures are put in place for adequate protection for 
the public, workers and the environment. ??????????????? ??????? ??????????????
they are working with and the dangers so that the correct procedures are carried 
out if necessary. For example a spillage may need to be documented correctly 
and the appropriate measures taken to prevent toxicity. Product labelling should 
be mandatory, not only in the workplace but for all products that contain 
nanoparticles.  As already stated this can be problematic as manufacturers may 
buy products from abroad from companies who are not as rigorous when it 
comes to identifying ingredients. Therefore I would suggest an international 
standard for labelling, with recommendations for companies to buy from other 
companies who adhere to this standard. Another problem with regards to 
??????????????????????????????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????????????????????????
public perception of nanotechnology becomes the key issue here. For those who 
believe that nanotechnology is a positive thing, having nano ingredients can be 
an important selling point. For those who believe that nanotechnology has 
negative aspects, consumers may believe by using products containing 
nanoparticles could reduce sales. ?????????????????????????????????????????????????
a product on the ingredients list to show that nanoparticles are present is 
meaningless until the public become better informed about the potential 
benefits/hazards associated with nanoparticles. This leads me to suggest that for 
greater transparency, the government should provide the public with more 
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information about nanotechnology so that the public can make better-informed 
choices about products they use. This data would be updated as and when new 
data is established.  
 
Another important issue is that safety data should be made available for public 
scrutiny and strictures placed on the use or misuse of confidentiality shields 
(Kimbrell, 2009). The suggestion by the European Commission to create a web 
platform with references to all relevant information sources, which would 
include registries and data-bases would imply that there is a need for better 
accessible information and increased transparency (Europa, 2009). This analysis 
will also include those nanoparticles that currently sit outside the existing 
framework of notification, registration or authorisation schemes, by lowering the 
One Tonne Limit in REACH to a realistic limit such as 100 g, the limit for 
notification for the French registry. This is discussed further in section ?7.3.6.1. 
The Objectives of a Registry?. 
 
Public participation must become more open and meaningful from all interested 
and affected parties, such as government and corporate alliances to be able to 
create a more workable regulatory system for nanotechnology (Kimbrell, 2009). 
All processes and discussions must be driven by social needs, which are 
identified through informed deliberation instead of false presumptions of 
technological inevitability for benefit. 
 
When forming the principles for good governance, it is also important to look at 
the wider impacts from the wide-ranging effects of nanotechnology including the 
social and ethical implications, which must be considered (Kimbrell, 2009). A 
???????????????????????????????????????????????????????????????????????????????????
is necessary due to their complex risks and potential ethical and social 
challenges. A suggested way forward is through adequate government funding to 
provide the social sciences the means to analyse nanoparticle implications 
alongside the health and environmental sciences.  
 
Companies that manufacture nanoparticle products should also be part of the 
regulatory scheme due to the monitoring and recording of data associated with 
	  	  	   	  	  	  	  	  154	  
their manufacture, as well as part of their duty of care towards their employees. 
?????????????????????????????????????????????manufacturer or seller of a product 
generally would not need to warn the public about the contents of their products 
unless the contents could put the public at risk of harm. Warnings would be 
expected on products that could cause risk allowing the consumer to choose 
whether to purchase/use the product or not. Unfortunately because of the 
uncertainty surrounding nanoparticles, manufacturers are in a difficult position. 
They have a duty to instruct users on the safe use of their product. Companies 
also have a duty to report any reasonable suspicion of a material appearing to 
pose a threat to human health or the environment at the earliest opportunity. If 
the manufacturer or importer has completed a checklist with REACH to the best 
of their ability, due to the substance being hazardous or over the one tonne limit, 
they would gain protection against legal action if the nanomaterial subsequently 
proved to be harmful in some way. Currently nanoparticles are treated the same 
as their bulk counter part and are regulated as such but it is my opinion that 
manufacturers should keep up to date with scientific knowledge, advances and 
discoveries as well as test and monitor their own products. Therefore I believe 
that it is the duty of the manufacturer to raise concerns about a product that they 
may deem unsafe rather than rely on testing by another company.  
 
These suggested eight principles form a basis for good governance for a basic 
model for nanoparticle regulation. They are based on the precautionary principle, 
which allows the development of nanoparticle products with caution alongside 
stringent monitoring and recording systems. ????? ???? ??? ??? ?????? ?? ????????
???????????? ???????????????? ??? ???????????????????? ?????????????????? ???????? ??????
regulated.  
 
There has been much varied discourse being generated from within the UK and 
???????? ???????? ???????????? ????? ??????????? ??????????? ????? ????? ?????? ??????
regulating nanotechnology. It was however the Royal Society and Royal 
Academy of Engineering report (2004?? ????oscience and Nanotechnologies: 
opportunities and uncertainti??????????????????????????????????, to examine the 
current regulations in relation to nanoparticles. The interesting point here to note 
	  	  	   	  	  	  	  	  155	  
is that this report was made in 2004 and so far to date (2016) there has been no 
update.  
All recent and available information on nanoparticles was reviewed by HSE to 
access the physicochemical and toxicological hazards that can occur as a result 
of workplace and occupational exposure. During this process, it was noted that 
little research existed on novel nanoparticles, but more on materials that had been 
downsized to the nanoscale. While the UK Government has since accepted these 
recommendations it has to date not implemented them (HSE, 2004). Importantly, 
the findings from this study strengthens an understanding of the reductive 
process of miniaturisation but unfortunately offers less knowledge for novel 
materials produced from other techniques, and potentially drives a regulatory 
view of nanotechnology products as just being downsized materials.  
 
The next section deals with REACH, the current regulatory framework on health 
and safety hazards and risks in the work place that has been standardised across 
the EU and the UK.  
 
 
7.3.1. REACH 
 
In the EU, the body known as Registration, Evaluation, Authorisation and 
restriction of CHemicals (REACH) came into force on the 1st June 2007 as a 
chemical regulator. REACH is constructed towards the labelling, classification, 
use, restrictions and marketing of all new chemicals and the management and 
assessment of existing chemicals. There are five main aims that REACH is 
engaged with which are shown in Table 7.2. 
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Number Aim 
1 Provision of a high-level of protection of human and environmental health 
and safety from chemical usage.  
2 Ensure that manufacturers and importers of chemicals for the market place 
understand and manage the risks associated with their use.  
3 To allow substances in the EU market to have free movement.  
4 To allow the chemical industry in the EU to be enhanced by 
competitiveness and innovation.  
5 To allow a choice of methods of assessment of the hazardous properties of 
substances.  
 
Table 7.2. Five aims of REACH.  
 
REACH applies to substances imported into or manufactured in the EU in 
quantities of one tonne or more per year. It applies to all individual chemical 
substances on their own in preparations, or in articles (Ward and Harley, 2010). 
There are some exceptions such as radioactive substances, waste, plant 
protection products and biocides, and human and veterinary medicines. 
 
When REACH came into force in 2007 it established a new authorising system 
requiring ?registration and evaluation of existing and new chemical substances? 
(EP and CEU, 2006: WP) and new chemical legislation for the 
commercialisation and manufacturing of chemical substances for the EU market. 
This registration process compels importers and manufacturers to collate 
information on the substances that they import, produce or use. Information is 
then used to assess potential hazards and is added to a registration dossier that is 
sent to the European Chemicals Agency (ECHA), where the properties of the 
substance can be assessed for any risks to human health and/or the environment. 
Risk management strategies can subsequently be developed for the various uses 
of the substance (Ward and Harley, 2010). This moves the responsibility from 
authorities to industry, with regulation prohibiting manufacture or sale of any 
substance in the EU that has not been registered with ECHA, providing that one 
tonne or more is sold per annum.  
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To be compliant with REACH, all chemical suppliers (above one tonne) are 
required by EU directives to find and provide information to the recipients of 
goods on physicochemical and toxicological hazards that are present in their 
chemicals. This directive comes under the EU Standardised Classification and 
Labelling (C+L) and the Safety Data Sheets (SDS). Standardised testing of 
industrial chemicals for hazardous properties that are new to the market must 
also be undertaken. Recipients can use this information to assess and manage 
workplace exposure to any hazardous chemical, to reduce and minimise health 
and safety risks (HSE, 2004). 
 
Many substances have already been marketed without having their properties 
being investigated because they are less than the one tonne per annum. 
Legislation requires that suppliers must produce a set of information detailing the 
properties of a new substance before it goes to market, which is known as the 
Notification of New Substances (NONS) (HSE, 2004). The database of existing 
substances, referred to as the European Inventory of Existing Commercial 
Chemical Substances (EINECS) label substances already on the database as 
?????????? and any substance that is added later as ????? (HSE, 2004). It is the 
responsibility of the supplier to investigate a substance and determine if it is on 
the EINECS. HSE (2004) has argued that REACH will be key for developing 
new legislation that will have major consequences for nanotechnology, although 
at the present time REACH does not directly address nanomaterials as a distinct 
phenomenon, only through prior technological lenses. Importantly, this may well 
be based on whether a nanomaterial will require NONS, which can be based on 
the one tonne limit.  
 
Chaundry et al (2005) has identified gaps for environmental regulation in both 
the EU and the UK, with regards to the question of whether a nanoscale 
substance was equivalent to its bulk counter part or named as a new substance 
under REACH. REACH (Leeuwen and Vermeire, 2007: 64) defines a new 
substance as:  
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?A chemical element and its compounds in the natural state or 
obtained by any manufacturing process, including any additive 
necessary to preserve its stability and any impurity deriving from the 
process used, but excluding any solvent which may be separated 
without affecting the stability of the substance or changing its 
composition.?  
 
How nanoparticles are perceived will determine whether different hazard 
information needs to be produced on the registration dossier if these materials are 
over the one tonne limit for the year. If nanoparticles are believed to be the same 
as the registered bulk material then all hazard information data would need to be 
discussed (Chaundry et al, 2006). 
 
Questions are being raised by many stakeholder groups including the European 
Trade Union Confederation (ETUC) and Friends of the Earth Europe over the 
uncertainty and inadequacy of regulations associated with the nanotechnology 
industry. This has been attributed to nanomaterials being covered by the 
????????????? ??????????? ??? chemical substance, which may not be the ?best? 
definition. Therefore it is necessary to examine how REACH defines a chemical 
??????????????????????????????????????????????????????????????????????????????????
???????????? 
 
 
7.3.1.1. Definition of a Chemical Substance and Nano 
 
Importantly there is no provision in REACH that applies directly to 
nanomaterials. Under REACH, all chemical substances need to be registered yet 
no specific nanomaterial can be registered, even though core materials such as 
silver, titanium dioxide, carbon and gold ???? ????????? 2012). This poses the 
question as to whether nanomaterials are to be considered the same or different 
to the bulk material? And does REACH regard them as the same? This is a 
pivotal question for regulators and manufacturers. Either way, it will have a 
?????? ??????? ??? ??????????????? ????????????? ?????? ??? ??????? ??????????? ??? ??
nanoparticle were to be treated as a different substance, then hazard information 
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would have to be produced for the registration dossier (if the substance is of one 
tonne or more per year.) Yet if the substance is classed as equal to the registered 
bulk material, then the hazard data would be given as the same but this is open to 
debate due to nanomaterials having different properties to their bulk counterparts 
(Chaundry et al, 2006). 
 
The definition of a ?????????? ?????????? as defined by Article 3 in REACH: 
(ECHA ? 11 ? B ? 10 ?EN, 11/2011: WP) 
 
?A chemical element and its compound in the natural state or 
obtained by any manufacturing process, including any additive 
necessary to preserve its stability and any impurity deriving from the 
process used, but excluding any solvent which may be separated 
without affecting the stability of the substance or changing its 
composition.? 
 
The definition appears to be wide ranging and almost all encompassing and 
clearly goes beyond regulation of pure chemical compounds produced naturally 
or synthetically. The term covers both substances obtained by a manufacturing 
process and substances in their natural state and which can both include several 
constituents within the substances and be taken into account as far as possible 
when identifying the substance. 
 
It could be argued then that nanomaterials are regulated by REACH due to being 
covered by the definition of a chemical ???????????, although there are no 
explicit regulations or specific mention of nanomaterials (Europa, 2009). A 
review by the European Commission, published in 2008, (CEC, 2008) argued 
that although there is no specific mention in REACH of nanomaterials ?a 
chemical substance? includes them (CEC, 2008a). It goes on to state that when 
an existing chemical substance, already placed on the market as a bulk substance, 
is introduced to the market in a nanomaterial form (nanoform), the registration 
dossier will have to be updated to include specific properties of that substance. 
The additional information, including different classification and labelling of the 
nanoform and additional risk management measures, will need to be included in 
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the registration dossier. The risk management measures and operational 
conditions will have to be communicated to the supply chain (CEC, 2008a).	  
 
The Commission Communication on the 2nd Regulatory Review on 
Nanomaterials (October 2012), as well as the REACH Review (February 2013) 
concluded that REACH and the CLP (classification, labelling and packaging) 
offer the best possible framework for the risk management of nanomaterials 
when they occur as substances or mixtures. However it has proven necessary that 
more specific requirements for nanomaterials are needed within this framework. 
The Commission is therefore considering a modification of some technical 
provisions in the REACH Annexes and a public consultation has been launched 
to this effect that from the 21st June ? 13th September to increase dialogue to aid 
in this area (ec.europa, 2013). 
 
Nanomaterials that fulfil the criteria for classification as hazardous under Reg. 
1272/2008 on CLP of substances and mixtures must be labelled and classified. 
This applies to nanomaterials in their own right, or as nanomaterials as special 
forms of the substance. Many of the related provisions including safety data 
sheets and classification and labelling apply already today independently of 
tonnage in which the substances are manufactured or imported.  
 
Until recently there was no specific guidance by ECHA concerning nanoparticles. 
Information on nanoparticles was included in a technical manual in an IUCLID 
(International Uniform Chemical Information Database) dossier that was part of 
each REACH registration. Best practises were included on nanoparticles as well 
as any nanomaterials information. This is particularly important when 
nanoparticles are not substances in their own right, and are part of or mixed with 
substances.  
 
Compounding the problem for companies seeking guidance on nanotechnology 
and nanoparticles there are no up to date guidelines for companies to follow. 
Existing guidelines that support REACH may not be appropriate for 
nanoparticles and their possible risks (SCENIHR, 2007; CEC, 2008a). Importers 
and manufacturers may be required to carry out a safety assessment if they 
	  	  	   	  	  	  	  	  161	  
??????? ??? ??????? ??? ???????? ??? ???? ??????????? ????? ??????????? ??????????????
profile may not be reliable. If quantities of one tonne per annum are produced, 
companies must register these materials. Therefore it may be more appropriate to 
develop an early warning system so that all importers/manufacturers of 
nanomaterials or products containing nanoparticles would be required to 
complete a standard checklist. This would be designed to focus on the 
functionality of the nanoparticles and explain why they have been produced and 
incorporated into the product. Monitoring the pathways of human and 
?????????????? ????????? ??????????? ???? ?????????? ????? ?????? ?????? ????? ??? ???
considered. The next section discusses the One Tonne Limit and the problems 
when trying to regulate nanoparticles under these guidelines.  
 
 
7.3.1.2. A One Tonne Limit 
 
The one tonne limit is the point where companies must register materials that are 
produced or imported, with a chemical safety assessment being required 
alongside risk assessments (C and EN, 2008). Importantly, chemical substances 
manufactured or imported in weights less than one tonne are exempt from this 
process, mitigating such manufacturers and importers from this obligation and a 
need to provide environmental exposure assessments or toxicological data. This 
raises a pivotal question for companies engaged in nanotechnology, should their 
products be required to undergo REACH assessment, as many might not have the 
required weight? (Chaundry et al, 2006; Franco et al, 2007). Chaundry et al 
(2006) suggested that the majority of nanotechnology products are of a low, sub-
one tonne weight and therefore will automatically fall outside the scope of 
REACH. For novel non-miniaturised nano-engineered products, the likelihood 
for REACH assessment is even lower, particularly where the nanomaterial 
constituent is lower than 0.1 percent of the final product and no registration is 
required. However, as Franco et al (2007) argued, there is a general lack of 
information and transparency concerning nanoparticle concentration and product 
formulation leading to substances of undetermined concentrations by weight, 
further complicating this aspect. This has given concern to the European 
Commission who states that if a substance is below the tonnage threshold but is 
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of a high enough concern then an authorisation and restriction process must be 
????????????????????????????????????????????????????????????????f concern must 
have authorisation for use and before market entrance (SCENIHR, 2006; ETUC, 
2008). The opinions of SCENIHR and ETUC could put pressure on REACH to 
place further restrictions on nanomaterials until further investigations into HSE 
take place.  
 
The French Registry for nanomaterials believe that the one tonne limit in 
REACH is far too high and have lowered it to 100 g of substance at the 
nanoscale, produced, imported, or distributed during the previous year, that must 
be registered and submitted to the French National Agency for Food Safety, 
Environment and Labour (safenano, 2014). This is still a large amount of 
nanoparticles but it will ensure that the substances that reach this limit will be 
authorised and registered. In my opinion, a lower threshold of 50 g would be 
more appropriate but any weight limit should be evidence based. This also 
suggests that the French government see nanoparticles as different substances to 
their bulk counterparts. 
 
Importantly, and an area often overlooked within REACH, is that nanomaterials 
properties may change over time. In other words, their size and shape (leading to 
changes in weight) may fluctuate, resulting in further complications to regulation. 
In such circumstances, regulators must decide a course of action in the face of 
such uncertainty (Porter, et al, 2011). While it has been argued that the move to 
more nuanced regulation is possible, it has also been stated that regulators lack 
the basic information needed to enable more fit-for-purpose decision making 
(Porter et al, 2011). 
 
Although there are recognised challenges for the one tonne limit, EC funded 
research in 2008 has started to address methodologies for identifying hazards of 
nanoscale substances through the 7th Research Framework Programme (FP7). 
Shatkin (2008: 144) stated that:  
 
?It will be necessary to carefully monitor over the next few years 
whether the [one tonne per year]  threshold for registration and the 
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information requirements under REACH are adequate to address 
potential risks from particles on a nanoscale.?  
 
With so much ambiguity about no requirement to test below the one tonne limit, 
ECHA suggested a ???? ?????? ??? ??????? principle should be adhered to in 
REACH. This would prohibit chemicals without data to support their safety from 
being registered, and make a step to address the difficulties faced from the one 
tonne limit. In this scenario, REACH would have the data before commercial 
manufacture, marketing and the use of nanoparticles to limit harm to human 
health or the environment. ECHA also believes that industry needs to be 
encouraged to fill some of the gaps in scientific knowledge for the safety of 
nanomaterials, particularly any knowledge of the fate and persistence of 
nanoparticles in the area of HSE (ETUC, 2008). Under the current system of the 
one tonne limit, this can only be a suggestion at the present time.    
 
Within discourse about the one tonne limit, there are many repetitive themes in 
respect of nanomaterials. Thus without changes to establish more fit-for-purpose 
regulation continued arguments will be made towards responsible commercial 
practice, particularly in sectors where organisations have opportunities to act 
irresponsibly in order to gain competitive advantage or where current legislation 
is not designed to protect against unexpected risks. An example of this would be 
the cosmetics industry via the existing Cosmetic Directive, (76/768/EEC) where 
?????????????????????????????????????????????????????????????????????????????????
use before being placed in the market place. There is however no specific 
reference or safety assessment for nanomaterials (National Archives, 2011), 
which may create the view that since testing has been carried out products are 
safe. Thus a precautionary testing approach must be coupled with fit-for-purpose 
testing.  
 
In the following section, the precautionary principle is explored as a regulatory 
system to induce safety, with consideration being given to this aspect in and 
outside of REACH.  
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7.3.1.3. The Precautionary Principle 
 
With many aspects of novel products not being knowable at the time of 
??????????????????? ?????????? ????? ????? ????? ????? ?? ?better safe than sorry??
approach should be taken (DiGangi, 2004). REACH for example is based upon 
this principle, which simply can be regar??????????????the precept that an action 
should not be taken if the consequences are uncertain and potentially dangerous??
(Collins English Dictionary [Digital Edition], 2009: WP). A more technical 
definition can be taken from The Precautionary Principle Website  (2015: WP):  
 
?When human activities may lead to morally unacceptable harm that 
is scientifically plausible but uncertain, actions shall be taken to 
avoid or diminish that harm. Morally unacceptable harm refers to 
harm to humans or the environment that is: 
 
?  Threatening to human life or health; 
?  Serious and effectively irreversible; 
?  Inequitable to present or future generations; 
?  Imposed without adequate consideration of the human rights of 
those affected? 
 
This guiding principle requires manufacturers and industries to provide 
information concerning the safety of chemicals, and restricting or preventing the 
use of the most dangerous before they are placed on the market. While this may 
appear a straightforward task, considering the numerous problems of opacity and 
paucity of data for nanomaterials, this is potentially far more difficult than it may 
at first appear. Although REACH is based on the precautionary principle, the 
problem is created by the belief that nanomaterials are the same as their bulk 
counterparts. REACH adheres to a ?no data ? no market, no data ? ??? ????? 
policy, which is certainly problematic. More that this though and looking again 
at REACH, the precautionary principle has no set standard text and many of the 
suggested formulations differ in important aspects (Sandin, 1999). Also there is 
no version that answers the serious questions that are necessary before moving 
forward to make regulatory decisions (Marchant, 2003). This includes scenarios 
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such as the level of risk that is acceptable, how can benefits be weighed against 
risks when using technology, and which types of data is suitable for a 
manufacturer to submit that will satisfy the principle (Marchant, 2003).  
 
Unfortunately, if there are no specific guidelines or criteria to answer these 
questions then the precautionary principle could be prone to capricious or 
arbitrary decision making, as well as the potential for mischief making. An 
example of this is the prohibition of the sale of cranberry juice containing 
vitamin C in Denmark due to scientific uncertainty from a possible over 
enrichment of vitamins  (Marchant and Mossman, 2004). Denmark argued that 
there was no nutritional need for this type of food, as their population was not 
lacking in a vitamin deficient diet. ????????????? who is a maker of cranberry 
juice, complained to the Commission of the European Communities, who stated 
that Denmark had violated Article 28 of The Treaty Establishing the European 
Communities that prohibits quantitative trade barriers. Denmark had used Article 
30 of the Treaty to avoid the effects of Article 28, permitting a trade restriction 
due to their belief it could harm human health. The commission stated that this 
argument by Denmark was inapplicable so Denmark refused the sale of the 
Cranberry juice because of inadequate labelling (Harrington, 2006). 
 
The precautionary principle is often brought into play when the situation in 
question has the potential to become hazardous (Phoenix and Treder, 2003). 
According to Phoenix and Treder at the Centre for Responsible Nanotechnology, 
there are two forms of the precautionary principle, including (1) the strict form 
???? ???? ???? ??????? ?????? ???? ????????? ????? ????????????? ????????, when taking 
action may pose a potential risk as described by Phoenix and Treder (2003: WP): 
 
?The principle, itself a topic of debate, was designed to reduce 
environmental and health risks by limiting scientific exploration 
when its impact is in doubt.? 
 
???? ????????? ????? ????????? ?????????????? ????????????? ????? ???? ?????? ????????????
and if they are available and also includes taking responsibility for any potential 
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risks that may arise. This is set out in the Rio Declaration on Environment and 
Development, which states in Article 15 (WP):  
 
?Where there are threats of serious or irreversible damage, lack of 
full scientific certainty shall not be used as a reason for postponing 
cost ? effective measures to prevent environmental degradation.? 
 
Looking at this more bluntly, precautionary measures should be taken even if 
there is a lack of certainty, as inaction may result in harm. However the strict 
form of the precautionary principle would argue that inaction is preferable if 
taking action will cause more harm (Phoenix and Treder, 2003). This is clearly a 
difficult decision-making process and one that should where possible be based on 
????????????????? 
 
???????????????????????????????????????????????????????????????????????????????
rather than a cautionary one (Tickner et al, 1999). Less risky alternatives need to 
be sought with suitable efforts made to mitigate any potential risks. As Phoenix 
and Treder (2013: WP) stated that: ?The litmus test for knowing when to apply 
the precautionary principle is the combination of threat of harm and scientific 
uncertainty?.  
 
An argument can be made that the precautionary principle should be used when 
dealing with nanomaterials due to the claim that some nanomaterials can cause 
lung cancer, heart and lung disease and even death (Donaldson et al, 2005). 
Warheit et al (2004) have however suggested the following difficulties without 
the guidance of the precautionary principle, shown in Table 7.3. 
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Table 7.3. Difficulties Without the Precautionary Principle.  
 
With evidence to suggest that single walled nanomaterials have the ability to 
cause toxic damage to humans, Warheit et al (2004) have argued for a 
precautionary approach to be taken. If followed, Manson (2004) has suggested 
the following benefits shown in Table 7.4.  
 
Number Benefit 
1 Prohibit untested and potentially unsafe chemicals from being released into 
the market place.  
2 Inhibit assessments for EHS would become a prerequisite before 
commercialisation 
3 Nanomaterials would be assessed as new substances and not their bulk 
counterparts as they have unique physical properties that have distinctive 
hazard properties. 
4 An assessment of the social and ethical consequences of the impacts of 
nanotechnologies would take place. 
5 Workers and communities would have more protection.   
 
Table 7.4. Benefits With the Precautionary Principle.  
 
Number Difficulty 
1 The burden of proof lies with the government to prove that there is a 
potential for harm due to ?????????? ????????? 
2 Under the REACH regulation, the threshold for registration of chemicals is 
1 tonne but nanomaterials have the potential to fall under this threshold 
because of their small size. 
3 ?????????????????????????????????????????????????????????????????????????????
the usage or the product at the end of life stage where nanomaterials may 
become unbound and be released into the environment. 
4 Currently there is no equipment able to detect nanomaterials in the 
environment or the workplace, which leads to a lack of ability to enforce 
regulation. 
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The precautionary principle could create a more appropriate guide for 
implementing nanotechnologies yet there are still many aspects needing to be 
considered before such an approach can be made workable. Currently neither the 
precautionary principle nor traditional methods of risk management are 
acceptable methods for nanotechnology regulation (Wilson, 2006; Florini et al, 
2006; Lin, 2007). ETUC acknowledges that there are significant uncertainties 
surrounding nanotechnologies and their benefits to society (ETUC, 2008). They 
realise that nanotechnologies have the potential to inflict harm on human health 
and the environment therefore they want the precautionary principle to be 
applied to all nanotechnologies.  
 
As previously discussed in section ?7.3. Regulating Nanotechnology?, the 
precautionary principle could be used as a basis for a precautionary foundation 
regulatory regime. By proceeding with caution and with careful monitoring and 
recording of all nanoparticle testing and product data, the precautionary principle 
could be a useful regulatory tool for nanotechnology. As no	   version of the 
precautionary principle answers the critical questions that need to be considered 
in moving forward with regulatory decisions, such as; what level of harm is 
required to trigger the principle, what level of risk is acceptable, and how should 
risks and benefits of a new technology be weighed up, I suggest a cautionary 
approach to allow the development of new technologies and minimalise risk. 
 
Considering the challenges raised in this section of the precautionary principle, 
the next section moves on to examine the control of substances hazardous to 
health, through which some aspects of regulation of materials can also be 
achieved.  
 
 
7.3.4. The Control of Substances Hazardous to Health  
 
The control of substances hazardous to health 2002 (COSHH) is a UK based 
statutory instrument that obligates employers to protect their workers and other 
persons from exposure to substances hazardous to health. COSHH encompasses 
many vehicles for reducing potential harm, through risk assessments, control of 
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exposure, health surveillance as well as incident planning. Arguably, COSHH 
sets a minimum standard determined by employers, who are responsible for 
implementation. From a broad perspective COSHH enables many aspects to be 
considered and internally regulated. Unfortunately, the paucity of knowledge for 
?????????????? ???? ?????????????? ???????? ??????????? ???? ?????????? ???????????
COSHH assessments (HSE, 2004). As stated by HSE (2004), there are three 
main failures based on a lack of knowledge for nanoparticles as shown in Table 
7.5.  
 
 
Table 7.5. Perceived failures in knowledge for nanoparticle COSHH. 
 
Perhaps one of the greatest challenges for COSHH and nanotechnology is the 
expectation for employers to have knowledge capable of determining what 
procedures to carry out for what is a highly complex and technological area.  
 
Advice from HSE (2004) suggested that nanoparticle dust can be hazardous at or 
above 4 mg/m3 and that workers must be protected against it. Coupled with a 
difficulty of measuring nanoparticles in the working environment, is the arguably 
greater problem that personal protective equipment (PPE) is known not to be 
effective. Thus the question can be asked, what should be done about 
nanotechnology phenomena such as this? The Royal Society and The Royal 
Academy of Engineering Report have suggested that occupational exposure 
limits for manufactured nanoparticles should be lowered, which in part addresses 
some of the concern. They base their evidence on current legislation in the UK 
that allows a workplace exposure limit (WEL) assessed on the mass of inhaled 
particles (larger sized particles). They claim that if a worker becomes exposed to 
a mass of inhaled nanoparticles, this would be a vast amount, putting the worker 
at potential risk. Therefore the current WEL may not be sufficient protection 
Number Perceived failure of knowledge 
1 Insufficient toxicological and hazard information for most nanoparticles.  
2 No reliable or cost-effective measurements for standard exposure.  
3 No agreed or standard definition on an appropriate dose that can be used 
in a hazard study.  
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against exposure to inhaled nanoparticles. HSE (2004) states that there is not 
enough data to change the WEL at the present time and that there are no practical 
methods available for measuring personal exposure in the workplace. Machinery 
is too bulky or large, therefore creating a need for portable equipment. Currently 
(2016) there is still not enough data and any portable measuring equipment has 
proven inadequate. 
 
Further to these issues, when examining the COSHH health surveillance, HSE 
(2004) claimed that there is not enough information to assume that nanoparticles 
cause health risks, thus no valid assessments can be made. This is a disconcerting 
view as not having enough information is not the same as not having any 
information. Again, this can impact on employer decision-making for what to do 
in these circumstances.   
 
When assessing the use of nanoparticles under the Dangerous Substances and 
Explosive Atmospheric Regulations (DSEAR), HSE (2004) states that it is 
??????????????????????????????????????????????????????????????????????????????????
of larger sized particles. Better understanding of nanoparticle uncertainties 
particularly in the area of flammability and explosivity, is therefore needed by 
the user (Pritchard, 2004). 
 
This section has again highlighted the challenges for decision-making against a 
backdrop of adequate and fit-for-purpose information. In the following section a 
different vehicle for regulation is considered, which is the international 
organisation for standardisation.  
 
 
7.3.5. International Organisation for Standardisation  
 
As previously mentioned, there are many types of voluntary regulatory systems 
that can be adopted by organisations, with a further example of this being the 
International Organisation for Standardisation (ISO). ISO sets environmental 
management system standards and is m???? ??? ????? ?????????? ????????? ????????
from over one hundred countries (Coglianese, 2010). It has developed over 
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10,000 standards since its formation in 1947. An environmental management 
system (EMS) can produce benefits for a company as well as providing benefits 
for society as a whole by allowing policymaking to be implemented by the 
organisation or business internally. Importantly, and while REACH has not 
specifically addressed nanotechnology, ISO has moved to examine 
nanotechnology, and nanoparticles through ISO 10808: 2010 Nanotechnologies 
Characterisation of Nanoparticles in Inhalation Exposure Chambers for 
Inhalation Toxicity Testing. This is a set of guidelines to help industry assess 
risks due to the growth of nanoscale-based products and was published to ensure 
that any results from airborne toxicity analysis would be generalisable amongst 
the global community. There are four main areas that have been considered in 
ISO 10808: 2010, on a self-regulatory basis and are shown in Table 7.6.  
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Features Description 
Performance 
standards 
A performance limit is specified, which workers cannot be exposed 
beyond to a specific hazardous chemical, although no advice is given 
for how to achieve this (Viscusi, 1983). Flexibility of methods is 
enabled thus allowing companies to find cheap methods to attain the 
required performance level (Gunningham, 1996), and may expose 
workers due to poor methods being selected. Arguably, self-regulation 
is open to abuse if not monitored correctly. For example, if those 
regulating the performance standards do not posses the appropriate 
monitoring equipment or it is deemed too costly to measure the 
performance of a number of companies, workers may be exposed.  
Emission 
thresholds 
Thresholds can be set to prevent human health or environmental risk 
and fines enforced if the set limit of exposure is exceeded. This method 
requires the knowledge and understanding of what is being emitted and 
what dose is known to be harmless (Coglianese, 2010). 
Information 
disclosure 
This can be seen to be a popular and effective method for companies 
who wish to self regulate. Information can be collated and disclosed to 
the government and public if so desired by the company (Graham, 
2002). This type of regulation has been used in different industries, 
potentially shaming companies into improving their performance. In 
the chemical industry, risk to stock prices and media scrutiny is often 
an incentive for good behaviour (Hamilton 2005). 
Management 
based 
regulation 
This is similar to performance standards and information disclosure 
except it allows companies to choose their own prevention strategies 
(Coglianese and Lazer, ??????? ??? ??? ?????? ??????? ?????????? ??lf-
???????????????????????? Kagan, 1982) where companies are expected 
to comply with criteria, which allows them to reach their target.  Often 
this is less costly and more efficient than regulations imposed by 
governments, which encourages companies to be more compliant. It 
also enables experimentation with better and more innovative solutions 
(Ayres and Braithwaite, 1992). 
 
Table 7.6. Main features for ISO 10808: 2010 nanoparticle regulation. 
The main features of this ISO document potentially enables company self-
regulation, placing the onus on the companies working with these materials. 
Arguably however, if there is still a paucity of information, internal decision-
making within a company may still be challenging. One of the ways forward 
	  	  	   	  	  	  	  	  173	  
taken up by some European governments is to create a nanomaterial registry. 
This notion is discussed in the next few sections, where the objectives of a 
registry and the monitoring of nanosubstances are examined.   
 
 
7.3.6. Registries 
 
Facing a growing challenge of questions being raised about the safety and risk 
aspects posed by nanomaterials, and coupled with a lack of specific regulation, 
some governments have decided to try to understand the difference between bulk 
scale ???????????????????????? ??????????????????????????????????????????????? 
of regulation and legislation. Countries such as France, Belgium and Denmark 
decided that in an interim period, while there was still a paucity of evidence, and 
dispute over findings, a way forward should include identifying and recording 
the import and use of all materials in the nano form.  
 
In January 2013, France became the first European country to necessitate the 
identification of the use of ???????????? ????? ????????????? ??????? by 
manufacturers that ????????? ??????????? ???????? ???? ??????????? as required by 
Articles L. 523?1 to L.523-5 of the Environmental Code (www.r-nano.fr, 2014), 
with the ability to register a declaration online at the website www.r-nano.fr. The 
rationale cited by the French government was on the basis that a registry was 
essential due to the lack of knowledge surrounding the execution of 
nanomaterials into the marketplace. Belgium and Denmark have followed suit 
each with their own registry with the purpose of establishing a record of products, 
articles and mixtures containing nanomaterials that are for sale to the general 
public. From the French registry alone there have been one thousand three 
hundred and seventeen consumer products containing nanomaterials registered 
??? ????? ???????? ??? ????????? ??????????????? ????? ??????? ????????? ????????
these products ar?? ????? ???? ????? ??? ???? ??????????????? ????????? ?????? ??????? ???
NGOs, regulatory agencies and other organisations about the many more 
products not currently registered. Again and to re-iterate, these uncertainties are 
inherent in new technologies but are arguably more so in nanotechnologies 
(CNBSS, 2014). 
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The French government has made it a necessary requirement that any company 
on French territory must register so that improved knowledge of worker exposure 
to nanoparticles can be documented. Information concerning the substance such 
as usage, quantities used, a noting of the sector (where the substance is used), 
quantity, shape and size of the nanoparticle must also be recorded. This will 
allow for a more accurate and ???????????????????????? for any workers that are 
???????? ??? ?substances with a nanoparticle status?? ??????? 2014: WP).  It is 
hoped that this registry will become the first step to understanding worker 
exposure to nanoparticles, through realising the risks and developing an 
appropriate regulatory scheme. 
 
Within a registry comes a requirement to examine the way that nanomaterials are 
classified and engage with the issue of parity between substances when they are 
registered. The French registry (CBNSS, 2014: WP) states that nanoscale 
substances are: 
 
????????? ??? ???? ???????? ?? ??? ???? ??????????? ????? ???? ??????????
manufactured intentionally at the nanoscale, containing particles in 
an unbound state or as an aggregate or as an agglomerate and 
where, a minimal proportion of the particles, in the number size 
distribution, one or more external dimensions is in the size range 
1nm ? 100nm.? 
 
Importantly, in specific cases and where warranted by concerns for the 
environment, health, safety or competitiveness, the minimal number size 
distribution threshold maybe reduced. While reducing certainty in some ways, 
this approach creates an opportunity for greater reflexivity. An example of this 
can be seen by the definition of fullerenes, graphene flakes and SWCNTs with 
one or more external dimensions below 1 nm, which should be considered as a 
substance with nanoparticle status according to this registry.  
 
 
 
 
	  	  	   	  	  	  	  	  175	  
7.3.6.1. The Objectives of a Registry 
 
There are multiple drivers for governments to implement registries and for 
organisations to use them, with some of these aspects being considered in this 
section. Looking at the three governments of Belgium, France, and Denmark, all 
three have set out a decree for mandatory reporting, based on the French system. 
In essence, all three systems are roughly comparable, with a high similarity. The 
objectives of the French decree of mandatory reporting (Décret no. 2012 ? 232 
du 17 février 2012), are to gather information on nanomaterials including 
properties, applications, toxicological and eco-toxicological data as well as 
gaining insight into the level of production, importation and distribution into the 
marketplace which would ensure traceability.  
 
The decree defines ??????????? ?? ??????? ????????????????? as manufactured 
substances, which display measured nanoscale phenomena that contain primary 
particles, aggregates or agglomerates (CNBSS, 2014). This also includes 
fullerenes, graphene flakes and carbon nanotubes, and is similar to that of the EU 
Commission in 2011 (2011/696/EU). This decree applies to nanomaterials either 
alone, in a mixture or inside/coating a substance. There is a requirement for an 
annual declaration in May each year, starting in May 2013, to be submitted to the 
French National Agency for Food Safety, Environment and Labour (ANSES). 
Importantly, the mandatory declaration must be made once 100 g of substance at 
the nanoscale is produced, distributed or imported during the previous year. 
Financial penalties will be awarded for non-compliance (safenano, 2014). 
Currently REACH requires registration at one tonne and this potentially suggests 
that France, Belgium and Denmark believe that the one tonne limit is inadequate 
for nanomaterials. Although the 100 g limit for registration addresses some of the 
???????????????????????????????????????????????????????????????????????????????
still be a relatively large amount, and raises the concern about weight being the 
driver for registration.  
 
The Belgians followed the French idea of a nanomaterial registry by announcing 
in February 2014 that they have ratified a ?????????????-?????????? ????????
requiring companies to register mixtures and substances containing 
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nanomaterials that are to be taken to the market place in Belgium. Under current 
Belgian legislation?? ??? ??????? ??? ???? ?????????????? ?????????? ?????????????? ???
???? ???????????????????? ???????????????????????????????nanomaterials must be 
registered and then evaluated to see if there is a necessity for the whole product 
to be registered. This decree concerning the Belgian Nanomaterial Register is 
??????????????????????????????????????????????? promotes:  
 
? Better protection of human health during the evolution of 
nanotechnology; 
? Better knowledge of exposure risks;  
? Traceability to gain confidence for workers and the public; and  
? Collate information on a database for future reference for national and 
EU level (NIA, 2015: WP).  
 
 ????????????????????????????????????????????????????????????????????????????????
fast response by health authorities, which allows the relevant information 
concerning the toxicology to be conveyed to HSE. It is hoped that this 
transparency will promote trust in the technology by consumers, workers and the 
general public.  
 
The date for the start of registration of substances in the Belgian Registry is 
January 1st 2016 and mixtures need to be registered by January 1st 2017. This has 
been argued as enabling the Belgian authorities to have sufficient time to assess 
products that contain nanomaterials, which may need to be included in the 
Registry 2017. 
 
Outside of France, Belgium and Denmark, a number of countries and 
organisations are sponsoring nanomaterial testing. The USA for instance, 
through the EPA, is sponsoring an examination into the environmental effects of 
fullerenes, and various single/multi-walled carbon nanotubes and nanoparticles. 
???????????????????????????????????????????????????????????????????????????????
efforts to enhance its regulatory oversight of nanoscale materials (EPA, 2014). 
The EPA has taken what might be described as an active participation in the 
Working Party on Manufactured Nanomaterials (WPMN), which engages in an 
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assortment of schemes that will advance in an understanding of the potential 
benefits and risks of nanomaterials. They also contribute to these ventures, with 
the aim of helping leverage international resources and expertise, in particular 
the safety testing of the Representative Set of Manufactured Nanomaterials, 
which has the potential to fill data gaps. This suggests that the USA has an 
interest in contributing to regulation beyond its own national borders, with its 
results being included in registries in Belgium, France and Denmark. Alongside 
this, the USA has en?????? ??? ?? ?????????? ????????? ???????? ???? ??????????????
????????????????? ???????????? ???????????? ??? ??????? ??? ??????? ????????-making. 
The purposes of Nanoparticle Registry (2014) are shown in Table 7.7. 
 
Number Purpose 
1 To build: A repository of curated nanomaterial information by 
systematically archiving data from a broad collection of publicly available 
nanomaterial resources 
2 To deliver: Authoritative and useable information on the interactions of 
well ? characterised nanomaterials in biological and environmental 
systems via a public website 
3 To provide: Tools for searching and viewing data 
4 To improve: The quality of nanomaterial information by driving standards 
of accepted procedures and reporting requirements 
5 To promote: The use of a well defined minimal information about 
nanomaterials (MIAN) framework and of common nanomaterial standards 
6 To identify: Reliable information about nanomaterials that can be used in 
regulatory decision making 
 
Table 7.7. Purpose of the USA nanoparticle registry.  
 
Pivotal to any registry is the capability of monitoring exposure to products, 
which is examined in the following section.  
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7.3.6.2. Registries to Monitor Exposure 
 
There has been much positive discussion in favour of a registry system for a 
?????????????????????????????????????or those ???????????????????????????????????
?????? ?????? ??? ????????? ???????????? ????? ?????? ??? ??? ??????? ??? ??? ?????????? ???
released under normal or reasonably foreseeable conditions of use? (CNBSS, 
2014: WP). This is a broad and encompassing approach that may capture many 
nanoparticle products.  
 
Hansen et al, (2007) has given an overview of the registry concept and 
developed a method for dividing the nanomaterials into sub-categories. This is 
significant for identifying hazards to enable risk assessments to take place, where 
sub-categories can be classified and divided into materials containing 
nanoparticles, and nanoscale objects that are suspended into solids, and where 
the nanoscale object may break free. The category perceived as giving the most 
concern is that of nanoscale objects migrating into the environment, particularly 
for accidental splash exposure and release (Hansen et al, 2007). This arguably 
creates a necessity for accurate reporting and recording of data. 
 
Although the French registry is monitoring the exposure of workers to 
nanoparticles, not consumers, it must cover the traceability of these nanoparticles 
in goods as this has an impact on consumer risk. This is an important point and 
four scenarios have been created to demonstrate this (CNBSS, 2014), as detailed 
in Table 7.8.  
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Table 7.8. Scenarios registries may monitor. 
 
Arguably with the use of registries, moderate traceability of nanomaterials can be 
documented. The four possible scenarios in table 7.8 created as examples, 
demonstrate the difficulty of accuracy without the availability of machinery able 
to record and take precise measurements of nanomaterials.  
 
 
7.4. Insights from Different Sectors 
 
While multiple approaches have been used to engage with nanotechnology 
through regulation, albeit often not directly, this section aims to pull together 
insights from different sectors currently engaging with nanotechnology products. 
Critical to the discourses regarding nanotechnology regulation is the potential not 
only to regulate products through stakeholders, but also how products should be 
Number Scenario 
1 The nanoparticle substance is sold to a consumer. This substance could be 
in the form of material or mixture. When the consumer uses the substance 
under normal conditions, nanoparticles are released, potentially putting the 
??????????????????or the environment at risk. 
2 The nanoparticle substance is sold to the consumer but the nanoparticles are 
bound inside a mixture or to a material, therefore rendering the substance 
?????? under normal conditions. Abnormal usage has the potential to create 
risks to the environment if these substances are not recycled appropriately. 
3 The substance containing nanoparticles is sold to the consumer as a mixture 
or material where the nanoparticles are bound within them. Traceability of 
the substance throughout the full length of the chain of production is 
necessary to maintain a lower risk to the consumer. 
4 The nanoparticle substance is consumed during the production process 
therefore any potential threat from nanoparticles is negated. However, this 
needs to be a controlled consumption to avoid any of the nanoscale ? waste 
???????????????????????? ????? ???????????????????????????? ??????????????? ???
limited although it is necessary to make sure that all the substance has been 
consumed during the production process. 
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labelled (USDA, 2003: WP). Not only is this a consumer protection issue, but 
also in principal it acts to reduce consumer fears, which have been detrimental to 
other high technology products (Porter, 2012). Drawing on three distinct areas of 
nano foods, cosmetics and nanomedicine, current strategies for regulating 
nanoparticle products are examined in the following three sub-sections.  
 
 
7.4.1. Regulating Nano Foods 
 
Different approaches to nanomaterials have been taken throughout different 
sectors and related to different product applications. For example, 
nanotechnology related to food is at present regulated under general food 
production systems (Brazell, 2012). While the debates continue, the only real 
move towards specific regulation has been through an amendment to Legislation 
1169/2011, where all nanoscale substances must be listed in the ingredients 
followed in ????????? ??? ???? ????? ??????? ??????????? ??????? ???? ??????????
defined nanomaterials as:   
 
?Any intentionally manufactured material, containing particles, in an 
unbound state or as an aggregate or as an agglomerate and where, 
for 50 % or more of the particles in the number size distribution, one 
or more external dimensions is in the size range 1 nm to 100 nm?. 
 
Considering this definition, it is clear that there may be profound differences 
between products based on sizes and percentages of products in all three physical 
dimensions. In practicality, this may result in substantial differences in health 
and safety, as well as potential benefits from any product.  
 
Examining the arena of nanotechnology foods, the European Food Safety 
Authority (EFSA) has been active in the EU, examining the need for 
nanotechnology specific regulation. It is fair to say that the EFSA is concerned 
about its responsibilities regarding nanoparticles due to uncertainties surrounding 
scientific opinion (EFSA, 2008). It published a Scientific Statement in 2008 on 
the safety of silver nanoparticles as an application had been made to include 
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silver hydrosols as an approved substance for food supplements (Porter, 2012). 
EFSA declared in the Statement that there is insufficient evidence on the safety 
of silver nanoparticles to use them in food substances. In what appears to be an 
approach in line with the precautionary principle, the EFSA claimed substantive 
knowledge gaps that would create unknowable risks. 
 
In 2008, The European Commission proposed a rewrite of the Novel Foods 
Legislation to include new technologies. This was explicitly for 
nanotechnologies and in 2009; the proposal was endorsed by the European 
Parliament who urged the introduction of mandatory labelling to list ingredients 
and also proposed the inclusion of a definition of nanoparticles (Porter, 2012). 
Other proposals by the European Commission included nanomaterial specific 
????????????? ???? ???????????????? ????-???????? ????????????????????????????????
using nanotechnology or that contain nanomaterials must be assessed and then 
authorised before sale. This could have created problems for the 
commercialisation of foods containing nanoparticles but the European Council 
decided that the revised Regulation (June 2009) would not make the 
authorisation of these foods conditional upon test methodologies being 
developed (Porter, 2012). 
 
To address this issue in regard to nano-foods, the EU has moved to update its 
current regulations in regard to food additives. This appears to be based on the 
????????? ????????????? ?????????? ??? ????????????? ??????? ??????? ???? ?????
Safety, which has recently stated that nanotechnology products should have a 
separate lower limit value to those of the bulk forms (Halliday, 2007). To date 
this change is still being discussed, with no changes to the regulation at this time. 
Even though it is still in the discussion stage, it is suggestive of a moving 
perception that bulk material physicality cannot be regarded as the same as at the 
nanoscale.  
 
There is a requirement that all new food products and ingredients need to have 
received pre-market approval by the EU Novel Foods Regulation. To partially 
encompass changes to the food landscape by nanotechnology, the European 
Commission has proposed a revision (CEC, 2008b) to define novel foods to 
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include any foods that have been modified by new production processes such as 
nanoscience or nanotechnology that potentially could impact on the food. This 
revision requires that an application to the European Commission must be made 
to authorise a novel food to be used as an ingredient so that the European Food 
Safety Authority (EFSA) can evaluate whether the food is dangerous to 
consumers. An assessment must be made on the intended use of the food and an 
examination of the nutritional content and composition as well as any chemical 
and microbiological contaminants. Other studies are also required such as 
allergenicity (whether a substance causes an allergy) and toxicology as well as 
any details of the manufacturing process (Hansen, 2009). While attempting to 
??????????????????????????????????????????-food, there are still issues that need 
to be addressed. In particular, this revision does not make any distinction 
regarding nanoparticle size, enabling nanomaterials, which have a bulk scale 
counterpart to not sit outside of new safety assessments, as long as the substance 
has been approved in its bulk state (Hansen, 2009). The EFSA have concluded 
that when risk assessment guidance recommends that the special properties of 
nanoparticles should be considered, a review will take place (EFSA, 2008). 
While, there is still much offered potential scientific and health benefits offered 
by nano-foods, there is clearly much to draw out for the best way forward for 
packaging and labelling nano-foods.  
 
Moving on from examining nanotechnology food based regulation; the next 
section examines another major sector of cosmetics, in cosmetics regulation.  
 
 
7.4.2. Regulating Cosmetics 
 
Nanotechnology has attracted much attention from the cosmetics sector, but has 
also generated attention from regulators for how to engage with this physical 
phenomenon. The Cosmetics Directive (1976)  (76/768/EEC) is the basis of EU 
cosmetic regulation, which is made up of over fifty amendments that have been 
added over the past thirty years. With advancements in technology and in 
particular nanotechnology and perceived legal uncertainties (Porter, 2012), the 
EU revised the Directive into a new Regulation (EC No 1223/2009, EU 2009c) 
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that took effect in 2013. This shift, mentioned nanomaterials directly in the 
Cosmetic Regulation (EU, 2009c) stating that they are to be limited to 
biopersistent and intentionally manufactured (engineered) materials. The revision 
of the cosmetics regulatory regime was a defining moment for nanotechnology as 
cosmetic nanomaterials were addressed explicitly for the first time (Brazell, 
2012).  
 
Before updating the Cosmetics Directive, Annex II set out a list of prohibited 
substances and Annex III set out those substances that may be used in certain 
conditions or with restrictions, although there was no reference to particle size. 
This meant that the Old Cosmetics Directive did not restrict nanoscale substances 
judging them to be the same (therefore safe) as their bulk counterparts (Brazell, 
2012).  The Old Cosmetics Directive does make reference to health and safety by 
not allowing products that may cause harm to human health to be allowed on to 
the market in the EU (Article 2, Old Cosmetics Directive, 1976, Brazell, 2012). 
The manufacturer must keep a dossier to hand over to the authorities of the 
Member States if required. This has to include the microbiological and physico-
chemical specifications of not only the finished product but also the raw 
materials including an assessment of how the product may impact on human 
health (Article 7a, Old Cosmetics Directive, 1976, Brazell, 2012). The Scientific 
?????????????????????????????????????????????????????????????????????????? 
to cover health and safety issues such as: ?????? ?????????? ??????? ?????????
irritation, skin absorption, reproductive toxicity, inhalation toxicity, and 
???????????????????????????????????? (Brazell, 2012: 174). 
 
Article 13 of the New Cosmetic Regulation requires specific information to be 
submitted to the Commission about each cosmetic product before 
commercialisation, which includes disclosure of, ?the presence of substances in 
the form of nanomaterials?. For products containing nanomaterials in accordance 
with Article 16, the Commission must be informed six months prior to a product 
being placed on the market if it contains nanomaterials. Specifically, six criteria 
must be met, as detailed in Table 7.9. 
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Number Criteria 
1 Identification of the nanomaterial. 
2 Chemical properties.  
3 Particle and physical size.  
4 An estimation of the amount of nanomaterial in the product.  
5 A toxicological profile of the nanomaterial.  
6 Any foreseeable exposure level of the product.  
 
Table 7.9. Article 16 for nanomaterial containing cosmetic products.   
 
As has been mentioned for other regulatory aspects in this study, there is still an 
issue for any criteria requiring an understanding of the underlying science of 
nanotechnology products.  
 
Importantly, cosmetics manufacturers are required to assess the safety of any 
product they wish to market under the 1976 Cosmetic Directive by considering, 
?the general toxicological profile of the ingredients, their chemical structure and 
?????? ?????? ??? ????????? (Chilcott and Price, 2008: 320). The Competent 
Authorities in Member States must also be notified when manufacturers are 
placing a product on the market.  
 
The Scientific Committee on Consumer Safety (SCCS) can provide an opinion 
on a nanomaterial if the Commission has concerns over its safety. A report by the 
SCCS must be made within six months and any extra data that is required must 
be provided. The Commission must also catalogue any nanomaterial placed on 
the market that is contained in a cosmetic product and report it to the European 
Parliament and Council on a yearly basis to demonstrate the increasing use of 
nanomaterials in cosmetics (Porter, 2012). 
 
Both the raw materials and the finished cosmetic products come under the EU 
Cosmetic Directive EC 76/768/EEC and EC 1223/2009 and REACH EC 
1907/2006 and CLP (Classification, Labelling and Packaging) Regulation ? EC 
1272/2008. Any non?EU importers/exporters of finished cosmetics or cosmetic 
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ingredients must comply with these regulations before their cosmetic products 
are placed on the market (CIRS, 2013).  
Under REACH, there are some exemptions for cosmetic products. These relate to 
human health exposure hazards but other risks, such as environmental hazards 
from bioaccumulation, have the potential for a cosmetic product to fall under the 
assessment scheme of REACH (Brazell, 2012). Any information not covered by 
REACH that is required, is collated by questionnaire by the formulator and 
passed to the supplier, allowing any necessary information needed for regulatory 
compliance or perhaps to defend any liability claim. The regulation for the safety 
of cosmetic products is regulated under the Product Safety Directive (Brazell, 
2012). 
 
In 2007, the SCCP taking into consideration the suggestions in the report 
Nanoscience and Nanotechnologies: opportunities and uncertainties, June 2004 
from the Royal Society concluded that nanoparticles should be treated as new 
chemicals instead of their bulk counterparts, from the aspect of risk from skin 
absorption in healthy or diseased skin (SCCP, 1147/07, 2007). They also 
addressed the question as to whether the Notes for Guidance needed to be revised 
in respect of nanoscale titanium dioxide and zinc oxide. Brazell (2012: 177) has 
argued that ????? ???? ???????????? ??????? ????? ??????? ???????? ???????????
nanomaterials needs to be evaluated on a case?by? ???????????? 
 
Article 13 of the new Cosmetics Regulation states that the producer of each 
cosmetic product must give specific information such as: category, name, 
country of origin, any nanomaterials present, and the framework for the 
formulation, before being placed on the market (Article 13, 1223/2009). The 
person that places the cosmetic product in the EU market has the responsibility 
of keeping the product traceable throughout the supply chain. 
 
Article 16 of the new Cosmetics Regulation covers the new requirements for 
cosmetic products containing nanomaterials. Its priority is to require the product 
to be safe, stipulating that human health must be ensured. This notification must 
include: amount of nanoparticles contained in the product, size of particles, 
identification of the nanoparticles plus its chemical name, safety data and 
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toxicological profile, and any foreseeable risk or exposure hazards. If there is 
insufficient safety data, the SCCP may request that the nanoparticle be prohibited 
and placed in Annex II. Any materials placed in Annex III can be used but are 
subject to restrictions, which is to prevent any potential health risks from the 
nanomaterial. Labelling has also received attention with Article 19 (1) (g) 
stipulating that nanomaterials must be labelled ?????? and included in the list of 
ingredients. An example of this would be zinc oxide ??????? 
 
In 2014, the European Commission placed a catalogue on the market to be made 
publicly available and regularly updated, for all nanomaterials that are currently 
used in cosmetic products (Article 16 (10) (a): 2009). The aim is for all possible 
and foreseeable risks and exposure conditions to be included. An annual status 
report must be submitted to the European Parliament and Council that will 
include updates on safety assessments and guides, plus any information on 
international cooperation programmes (Brazell, 2012). 
 
Article 20 states that by July 2016, the European Commission must draft a report 
on the subject of advertising claims made by cosmetics containing nanoparticles. 
Advertisements must not be allowed to mislead the consumer into believing that 
a cosmetic product has functions or characteristics that it does not. Therefore 
Article 20 (1) prohibits the use of trademarks, pictures, names, texts, or other 
???????????????????????????????????????????????????????????????????????????????
used to signify nanomaterials are being used when there are no nanomaterials 
contained in the product.  
 
The adaptive process of requiring new information is expected to continue, with 
a new review being due to take place to amend the whole regime where 
necessary in 2018. This will take into account any new information on health and 
safety and look at any scientific progress that has been made (Article 16 (11): 
2009). This approach is clearly seeking to build information about these products 
and to inform the consumer, on the basis of these products containing 
nanomaterials constituents.  
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Stepping beyond cosmetics, the next section explores pharmaceuticals and 
nanomedicine.  
 
 
7.4.3. Regulating Nanomedicine 
 
The pharmaceuticals sector is regarded as highly regulated (Brazell, 2012), 
particularly for safety, efficacy and quality (Mann and Andrews, 2014). 
Arguably, pharmaceutical products must abide by a relatively higher standard of 
regulations than the previously mentioned products in the last two sections. 
Alongside this is the need of government approval through regulatory bodies 
(Abraham and Lewis, 2002) for medicinal products, with information required 
for the product physicality, uses, labelling and packaging before it is marketed 
(Mann and Andrews, 2014). It is also a requirement of the pharmaceutical 
companies to track the effects of the product on the consumer and to report any 
unfavourable effects through pharmacovigilance (Brazell, 2012). 
 
Medicinal products in the EU are regulated through a variety of regulations 
depending on the perceived risk of the drug, and how much information is 
currently available already on its physicality (Jackson, 2012). There is specific 
regulation for medicinal items used for blood products, products for paediatric 
use, herbal products used for medicinal purposes, and orphan drugs. A set of 
community guidelines; ????????????????????????????????????????????????????????
U????? have been published to support this legislation, which includes both 
scientific and regulatory guidelines (ec.europa.eu, 2012: WP). 
 
Currently, the regulatory framework does not contain any specific requirements 
for nanoparticles. In 2006, the European Medicines Agency (EMA) published 
???????? ???????????? ???????? ????? ????????? ???????? ????????????? - EMA, 2006, 
iron nanoparticle based products - EMA, 2011a, and liposomes - EMA 2011b 
(ema.europa.eu: ???????????????????????????????????????????????????????up by 
the EMA to give support to the Agency with guidelines to nanomedicines, 
specialist scientific knowledge and ???? ?????????? ??????????? ??????????????? 
2011). 
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When constructing legislation for nanomaterial products it is important to carry 
out a careful risk management and risk assessment on a case-by-case basis before 
any product can go to market. A significant point to remember is that medicines 
containing nanoparticles have potential risks attached that are still unknown, 
therefore the EMA requires a complete and thorough evaluation that must be 
recorded and the information held in registration dossiers (Bleeker et al, 2012). 
 
Article 11.3 (b) and 19.2 (b) of REACH states that all medicinal products 
marketed in the EU must have marketing authorisation (MA). A medicinal 
product is defined as a substance or a mixture of substances to be used to prevent 
or treat disease, or be dispensed to aid medical diagnosis or to restore, correct or 
modify physiological human functions. It may also include micro ? organisms 
such as vaccines as well as natural occurring plant extracts. All of these products 
must be authorised by a governmental body recognised by REACH or the EU 
agency (Brazell, 2012). For any product to have MA, its safety must be proven 
alongside its quality and efficacy. This involves rigorous pre-clinical testing and 
clinical testing, carried out by EU procedures to reach EU standards. All data 
supplied must demonstrate control, stability, and characterisation of the product 
to prove its quality (Article 6 Directive 2001/83/EC). 
 
Importantly, many medicinal products that contain nanoparticles have been on 
the market for several years, often to aid in drug delivery (Brazell, 2012). A term 
that has arisen in this area is nanopharmaceuticals (this includes nanoparticle and 
liposome drug delivery systems) ???? ?????????? ??? ???? ??????? ????? ???? ???????
system of delivery. Many of these systems have already got approval under 
existing regulations (Brazell, 2012), which is due to the processes being argued 
as being well understood. However, the system of delivery can have numerous 
effects including the positive and negative. The positive effect is the potential for 
the nanoparticles to have an affinity for tumours aiding in the direct treatment of 
cancers but the negative aspect could potentially cause immunological effects 
such as surface modifications that are not shown by the bulk form (Brazell, 
2012). This poses the question as to whether nanopharmaceuticals should be 
treated as separate entities and require new authorisation as the bulk form of the 
chemical has already been authorised? There is also the potential for 
	  	  	   	  	  	  	  	  189	  
nanopharmaceuticals to reach tissues and cells that larger pharmaceuticals may 
not and the possibility for novel effects to also take place, but is coupled with a 
risk that these nanomaterials may create different pathways throughout the body.  
One of the biggest challenges facing the creation of nanomaterial legislation in 
the pharmaceutical sector is the difference in their stipulative definition by 
different stakeholders????????????????????? ????????????????????????????????
(CHMP) states that ???? ???? ??????????????? ??????? the definition: ???????? ????
???????????????????????????????????????????????????????????????????????????????
???????????????? (Bleeker et al, 2012: WP). EMA produced a 2006 Reflection 
Paper (EMEA, 2006) that sets out the definition of the nanoscale as being from 
0.2 nm at the atomic level to approximately100 nm (ema.europa.eu: 2006).  Yet 
on their website they claim that the upper limit is 1,000 nm instead of 100 nm, 
creating further confusion. EMA also consider liposomes, with particle sizes 
over 100 nm to be nanomedicines and take the lower limit to be 0.2 nm instead 
of 0.1 nm as the EC definition states (EMEA, 2006). Unfortunately, these 
unclear statements create further opacity and in many ways obligate stakeholders 
to develop an in depth understanding of the underlying science.  
 
???? ????? ?????????? ???? ??????????? ????????? ??????????? ??????? ???????
Commission on Human Medicines in 2006 carried out a survey looking at all the 
nanoparticle studies and literature relating to healthcare and nanomaterials (mhra, 
2006). They concluded that the chemical toxicity of bulk materials should not be 
an indication of the toxicity of materials at the nanoscale. They also indicated 
that previous nanotoxicology reviews on nanomaterials contained in health care 
products is limited and possibly irrelevant, observing that the safety data 
obtained on particles at the nanoscale with diameters between 100 ? 1000 nm 
(including the majority of drug delivery vehicles) does not always transfer 
directly to particles of 1 ? 100 nm diameter (mhra, 2006). 
 
When examining medical devices, (products that include those that may be used 
inside the body or in surgery, such as nanoprobes, nanostructured scaffolds used 
for tissue replacements, and implantable nanoelectric systems) the EC New and 
Emerging Technologies Working Group (N&ETWG, 2007) concluded that 
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nanoscale products should be treated as a high-risk group. They (N&ETWG, 
2007: 6) stated that: 
 
?All devices incorporating or consisting of particles, components or 
devices at the nanoscale are in Class III unless they are encapsulated 
or bound in such a manner that they cannot be released to the 
????????????????? tissues, cells or molecules.? 
 
It was also recommended by the Working Group that regulatory guidance for 
stakeholders should be developed, due to the many unknown risks surrounding 
nanotechnology. Currently, a document is being prepared - ????????????????ce 
?????????? to deal with medical devices that contain nanoparticles plus the 
?????????????? ???????????????? ????????????? ??????????????????? ????????????????
the International Organisation for Standardisation (ISO/TC194/WG17) to 
evaluate the biological impact of medical devices that contain nanoparticles 
(isotc, 2012). A revised regulation is currently being developed to make 
provisions for medical devices that contain nanomaterials (ec.europa.eu, 2012: 
WP). 
 
The N&ET?????????????????????TWG, 2007: WP) also did not give a precise 
definition of ?????? but states that  ?There is no scientifically based cut ? off 
point to define nanoscale. The size below which nanomaterials can display 
specific properties varies for different materials? (ec.europa.eu, 2012: WP). 
??????????????? ??? ?????????? ??? ???? ????????????? ??????????????? ???????
nanomaterials need specific requirements.  
 
After much consideration of the national and EU regulations, the major themes 
are pulled together in the following summary.  
 
 
7.5. Summary 
 
This chapter has examined UK and EU based regulations for how they interact 
with high technology products, and in particular nanotechnology and 
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nanoparticle products. Consideration has been made of various regulatory 
systems such as REACH, ISO, COSHH and registries, and while arguing that 
they all have something to offer nanoparticle regulation, there is still much to be 
done if any of these systems are to effectively be of use to safeguard against 
societal and environmental harm from nanotechnology. It is of course recognised 
that there is a balancing act between safeguarding and promoting commercial 
activities and product innovation that can enhance the economy and societal 
health for example. Having taken a bricolage approach to numerous sectors and 
regulatory instruments, there are clear emergent themes, with the most pivotal 
being a lack of scientific data. This aspect has been addressed in previous 
chapters also, but arguably, the greatest foreseeable barrier to regulation is the 
unknown physicality of nanoparticle products, which have received at best 
limited scientific attention outside of R&D testing. Thus, without a greater 
scientific focus being made towards the actuality of these products it is difficult 
to see a way forward for fit-for-purpose regulation. More than this, with the 
EFSA implementing the precautionary principle for nanomaterials food additives, 
due to a paucity of data, there is some urgency in addressing this.  
 
Overviewing the most prominent and noteworthy discourses regarding 
nanotechnology regulation, there is a very real possibility that nanotechnology 
products are being commercialised without adequate safety testing to elucidate 
mitigation measures. On this basis, and as discussed within this chapter, the 
notion of case-by-case testing for these products is suggested, depending on 
currently held data, product application and sector.  
 
To draw this study to a close, the following chapter on discussion and 
conclusions will take a broad overview of research findings, while making 
suggestions for how regulation might be used for nanotechnology and 
nanoparticle products.  
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Chapter 8. Discussion and Conclusions 
 
 
8.1. Introduction  
 
Nanotechnology is a pervasive collection of high technology products that has 
??????? ?? ????? ?????? ????? ???? ????? ??????? ??????? ??????????? ???????? ????
speculative persuasive marketing claims. Within this zeitgeist, thousands of 
products are currently being sold in the global market place containing 
nanomaterials. Due to their enhanced properties, they have received much 
commercial interest, but with limited attempts to produce nanotechnology and 
nanoparticle specific regulation. Although the difference between nanoscale and 
bulk materials is readily acknowledged in scientific arenas, from a regulatory 
perspective, law has been slow to acknowledge this difference in a meaningful 
way, and has predominantly relied on current bulk scale regulations instead of 
implementing specific nano-based regulations. This has at some level been 
beneficial to product manufacturers facilitating quicker routes to market in line 
with neo-liberalist frameworks.   
 
This study has examined numerous aspects of the journey of nanoparticle 
products from inception through to disposal, via a bricolage approach to better 
understand how nanoparticles ?should? be regulated to ensure that commercial 
innovation is encouraged, while risks are mitigated. This has led to several main 
themes being explored, including neo-liberal technology frameworks, what 
nanoparticles are from a discursive and physical perspective, how these products 
are used commercially, their perceived risks and benefits as well as how to insure 
such products. This has been alongside health, safety and environmental 
implications, leading to current regulatory approaches and discourses being used 
to frame the nanotechnology and nanoparticle regulatory challenge. As such this 
???????? ?????? ??? ???????? ?????????? ??? ?????? ????????????? ??? ?????????? ?? ??????
overview, engaging in a discussion of key themes, drawing conclusions, making 
recommendations based on research findings, suggesting future work, and 
recognising research limitations. As a starting point, the following section 
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examines the purpose of this study, to provide a research overview and 
contextualise all other chapter sections.  
 
  
8.2. The Purpose of This Study  
 
Many articles from a variety of disciplines have considered the potential 
challenges posed by nanotechnology and in particular nanoparticle products to 
the current regulatory landscape. This study set out to address the question 
derived from my emic sensitisation and etic grounding within the extant 
??????????? ???? ????? ??????? ?????????????? ??? ?????????? ??? ????? ????? ??? ??????????
while business innovation and commercialisation is encouraged?????????????????
has recognised that regulation is a balancing act between these and many other 
??????????????????????????????????????????????????????????????????????????????????
Problematically, what is right for one stakeholder may well be wrong for another. 
Thus, this study sought to encompass the notion that regulation is culturally 
embedded within particular timeframes, where through time, regulatory drivers 
can change. Following on from this thought, in this study regulation is 
considered as evolving a??? ?????????? ?????? ??????? ??? ?? ?????????? ????? ??? ????
process.  
 
Through this study, my aim was to elucidate regulatory issues and structures that 
are relevant to nanotechnology and nanoparticles. This led to several research 
questions which have been specifically addressed in this study, that have firmly 
sought to ground this study within a need to engage with nanoparticles 
constructed as physical entities to better regulate their commercial promises but 
limit their risks. Taking this view meant that an overview of nanoparticles was 
carried out from inception through to manufacture, usage and disposal. This 
approach is novel and coupled with the previously mentioned factors has 
answered questions regarding how to regulate nanoparticles, but also importantly, 
raised new questions, based on this study.  
 
Moving into this chapter further for the discussion and conclusions drawn, the 
next section provides a brief research overview.  
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8.3. Research Overview 
 
Overviewing the extant literature showed that although there has been much 
debate regarding nanotechnology and nanoparticle products, there was still much 
to unpick. This study undertook the selected targeting of research areas discussed 
in the last section, with this section providing a brief review of extant literature, 
to again remind the reader.  
 
Targeting what is arguably the greatest macro-scale deficiency within extant 
literature is the lack of direct discourse and recommendations for how 
nanoparticles should be regulated to minimise risk while encouraging innovative 
commercialisation. Although addressed in other high technology arenas, such as 
biotechnology and pharmaceuticals (Fraser, Daubert, and Van der Werf, 2011), 
there is often little discourse regarding the neo-liberalist influence on high 
technology regulation, such as nanotechnology. A lack of examination on this 
aspect has in general resulted in a failure for nanotechnology discourses to 
consider the functional foundational physicalities affecting nanotechnology 
regulation.  
 
Prior studies have predominantly constructed nanotechnology as just smaller 
products than their bulk counterparts, missing much of the nuance of 
nanoparticles, which I argue is critical for their regulation. This has been 
alongside little consideration of the potential influence and impact of wider 
socio-linguistic constructions of nanotechnology (Fadeel and Bennett, 2010). 
Pivotally, and while many areas outside of legal regulatory discourses have 
discussed aspects such as nano, nanotechnology and nanoparticle definitions 
(Delgado, 2010), attention paid through a regulatory lens has been limited.  
While I caution against concretising definitions, they are helpful demarcation 
points for working with complex, opaque and easily misunderstood high 
technology products (Harris, 2007).  
 
Within many disciplines examining nanotechnology and nanoparticles, are 
discussions about the use of these technologies. Unfortunately this has often been 
through ??????? ??? ????? stories, which overly simplify the phenomenon of 
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nanotechnology (Marchant et al, 2008). While helpful for aiding sense being 
made, much critical information can be missed out through this process. More 
than this though, these simplified factors, have often led to simple perceptions of 
how to regulate, but at the expense of poorly constructing the physical reality of 
these products.  
 
There has been much debate about the risk element of nanotechnology and 
nanoparticle products, particularly when positioned through bad stories (Poland 
et al, 2008). This has resulted in what I consider an overly pessimistic narrative 
of nanoparticle technologies, and with very little examination of how insurance 
is linked to risk for these products (Baxter, 2008).  
 
Receiving much critical attention in both scientific and legal literature is the 
examination of health, safety and environmental implications of nanoparticle 
products. While much scientific literature has focussed on demonstrating the 
potential damage to people and the environment from nanoparticles, studies have 
in essence bee?????????????????????????????????????????????????areas, with much 
still to be elucidated from practical use and exposure (Binion, 2008). More than 
???????????????????????????????????????????????????????????????????????????????????
world (Binion, 2008), it is questionable at what level testing is of practical use in 
its current form. It is recognised that there is a severe paucity of usable data to 
better help understand the physical aspects of nanoparticles, as well as 
nanotechnology. While it might appear that this is an insurmountable challenge, 
as mentioned previously, other sectors such as biotechnology and 
pharmaceuticals have much more actively engaged with the regulatory system to 
highlight challenges, and ways to deal with them.  
 
Finally, and summing up all of the previously discussed aspects in this section, is 
the need to synthesise all of these often conflicting discourses into an intelligible 
way forward for nanoparticle regulation. Reiterating the previous stance, that 
????????????????????? ???????????????????????????????????????????????? ??????????
???????????????????????? ??????????????????? ?????? ????? a practical and pragmatic 
approach from the extant literature and my sector sensitisation is needed, and 
discussed throughout this chapter.  
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The following section goes on to explore the themes considered in this section, 
while linking them to specific research questions for reader clarity.  
 
 
8.4. Discussion ? Key Findings 
 
Taking a broad overview of this study, this section discusses the key 
contributions to the knowledge base, and addresses the questions derived from 
my emic sensitisation and etic contextualisation against extant literature.  
 
????????????????????????????????? ??????????????????????????????????????????????ow 
should nanoparticles be regulated so that risk is minimised while business 
innovation and commercialisation is encouraged?? this is answered in Section 8.6, 
drawing on findings from this and other sections. Looking at the other research 
questions, the key findings are as follows:  
 
2. How are high technology products regulated, and how does the neo-
liberal regulatory framework influence this? 
 
Neo-???????? ??????????? ??????????? ???? ?????????????????? ??? ???????????
technologies as beneficial in several ways with variations, depending on the 
sector that products are sold into. This can include social, economic, and medical 
benefits, and for example, the commercialisation of a nanoparticle product that 
can act as a therapeutic to reduce disease states, while increasing/maintaining 
employment and generating taxable revenue etc. Many scholarly works have 
addressed neo-liberalist under pinnings for high technology regulation (Abraham 
and Lewis, 2002; Davis and Abraham, 2013), where a stance is roughly taken 
??????????????????????????????????????????????????????????????????????????????????
and nanoparticles have predominantly sat outside of this argument (often not 
being specifically cited), but yet at the same time, still exist within it, as a 
collection of high technology products. As such, commercial exploitation has 
been a core concern (even if the reason why was not fully understood), resulting 
in rapid and mass commercialisation of nanotechnology and nanoparticle 
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products. This has led in other more established sectors to arguments based on 
commercialisation first, and risk mitigation second (Fisher, 2009), and while not 
necessarily capturing the nuance of neo-liberalist arguments, it does show how 
commercial activity is a prime concern.   
 
3. What are nanotechnology and the product class of nanoparticles, from a 
scientific and socio-linguistic perspective? 
 
??????????????????????????????????????????????????????????????????????????????????
class from forerunner technologies such as micro-particles, and bulk scale 
materials (El-Shall and Edelstein, 1996). Nanoparticle physical action is often 
based on different physical mechanisms for their action with the physical world, 
meaning that the benefits of being nanoscale also necessitates a regulatory view 
????????????????????????? (Eastoe, Hollamby and Hudson, 2006). Importantly, this 
means that their risks cannot be assumed to be identical to larger scale products, 
and previous classifications of material and product safety, are largely unknown. 
This is a critical point for this study, and I argue obligates a stronger regulatory 
view that these products cannot be regarded as the same, unless demonstrated to 
be so through scientific testing. Finally, there is often confusion arrived at by 
interactions with socio-linguistic constructions of nanotechnology and 
nanoparticles (Boholm and Boholm, 2012), and as they are unhelpful should be 
avoided, and scientific definitions and language based constructions given a 
prime position.  
 
4. How are nanotechnology and nanoproducts used commercially, and what 
are the perceived negative and positive attributes potentially influencing 
their regulation? 
 
As mentioned throughout this study, there are numerous commercial products 
?????????? ?????? ??? ??? ??????????? ??????????????? ?????? ???? ????? ??? ?????? ??????? 
(CPI, 2014)?? ???? ????? ?????? ??? ?????? ??? ??? ??? ?????????? ??? ???d a sector without 
nanoparticles used somewhere, but of course, no definitive claim is being used to 
this literally being the case. With so many products being sold into many 
different sectors, this raises a variety of challenges, and discourses arising from 
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different stakeholders, for and against their use. As a foundation, I worked on the 
basis that discourse is not a neutral medium (Rorty, 2009) whereby the potential 
power of discourses must be considered for being able to influence how 
stakeholders make sense of nanoparticles and wish to regulate nanoparticle 
products (Weick, 1995). Drawing on these aspects and against a pervasive 
product usage, I argue that it is too simple a notion to suggest that nanoparticles 
???????????????????? ???????????????????? ?n other words as a single product class. 
Their usage in multiple sectors, with different applications and target users, 
suggests that nanoparticles should be regulated on a case-by-case basis, albeit 
potentially within demarcatable frameworks and reference points. More about 
this will be discussed in Section 8.6.  
 
5. How are nanoparticle products perceived from a risk perspective, and 
how does this influence their insurance? 
 
Against a backdrop of good and bad stories, there is much concern within extant 
literature about the potential risks for nanoparticles (Baxter, 2008??????????????????
into insurance discourses. At present, there is limited and often no provision for 
specific risk assessments of nanoparticle products, which is also echoed in other 
nanotechnology literature (Dana, 2012). This is highly problematic for risk and 
insurance-based decision-making, where a lack of information often means that 
?????????????????????????????????????????????????????????????? task is a lack 
of ????? world? data from scientific testing to validate assumptions and claims 
being made about nanoparticle product risks (Yon and Lead, 2008). In practical 
terms, this ultimately leaves many businesses, consumers and insurers with a 
difficult choice for how to proceed, within the two formers cases is whether to 
use or consume a product, or in the latter whether to insure (Baxter, 2008). 
Without fit-for-purpose testing to validate claims and discourses, it is unlikely 
that clarity in this area can be made.  
 
6. What are the health, safety and environmental implications of 
nanoparticle products, and how might regulation be used to address this 
issue? 
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Following on from the prior question, there are many concerns about the health, 
safety and environmental implications from nanoparticle products (Boucher, 
2008; WHO, 2008). While much has been said about this issue, in practical terms, 
very little has been carried out and achieved. Arguments are continually made 
about the danger of nanoparticle products, but little testing has been carried out, 
meaning that much information is still needed (Yon and Lead, 2008). More 
simply, an immediate focus must be made on linking claims with scientific data, 
as with the exemplar of CNTs being similar to asbestos for instance, health 
drivers are there for such data to be elucidated (Poland et al, 2008). Due to the 
variability of nanoparticles in different sectors with different applications, being 
used, and disposed of, this suggests in depth testing programmes to determine 
product safeties in multiple stages of the product?s life. It would seem practicable 
to implement a system similar to Pharmacovigilence (Mann and Andrews, 2014), 
whereby in certain sectors, required post-manufacture testing is carried out, and 
data collected.  
 
7. What are the regulatory approaches to nanotechnology and nanoparticles 
that might best result in regulation promoting innovative 
commercialisation while addressing needs to mitigate risk? 
 
This question and theme is considered in Section 8.6, due to the similarity with 
the overall main question driving this study.  
 
 
8.5. Conclusions of the Study  
 
This study has examined numerous aspects related to the regulation of 
nanoparticle products, with this section drawing the conclusions together. As part 
of this process and examined in this section are five major themes, including (1) 
the isthmus between science and law, (2) the complexity and opacity of 
nanotechnology, (3) paucity of data, (4) defining nanotechnology and 
nanoparticles, and finally, (5) regulating nanotechnology. Importantly, these 
sections are examined separately in the following sections, which enable 
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regulatory recommendations to be made, as well as suggestions for future work 
and study limitations in later sections in this chapter.  
 
 
8.5.1. The Isthmus between Science and Law.  
 
Nanotechnology is a pervasive collection of products that ??????????????????????????
sectors, with the number of products being commercialised growing year-on-year 
(Bowman, 2010). As well as having a physical presence, nanotechnology also 
exists in the social and legal world, where it is re-contextualised by individuals 
with different knowledge (i.e. scientists and legal actors). This has created 
challenges for the way that nanotechnology is engaged with, and scientifically 
and legally constructed through language (Macoubrie, 2005). Simply, scientists 
have predominantly framed nanotechnology as physical phenomena, with little 
consideration of the social and legal aspects for the implications of 
nanotechnology R&D, manufacture and commercialisation. Law however has 
had greater difficulties in engaging with the physicality of nanotechnology, with 
many legal actors not having the prerequisite knowledge to adequately engage 
with the physicality of these phenomena, and following social and legal 
structures (McHale, 2008). 
 
 
8.5.2. The Complexity and Opacity of Nanotechnology 
 
This study has focussed on nanoparticles as they are seen as the vanguard of 
nanotechnology R&D and commercialisation. As a product class nanoparticles 
????? ????????? ?????? ????????? ?????? ????? ??? ?? ??????? ??? ?????????????? ????
consumer-based applications. Nanoparticles are however a collection of highly 
complex and opaque physical entities, which often display unique properties 
distinct and unique from their bulk counterparts (Cientifica, 2003). While these 
properties make them desirable for commercial applications, understanding the 
physical aspects of the physical properties has been no small challenge for the 
natural sciences, with much still to learn (Munshi et al, 2007). Importantly, and 
even though the greatest volume of discourse has been driven by the natural 
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sciences, other disciplines such as law have had much to say about 
???????????????? ??? ????? ?????????? ???? ????????????? ????????? ???? ?????????
phenomena of nanotechnology, and at worst, which has frequently been the case, 
it has misconstructed the physical phenomena. This has created a challenge for 
???????????????????????????????????????????????????????????????????????????-based 
???????????????????????????????????????????????????????????????????????????????????
discourse (Beard and Easingwood, 1996). In turn this has created challenges for 
creating shared meaning for the physicality of nanoparticles and in the use of 
language for nanoparticles, which has often not been fit-for-purpose.    
 
 
8.5.3. Paucity of Data 
 
A lack of systematic scientific testing and research into the physical aspects of 
nanoparticles has created a paucity of information, for their physical 
characteristics and how they interact with biological systems (Yon and Lead, 
2008). The small size of nanoparticles means that they have a potential to 
interact with biological systems in ways that prior technologies have not 
managed, and for example, being able to pass through the blood-brain-barrier in 
humans (Jain et al, 2012). The increased ability for nanoparticle interaction has 
created challenges for prior testing systems to determine toxicity and the risk of 
products, and has highlighted a lack of fit-for-purpose nanoparticle testing (Hull 
and Bowman, 2010). More than this, there is currently a lack of skilled operators 
and equipment to test these aspects, and rationales for what things to test and 
why. Stakeholder decision-makers must engage with these challenges and decide 
how and what should be tested for nanoparticle products. They must also decide 
whether every type of nanoparticle needs to be assessed for toxicity or whether 
??????????????? ???????? ??????? ??? ????????? ???? ???????? ??? ?? ????????????????? ????
types of nanoparticle should be tested but in reality this is a daunting and 
virtually impossible task due to cost, lack of specialist equipment and analysts to 
determine results, and from a commercial perspective not appealing.  
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8.5.4. Defining Nanotechnology and Nanoparticles 
 
At present no legal definitions exist, and with debatable rationales within law for 
which natural sciences definition of nanotechnology or nanoparticles to use. It is 
important to recognise that definitions cannot solve the problems created by 
these technology products, but that it can create a foundation of shared 
knowledge between different practitioners and academics. Without legal 
definitions, challenges are created for legal stakeholders who are engaged with 
nanotechnology and nanoparticle regulation, particularly for what these 
phenomena are. So far nanomaterials have been defined by science, fitting into a 
range of measurements at the nanoscale but posing the question for a 
measurement slightly outside this range (El-Shall and Edelstein, 1996). For 
example, should a product with a size of 101 nm be considered a nanomaterial? 
At present no, and there is often virtually no consideration of what the bottom 
end of the scale is. More than this though, there has been an assumption that 
nanomaterials are stable in size, which is often not the case, and through the 
process of Ostwald Ripening (Liu et al, 2007) the size may vary, moving 
products in and outside of the nanoscale range (Binion, 2008). While a single 
definition cannot hope to capture the essence of a nanomaterial, nanotechnology, 
or nanoparticles it should be there as a linguistic sign to aid in clarity and shared 
meaning. It should also function to facilitate decision-making, particularly where 
difficult decisions are faced for such complex and opaque technology.   
 
 
8.5.5. Regulating Nanotechnology 
 
Currently there are no specific regulations in place to mitigate risks from 
nanomaterials; instead current regulations across many product sectors are relied 
upon (Hansen, 2009). REACH has the potential to regulate nanomaterials 
through the one tonne weight limit for registration but there is a misconception 
that nanomaterials can be regulated in such a way. Depending on the 
nanomaterial, very few products will attain the threshold requiring registration. 
The view that REACH is suitable for nanomaterials is predominantly misguided 
and has failed to take into account the low weight of most nanotechnology 
	  	  	   	  	  	  	  	  203	  
products. ??? ???????????? ?? ?????aterial did reach a one tonne manufacturing 
level, then in principle it would be examined through REACH, depending on the 
product sector (Ward and Harley, 2010). Importantly, and at present there are 
thousands of nanomaterial products in the global market ????????????????????????
????? ????????? ???? ????? ?????????? ???????? ???? ???-for-purposes product safety 
tests have been carried out, and with virtually no move towards a precautionary 
principle.  
 
 
8.6. Regulatory Recommendations 
 
After much examination and consideration of many themes arising from this 
study, this section draws multiple aspects together to highlight regulatory 
recommendations, to answer the main question driving this thesis ?????ow should 
nanoparticles be regulated so that risk is minimised while business innovation 
and commercialisation is encouraged??? 
 
As a starting point, the two main regulatory drivers are acknowledged, including 
facilitating the commercialisation of innovative products, while mitigating risk. 
Although it is easy to regard these drivers at opposite ends of a regulatory 
spectrum, I believe that this approach is unhelpful, as it is more pragmatic to 
??????? ????? ??? ?????-in-??????? ??? ????? ??????? ???? ??????? ???? ???????????
recommendations, are to contextualise, balance and promote both of these 
agendas to benefit the market and society, without the recommendation of overly 
prohibitive regulatory barriers. Following on with the notion of pragmatism, a 
fundamental overhaul of current regulatory systems is rejected as unhelpful, and 
very unlikely to be taken seriously.  
 
At present, nanotechnology and nanoparticle products are regulated, but just not 
specifically as nanotechnology or nanoparticle products (Bowman, 2010). As 
discussed in this study, this has had advantages of rapid commercialisation but 
has left many questions unanswered for product safety and risk. Of course this 
does not mean to say that depending on a product being commercialised in a 
particular sector that there are no regulatory requirements, but that any testing 
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requirements are often based on pre-nanotechnology principles, where the ability 
to highlight toxicity, risks and adverse affects are potentially limited at present. 
Thus, I argue that there is a need for scientific tests to be developed that can 
determine the toxicity of nanoparticle products in line with current regulatory 
requirements based on the product application, and sector use. As an example, a 
nanoparticle therapeutic used as a pharmaceutical drug; there would already be a 
requirement for the regulation of product efficacy, safety, and quality. In 
??????????????????????????????????????????????????????????????????????????????????????
more simply, modify current regulatory requirements for more fit-for-purpose 
testing to determine nanoparticle safety, efficacy and quality. Following on with 
this example, challenges might well be raised for whether any nanoparticle 
product can receive an abridged route to market, on the future scenario that 
?????????????????????????????????????????????????????????????y, coupled with a legal 
right to utilise this route. I am keen not to heavily use pharmaceutical drugs as an 
example, as this example is one of more stringent regulation than most other 
sectors, and would skew recommendatory discourse. This leads however to a 
pertinent aspect worthy of consideration, which is that with a pervasive 
collection of products, how should nanoparticles be regulated? It might make 
sense to regulate based on for example size, shape and application, which might 
further suggest the creation of obligatory registries, which is currently a 
contested arena. Although contested, and with much to be worked out for 
practical use, this idea has much to offer, particularly if data is collected 
throughout the life cycle stages of nanoparticle products, with a potential for 
higher-risk product applications having a similar system to pharmacovigilance 
reporting.    
 
I believe that testing, reporting and cataloguing data is a vital aspect of 
addressing the aspect of risk and toxicity, which can lead to better regulatory 
decision-making. This is particularly pertinent for products, which might 
undergo Ostwald Ripening (changing, size and shape) resulting in different risks 
and toxicities along the life cycle, necessitating a holistic approach to testing at 
multiple product stages. A pivotal part of testing will no doubt be linked to 
whether it is perceived that nanoparticles can interact with other systems, such as 
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???????? ??????????? ????? ???? ??? ???????? ?????????? ???? ?????????????? ?? ?????????
with this aspect needing to be determined.  
 
While there has been much discussion of the use of systems such as REACH to 
engage with testing nanoparticles, the lack of specifics for how to do so makes 
this unfeasible. More than this, there is no requirement to test products that are 
manufactured with a weight limit of less than one tonne, which at present I am 
unaware of any product reaching this limit, meaning no testing. In many ways, 
discussions regarding the use of REACH in its current regulatory format are 
trapped within a pre-nano style of thinking, based on classical bulk manufacture, 
which nanotechnology sits outside of. I therefore believe that nanoparticle 
regulations require not just a shift in scientific testing, but in the way that we 
???????????????????????????????????????????????????????????????????????????????
manufacture and assess safety. Data must be collected that takes advantage of 
technology, enabling rapid collection and potential further assessment if adverse 
effects are noted. Due to the complexity of the challenge facing regulators, it is 
imperative that a wide variety of stakeholders from industry, academia, 
environmental groups and other areas work towards producing regulation that is 
specific, fit-for-purpose, and focuses on nanoparticles as not being a mirror 
image of bulk products for risk and toxicity.  
 
 
8.7. Limitations and Recommendations  
 
It is critical that the limitations of this study are examined, as they are an inherent 
part of the research process, and aid in a greater contextualisation and 
understanding of this study. As a starting point, it is recognised that contributions 
have been made to extant literature, but yet, as with arguably any research study, 
there are still limitations.  
 
Throughout this study, the question remained, how to view this study, where 
there were clear multiple conflicting regulatory drivers, embedded within the 
disciplines of law and science. Attempting to engage with this aspect, which was 
through the non-neutral lens of myself, meant a synthesis of both legal and 
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???????????????????????????????????????????????????????????????????????????????????????
?????? ??? ?????????????????????? ?????? ???????? and how successful any synthesis 
between subjects could be considered. Trying to balance the disciplines and 
regulatory views was no small undertaking, and resulted in many subjective 
choices being made. While through one perspective, it is a limitation; it has also 
brought to life a novel view for high technology regulation, where the study was 
constructed for the reader to engage with multiple conflicting aspects, while 
making overall sense of this complex area.  
 
Beyond the critique of this study, I turned my focus to myself as a researcher, 
which was not something pulled together at the end, but was undertaken 
??????????? ????? ????????????? ?? ???????????? ???????????? ???????????? ???? ??????
????????????????????????????????????????????Prior to this study I had worked as a 
scientist manager carrying out commercialisation activities for nanotechnology 
products in many of the sectors examined in this study. ???????????????????????????
as a manager scientist had created a sensitisation to nanotechnology and the 
potential hype but also physical risks of such technologies. In practical terms, 
this meant t????????????????????????????????????????????????????????????????????????
????? ??? ???? ??????? ??? ???????????? ?????????? ???? ???????????? ??? ????????????????
while still be the researcher through contextualising this information through a 
legal lens, thus an etic stance (Kottak, 2006).  
 
As this study sought to understand the regulation of nanoparticles as the 
vanguard of high technology R&D and product commercialisation, through 
inception, usage to end-of-life disposal, a heavy focus was made towards 
understanding the physicality of nanoparticles and the shortfall in law so far to 
have meaningfully engaged with these products, beyond overly simplistic 
discursive framings. While nanoparticles have been the focus they also highlight 
the regulatory challenges of many other high technology products particularly 
from the arena of nanotechnology. In this I argue that nanoparticles have acted as 
???????????????????????????????????????????????????????????????????????????????
what these products are and regulate based on product physicality.  
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This study has unpicked many challenges which in part are methodological and 
within the discipline of law. For example, prior examination of high technology 
products and sectors, including nanotechnology has demonstrated a potential 
lack of willingness for a host of regulatory actors to engage with the complexity 
and physicality of nanotechnology products. When comparing to other high 
technology arenas, such as pharmaceuticals, medical devices and biologics etc. 
this has not been the case, with an in depth and arguably more meaningful 
engagement particularly for product safety, efficacy and quality (Mann and 
Andrews, 2014). Thus the first suggestion for future work is that of a 
comparative analysis to be undertaken for these three other areas, which all deal 
with opaque, risk-laden and potentially harmful products, to determine what (if 
any) regulatory insights can be gleaned for safety, efficacy and quality. It is of 
course recognised that these other areas are within themselves much more 
heavily regulated, with ensuing costs and product lag times, but still set against a 
neo-liberalist driver of commercial innovation being a predominant aim 
(Abraham and Lewis, 2002). In practicality, these areas may have much to offer, 
as they all exist within a zeitgeist of needing to understand physical reactions 
from these products with their environment and users. Thus, notions of product 
physicality are not speculative, but driven towards being demonstrable through 
??????????? ??????????? ??????????????? ??? ?????? ??? ??????? ????? ??????????????? ???
???????????????????????????????????????????????????????????????????????????????????
nature of nanotechnology products as being inherently unknowable for their 
safety and efficacy, challenges this notion.  
 
Problematically, for a meaningful regulatory engagement with the physicality of 
nanoparticles and nanotechnology, greater efforts need to be made to embed 
regulatory theories within physical frameworks for how products interact with 
the world. At present, I suggest that law has predominantly taken a view to use a 
????????????????????????????????????????????????????????????????????????????????, 
at the expense of engaging with the specific nano aspects of the physicality of 
these products (Oberdörster, Oberdörster and Oberdörster, 2005; Beer et al, 
2012). ?????????????????????????????????????????????????????????????????????????????
????????? ???? ????? ????? ?? ???????? ?????????????? ??? ???? ???????? ??????????? ???
product physicality should be made. Likewise scientific discourses have taken a 
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somewhat opposite view, where regulation is predominantly an issue of 
physicality, missing out many other regulatory aspects and drivers (Kjølberg, 
2009). While both approaches have been insightful, they also have clear 
limitations, particularly for complex phenomena such as nanotechnology. It has 
to be made clear that both legal and scientific lenses are required to engage with 
nanoparticles and nanotechnology, and thus, the second suggestion for future 
work is to engage in a synthesis between disciplines, where regulation is viewed 
with both of these lenses in mind. This potentially grounds future work within a 
neo-liberalist framework of promoting innovation, but also more acutely 
considering wider regulatory aspects, through what might be considered a 
bricolage. Within itself, this is a perceptual change on the part of the researcher 
to more fully acknowledge the importance of knowledge from different 
????????????? ??? ???? ????????? ??? ???? ?????????????? ?????????? ????? ????? ????????????
such as nanotechnology and nanoparticles.  
 
Pivotal to any future work is a more critical approach towards the physicality of 
nanoparticles, which should be reflected in all of the main themes in this study, 
particularly for (1) risk and insurance, (2) health, safety and the environment, and 
(3) national and European regulations. I contend that only through this approach, 
will insights be drawn that will guide new testing required to understand product 
functioning, and that can echo throughout product R&D, commercialisation, 
usage and end-of life. Understanding the physicality of nanoparticles is 
?????????? ???? ???????????? ?????? ?????????? ??? ?? ???????? ??? ??????????????
conditions, and for producing a clearer reflection between regulation and product 
physicality. The lack of consideration for the key physical process of Ostwald 
Ripening in any legal literature, which can result in nanoparticles changing their 
size and toxicity, is demonstrative of this aspect. Due to the potential of 
nanoparticles to change size and shape through the Ostwald Ripening processes, 
future work should explore this aspect for how a regulatory system can engage 
????? ????????? ????? ????????? ????? ??????? ??????? ??????? ??? ??????????? ????-
products or aggregate into larger products above the nanoscale.  
 
Finally, the ability to use clearer language and have a usable definition of nano 
and related terms, for product physicality and regulation is required. Future work 
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should engage with this aspect for the production of a working definition. While 
there has been much discussion about the language of nanotechnology and 
nanoparticles, this has not extended much beyond etymology and tracing the use 
of words back to understand what nanotechnology means today. This is not a 
helpful approach, and is in many ways misleading. Although much consideration 
has been made towards nano definitions, it has often been through an overly 
simplistic lens of stating nano as being less than 100 nm, with no bottom limit, 
and a failure to engage with nano existing in a three-dimensional format, even at 
the nanoscale. Thus, definitions have misconstructed nanotechnology and 
nanoparticles, and for this to be rectified, language should be used as a refractive 
and reflective medium, simultaneously existing in between regulation and 
product physicality, while creating our interpretation of the physicality.  
 
 
8.8. Personal Reflections 
 
Before undertaking this study, my background had been within and utilised 
methodologies from the natural sciences and humanities, resulting in a mixture 
of quantitative and qualitative approaches to research studies. When using a 
natural sciences approach statistical methods to draw inferences from large 
populations to predict future outcomes were favoured. Alternatively, through the 
lens of a humanities researcher, my approach to social and physical life was 
through the analysis of the spoken word, transcribed, to enable textual analysis. 
Arguably this approach was most akin to this study, which was embedded within 
textual analysis, albeit without the transcription stage. Working with texts from 
different sources was thus not new to me, nor was the requirement to engage in 
interpretive analysis of documents and different author opinions. Importantly 
though, there are differences between my prior studies in humanities and this 
research. While engaging in this study and interpretive analysis, there was a 
?????? ?????? ??? ????????????? ??????? ??????????????? ???? ?????????????
methodology, commonly engaged with by humanities and social science 
researchers (Bryman and Bell, 2011). More explicitly, while there is of course a 
research spectrum for analysing textual documents, and on the one side 
subjectivism, and the other objectivism, it appears to me that this facet is less 
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frequently engaged with by legal research than other areas, at least for 
acknowledged and referenced methodology. Within itself, this is not necessarily 
a problem, but for a new researcher such as myself in this area of legal studies, it 
created a challenge for unpicking the method for textual analysis. Facing this 
difficulty, and as acknowledged in the first chapter, I undertook to engage with 
an emic and etic approach (Kottak, 2006). In practicality, this meant a deep 
introspective and reflexive process, drawing on my knowledge from working 
within the nanotechnology sectors (an emic approach), as well as channelling 
????????? ???????? ??? ????? ???????????? ???? ????? ??????????? Thus, and while 
engaging in a notional concept of content analysis, where prior corpus based 
textual analysis from within regulatory studies of high technology was unpicked, 
for wording, frequencies of thought, rationales and legal reasoning etc. to 
explicate this approach. ????????????? ?? ????? ??? ???????????? ?????? ?????? ????
?????? ??? ???????? ???), but more that this study is a reflection of the phenomena 
studied, and grounded within elucidated regulatory structures (nanotechnology 
regulation).  
 
By engaging with and carrying out this study, my opinions on many aspects of 
high technology regulation have changed, from those based on my experience 
from working within a nanotechnology company. At the start of the study, I 
worked within a paradigm (self, organisationally and sector constructed) that 
??????????????????????????????????????????????????????????????????????????? ??????
engaged with the extant literature, the more my view shifted to one of a 
balancing act between promoting technological innovation and mitigating risk. 
However, at some level I now believe this to be another misconstruction, in that 
it is too simple a construction of high technology regulation. Instead, and 
imbibing the underlying neo-liberal premise that there are macroscale drivers for 
technology promotion and a need to mitigate risk, there are in fact, many 
competing and conflicting drivers, which regulatory systems are embedded 
within. Thus the two pronged scale of technology promotion vs. risk mitigation 
is helpful for an approximation, but misses many other important factors.   
 
In practicality, while increasing my understanding of the complexity of high 
technology regulation, it has afforded the opportunity for me to engage with the 
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sponsoring company and meaningfully discuss the research findings from this 
study. This has led to many attitude shifts within the company, who have tried to 
utilise knowledge gained to more thoroughly consider the purpose of high 
technology regulation. In other words, regulation should be an inherent part of a 
????????????????????????????????????????????????????????????????????????????????
being funnelled through this lens. As I work within the sponsoring company, this 
has meant that instead of decisions being made for a process, and then regulatory 
???????? ??????????? ??? ????? ?????? ????? ????? ????? ????????????? ??????????? ????
journey of a process. I believe that this has had the effect of making 
organisational members, more akin to regulatory stakeholders within the 
company, as greater knowledge is sought and implemented.  
 
Finally, and on a more personal level, this study has enabled me to engage more 
meaningfully with high technology regulation, and as mentioned within the 
future work section, will enable further work to be carried out to utilise my 
knowledge sets from both the natural sciences and humanities, with future 
regulatory studies. As such this will allow questions based on how and why 
regulatory stakeholders within high technology companies engage with 
regulation, focussing for example on their discourses. Thus, this study will act as 
a platform for me to carry out further nuanced high technology regulatory 
research.  
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